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Dendritic cells (DCs) are professional antigen presenting cells of the mammalian 
immune system, and constitute a vital link between the adaptive and the innate 
immune systems. These cells are phenotypically and functionally highly 
heterogeneous, comprising at least 3 subsets in human: classical/conventional DC 
types 1 and 2 (cDC1, cDC2), and plasmacytoid DC (pDC). Additional heterogeneity 
has been described within the cDC2 compartment which can be divided into two 
populations, termed DC2 and DC3, more closely related to cDC1s or monocytes, 
respectively. DCs develop in the bone marrow (BM) under the control of lineage-
specific transcription factors (TFs). However, the cellular pathways and genetic 
factors that govern the development of human DC subpopulations from 
haematopoietic stem cells are not well known, in part due to their rarity in vivo.  
 
First, this work addressed the rarity of DCs via a novel in vitro culture system that 
favoured the production of large numbers of DCs from primary human CD34+ 
stem/progenitor cells. Two transcriptomic approaches were employed to verify the 
culture output: the NanoString assay and bulk RNA-Seq. The transcriptomic analyses 
confirmed that all DC subsets produced in culture exhibited appropriate transcription 
profiles and bore close resemblance their ex vivo-derived counterparts. 
Furthermore, these methods attested that Notch stimulation predisposed the culture 
output toward the production of cDC1, the rarest of the DC subsets.  
  
The culture system, confirmed to produce bona fide DC subsets, facilitated the 
interrogation of DC haematopoiesis to establish the phenotypic identities of putative 
progenitor and precursor populations. These early populations, derived from human 
BM, along with mature DCs, were subjected to single cell transcriptomics. Pseudo-
temporal ordering and lineage branching reconstruction analyses revealed two 
pathways of DC development, marked by differential expression of the TF IRF8 and 
explaining the origin of cDC2 heterogeneity. The IRF8high pathway generated pDC, 
cDC1 and DC2, while DC3 and monocytes developed along an IRF8low trajectory.  
Mass cytometry analysis validated the link between the two pathways in BM and DC 




Finally, the project focused on determining the role of IRF8 in the homeostasis of 
human cDC1s and pDCs, both of which develop through the IRF8high pathway and 
retain IRF8 expression as they mature. The previously established in vitro culture 
techniques were employed to generate sufficient DCs for low-input IRF8 chromatin 
immunoprecipitation, followed by high-throughput DNA sequencing (ChIP-Seq). The 
analysis of the ChIP-Seq data revealed that IRF8 maintains both the function and 
surface phenotype of cDC1s, while in pDCs it controls important functional modules.  
 
During this work, a wide variety of transcriptomic and genomic bioinformatic 
techniques and analyses enabled the verification of a novel human DC culture 
system (Kirkling and Cytlak et al., 2018), the identification of two pathways of human 
DC development (Cytlak and Resteu et al., 2020), and have generated new insights 
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Chapter 1. Introduction 
1.1 The roles of DCs in immunity 
Dendritic cells (DCs) are professional antigen-processing and presenting cells with 
critical roles in the regulation of immunity and inducing tolerance (Banchereau et al., 
2001; Steinman et al., 2003). The role of DCs in immunity can be summarised with 
two terms: (1) DCs act as sentinels, able to capture, process and present antigens 
and to migrate to lymphoid tissues to select rare, antigen-reactive T cell clones, and 
(2) DCs are sensors, responding to a variety of environmental stimuli by extensive 
differentiation and maturation (Steinman, 2006). The type of DC and the specific 
response induced by different stimuli shape the immunological outcome, e.g. by 
driving naïve T cell polarisation to T helper subsets, such as TH1, TH 2, TH 17, and TH 
22, or inducing tolerance (reviewed by Geissmann et al., 2010). Together with 
monocytes and macrophages, DCs form the mononuclear phagocyte system, which 
encompasses leukocytes with specialised antigen processing and presentation 
function (Haniffa et al., 2015). 
 
DCs reside in tissue in an immature state, continuously sampling their environment 
by endocytosis, macropinocytosis, and phagocytosis (British Society for Immunology, 
https://www.immunology.org). During pathogen invasion, DCs sense microbial 
products using a variety of pattern recognition receptors (PRRs) such as the toll-like 
receptors (TLRs), nucleotide-binding oligomerization domain-like receptors (NOD-like 
receptors), retinoic acid inducible gene 1-like receptors (RIG-I-like receptors) and C-
type lectins (CLEC) (Kassianos et al., 2012). Upon interaction with pathogens, DCs 
undergo complex cellular processes resulting in their activation (reviewed by Tibúrcio 
et al., 2019). DCs then migrate from tissue to draining lymph nodes, where they can 
induce an adaptive immune response (Banchereau and Steinman, 1998). In order to 
present the antigen to lymphocytes and induce their clonal selection, the internalised 
pathogen-derived peptides are processed and loaded onto major histocompatibility 
complex (MHC) molecules (reviewed by Mantegazza et al., 2013).  
 
1.1.1 Antigen presentation 
Most of the proteins involved in antigen processing and presentation are encoded by 
MHC genes. Only antigens presented within MHC complexes are able to trigger an 




1997). Peptides loaded onto MHC I molecules are recognised by CD8+ T cells, while 
peptides loaded onto MHC II molecules are presented to CD4+ helper T cells. 
However, the pathways that regulate the presentation in the context of MHC I and 
MHC II are very diverse. 
 
MHC I molecules are expressed ubiquitously on all human cell types, with the 
exception of erythrocytes (Lu et al., 2010). Their primary function is to display 
fragments from within the cell to CD8+ T cells as part of the cytosolic or endogenous 
pathway. Certain subsets of dendritic cells are also able to capture exogenous 
proteins and load peptides derived from them onto MHC Class I molecules (reviewed 
by Murphy and Weaver, 2017). The process of taking up exogenous antigens and 
their presentation on MHC Class I by APCs is known as cross-presentation (Bevan, 
1976). Cross-presentation allows DCs to activate cytotoxic CD8+ T cells for immune 
defence against viruses that do not infect DCs and tumours that originate from non-
DCs (reviewed by Kurts et al, 2010). The T cell activation in this context is referred to 
as cross-priming. Several pathways of cross presentation have been described. They 
include the endosome-to-cytosol pathway (illustrated in Figure 1.1 A) and the 
vacuolar pathway, involving the direct transport of antigens from the phagolysosome 
into a vesicular loading compartment, where peptides are allowed to be bound to 
mature MHC Class I molecules (reviewed by Murphy and Weaver, 2017).  
 
MHC II proteins are expressed primarily by APCs, including DCs, macrophages, and 
B cells (Ting and Trowsdale, 2002). Antigens are captured via endocytic vesicles and 
cell-surface receptors. The source of the peptide antigen may also be pathogens that 
have invaded the cell to replicate in intracellular vesicles (reviewed by Murphy and 
Weaver, 2017). The low pH of the vesicles activates the proteases and causes 
degradation of the captured antigen (Silberstein et al., 2018). On their way to the cell 
surface, the MHC II molecules assembled in the endoplasmic reticulum pass through 
the vesicles and bind the peptides, transporting them to the cell surface (Figure 1.1 
B). In DCs, antigen presentation by this pathway results in CD4+ T cell activation and 
polarisation. In addition, MHC II can be loaded with fragments derived from within the 
cells, generated via the autophagy pathway. This plays a role in the induction of 
tolerance to self-antigens, as well as a means of presentation of antigens derived 






Figure 1.1. Schematic of antigen presentation via MHC I (A) and MHC II (B) 
(Kobayashi and van den Elsen, 2012). 
A. Antigens are processed into peptides by the immunoproteasome, which is 
composed of multiple subunits, including LMP2. Peptides are transported into the 
endoplasmic reticulum (ER), where they are loaded into the groove of the MHC Class 
I complex, which is composed of a heavy chain and β2-microglobulin (β2m). MHC 
Class I complexes present antigens on the cell surface to CD8+ T cells.   
B. Antigens from extracellular sources, such as bacteria, are processed by 
endolysosomal enzymes into peptides. These peptides bind to the groove of the 
MHC Class II complex by displacing the class II-associated invariant chain peptide 
(CLIP), which is derived from the MHC Class II-associated invariant chain (Ii). HLA-
DO and HLA-DM regulate the antigen-loading process. The MHC Class II complex 
presents antigens to CD4+ T cells. MIIC, MHC Class II compartment; TAP, 





1.1.2 T cell polarisation  
A “three-signal model” (Kapsenberg, 2003), has been proposed to describe T cell 
polarisation by DCs (Figure 1.2). According to the model, the first step is the 
recognition of the antigen displayed in the context of MHC Class II by the DC and 
recognised by its cognate T cell receptor (TCR). As part of the second signal, also 
referred to as the co-stimulatory signal, the activated DC upregulates costimulatory 
molecules which recognise costimulatory molecules on the T cell surface. The third 
and final signal is the polarising signal - through pattern recognition receptor 
signalling, pathogens induce the DC to produce cytokines which drive T cell 
polarisation (e.g. IL-12 for TH1). 
 
 
Figure 1.2. Schematic of the three-signal model for T cell polarisation. 
First, the antigen in the context of MHC Class II displayed the DC and recognised by 
its cognate T cell receptor. Second, the activated DC upregulates costimulatory 
molecules (such as CD80, CD86) which recognise costimulatory molecules on the T 
cell surface (e.g. CD28). The third signal is the production of cytokines which drive T 
cell polarisation. Naïve T helper cells are able to differentiate into TH1 cells, which 
promote cytotoxic CD8+ T cells and cell-mediated immunity, and TH2 cells, which 
promote B cells and humoral immunity (Alberts et al., 2002). PAMP, pathogen-





1.1.3 Induction of tolerance 
An alternative outcome from a DC-T cell interaction is the induction of tolerance 
(Steinman et al., 2003). The mechanisms of DC-induced immune tolerance include: 
T cell anergy, clonal deletion, and induction of Tregs (reviewed by Hasegawa et al., 
2018). This interplay occurs under steady-state conditions, when a DC has 
undergone homeostatic “tolerogenic” maturation, as opposed to TLR-induced 
“immunogenic” maturation. The transcriptomic changes occurring during both types 
of maturation are similar in complexity and largely overlapping, the expression of 
interferon-stimulated genes being among the few discriminators of immunogenic and 
tolerogenic murine DCs (Dalod et al., 2014; Ardouin et al., 2016). Several signaling 
networks, involving NF-κB, β-catenin, and IRF4, are thought to regulate tolerogenic 
maturation in response to cues from the tissue microenvironment (Baratin et al., 
2015; Manicassamy et al., 2010; Vander Lugt et al., 2017).  
 
1.2 Peripheral blood dendritic cell subsets 
The DC pool in peripheral organs is constantly replenished by bone marrow-derived 
cells, traveling through blood (Collin and Bigley, 2018). At least three human DC 
subsets, which differentiate under the control of specific transcription factors and 
perform specialised functions, have been identified in steady-state blood: 2 subsets 
of myeloid/classical DC (cDC1 and cDC2), and plasmacytoid DC (pDC) (Guilliams et 
al., 2014; Bigley et al., 2016). All human DC subsets express MHC Class II 
molecules (HLA-DR) and lack lineage markers characteristic for T cells, B cells, and 
natural killer cells (CD3, 19, 20, 56) – (Collin et al., 2013). Classical dendritic cells 
(cDC) show a similar gene expression pattern in both blood and peripheral tissues, 
the blood subsets appearing less mature (Breton et al., 2015). 
 
1.2.1 Classical dendritic cells 
Classical dendritic cells were discovered in splenic tissue by Ralph Steinman and 
Zanvil Cohn in 1973. The extensively branched, motile, and mitochondria-rich cells 
were dubbed “dendritic cells” due to their distinct morphology (Katsnelson, 2006). At 
first, the cells seemed too rare to be relevant. However, it was later shown that DCs 
are extremely potent at stimulating T cell cytotoxicity and antibody responses 
(Nussenzweig et al., 1980; Inaba et al., 1983). All human cDCs express typical 




express CD11c, however DC can be distinguished by the lack of high CD14 
expression and the absence of marker CD88 (Collin et al., 2013).  
 
1.2.1.1 Classical dendritic cell type 1 
cDC1s are present in blood in small numbers, constituting 0.1% of mononuclear cells 
and 10% of human cDCs (Collin et al., 2013). They express characteristic surface 
antigens including BDCA3/CD141/THBD, CLEC9A, XCR1, FLT3, NECL2/CADM1, 
and TLR3 (Table 1.1; Guilliams et al., 2014). cDC1s and are specialised for the 
uptake and processing of material from late-apoptotic and necrotic cells due to the 
expression of the damaged cell-recognition molecule CLEC9A (Zhang et al., 2012). 
cDC1s are thought to be the most potent cross-presenting DCs in vivo 
(Embgenbroich and Burgdorf, 2018), specialised in taking up exogenous antigen and 
presenting it in the context of MHC Class I to CD8+ T cells (reviewed by Theisen and 
Murphy, 2017). An important feature of cDC1s is the sensing of viral nucleic acids 
with TLR3 (which recognises double-stranded RNA), as well as with TLR8 (which 
recognises foreign single-stranded RNA and short double-stranded RNA) (Gauzzi et 
al., 2010; Blasius and Beutler, 2010). The TLRs expressed by cDC1s also include 
TLR1, -2, -6 and -10 (Hemont et al., 2013).  
 
1.2.1.2 Classical dendritic cell type 2  
cDC2s comprise 1% of mononuclear cells in peripheral blood (Collin et al., 2013). 
The mature cells are known to express CD11c, BDCA1/CD1c, CD172/SIRPA, and 
ZBTB46 (Table 1.1; Guilliams et al., 2014). Additionally, cDC2s express a wide array 
of TLRs (TLR1-8 and -10) (Hemont et al., 2013). cDC2s determine the T helper cell 
response to an antigen by polarising naïve CD4+ T cells to drive TH1, TH2 or TH17 
responses (reviewed by Bigley et al., 2016). cDC2s have inferior cross presentation 
capacity compared to cDC1s (reviewed by Collin et al., 2013).  
 
A number of studies have identified heterogeneity among blood and tissue cDC2, 
defined by CD1c+ expression. Yin et al. (2017) split cDC2s by phenotype – 
specifically CD5 expression, CD5hi cells being more “DC-like”, and displaying higher 
levels of cDC2-specific genes, stronger migration, along with overrepresentation in 
lymph nodes, and CD5low cDC2s showing greater expression of monocyte-related 




cell transcriptomics and revealed the presence of two subsets distinct from 
monocytes in this compartment. Mass cytometry analyses helped identify similar 
heterogeneity in blood, along with different cDC2 phenotypes in skin (Alcántara-
Hernández et al., 2017). Additional cDC2 heterogeneity has recently been identified 
in human spleen via single cell transcriptomics (Brown et al., 2019). 
 
1.2.2 Plasmacytoid dendritic cell 
Plasmacytoid DCs were initially an enigmatic cell type observed in secondary 
lymphoid tissue (reviewed by Manz, 2018). Originally called “plasmacytoid T cells” or 
“plasmacytoid monocytes”, they were later re-classified as DCs (Grouard et al., 
1997). These cells are specialised to sense viral infection and bacterial components 
via TLR7 or TLR9 and respond with a massive production of type I interferons (IFNs) 
α, β, or ω. Due to this specialised function, pDCs are also called “natural interferon-
producing cells” (Colonna et al., 2004). Through IFN secretion, pDCs also support 
the function of other immune cells, including B cells and NK cells (Gowder, 2012). 
Recent studies identified heterogeneity in the phenotypic space formerly thought to 
be occupied exclusively by pDC. The classical pDC markers CD123, CD303, and 
CD304 were found on a pre-DC population, distinguished from pDC via the 
expression of CD33, CX3CR1, CD2, CD5, and CD327 (See el al., 2017). Pre-DCs 
(also termed AS DC in several studies) are phenotypically and functionally distinct 
from pDCs and display the ability to induce T cell proliferation and produce IL-12, 
while “pure” pDCs specialise in IFN α secretion (Villani et al., 2017). The 
contamination of the traditionally defined pDC gate with pre-DC/AS DC is therefore 
thought to be responsible for the T cell stimulation capabilities previously attributed to 
pDC (reviewed by Geissmann et al., 2010; Merad et al., 2013).  
 
1.2.3 Tissue dendritic cells 
 “Migratory” cDC1s and cDC2s are present in most non-lymphoid tissue 
compartments (Haniffa et al., 2015). Their main function is to acquire antigen and 
migrate to lymph nodes in order to present it to lymphocytes (reviewed by Collin et 
al., 2013). During homeostasis, pDCs are present in most peripheral tissues in low 
numbers. However, the size of the pDC population increases in skin and mucosa 




of the mononuclear phagocyte family, including monocyte-derived cells, tissue 
resident macrophages, and Langerhans cells (Haniffa et al., 2015).   
 
In steady state, lymphoid tissue contains non-migratory “resident” cDCs and pDCs 
that are likely derived from blood precursors, along with “migratory” tissue-derived 
DC (Segura et al., 2012). The number of both the “resident” and “migratory” DCs in 
lymph nodes increases in inflammation (reviewed by Collin et al., 2013).  
 
1.2.3.1 Langerhans cells 
Langerhans cells (LCs) were the first DC subset to be identified. They were 
described in 1868 by Paul Langerhans, who thought they were cutaneous nerve cells 
due to their dendritic morphology (British Society for Immunology, 
https://www.immunology.org). LCs were subsequently re-classified as DC, when over 
a century later, classical dendritic cells were discovered, and their role in antigen 
presentation was demonstrated (Steinman and Cohn, 1973). LC are thought to 
originate prenatally from yolk sac-derived primitive myeloid progenitors and reside in 
epidermal tissue, where they self-renew (Hoeffel et al., 2012). Severe inflammation 
has been shown to recruit de novo bone marrow progenitors, in waves of transient 
classical monocytes and likely cDC2s (reviewed by Collin and Milne, 2016). LCs are 
marked by Langerin expression (CD207), epithelial cell adhesion molecule (EPCAM) 
and higher CD1a expression than cDC2s (Table 1.1; Collin et al., 2013). Due to their 
“strategic” location within the skin barrier, LCs play crucial functions as immune 
sentinels. Their skin-resident functions include the sampling of tight junctions 
between keratinocytes and uptake and recognition of apoptotic cells. As migratory 
cells, LCs are also able to travel to lymph nodes and present antigen to promote 
immunity or induce tolerance (reviewed by West and Bennett, 2017).  
 
1.2.3.2 Inflammatory dendritic cells 
Monocyte-derived DC (moDC) have been shown to arise from classical monocytes 
and expand in inflammation (Qu et al., 2014). However, the contribution of the newly 
recruited moDC to the initiation of immunity is an unresolved problem in humans 
(Collin et al, 2013). Recent murine studies showed that the priming by moDCs 
enhanced the memory CD8+ T cell differentiation during acute infection, more than 




et al., 2019).  More recently in humans, Dutertre and colleagues (2019) defined 
CD14+ cDC2s as an inflammatory population distinct from monocytes, dependent on 
FLT3L (unlike monocytes), and expressing high IRF4 (unlike moDC).  
 
 
Table 1.1. Characteristics of human dendritic cell subsets. 
Dendritic cells can be divided into multiple subpopulations, based on surface 
markers, major transcription factors (TF) involved in their development and 
homeostasis, Toll-like receptors (TLR), secreted cytokines, and location (Bigley, et 





1.3 Monocyte subsets 
Like DCs, monocytes develop in the bone marrow, then circulate through the 
bloodstream, where they account for approximately 5% of leukocytes, before being 
recruited into tissues (Blumenreich, 1990; Patel et al., 2017). Monocytes are highly 
plastic and heterogeneous, able to differentiate into macrophages or moDC under 
inflammatory conditions (Chomarat et al., 2000). Human monocytes are divided in 3 
subsets: classical (CD14++CD16−), intermediate (CD14++CD16+), and non-classical 
(CD14dimCD16++) (Ziegler-Heitbrock et al., 2010). These subsets have differential 
abilities for cytokine production, migration, and promoting T cell proliferation (Tolouei 
Semnani et al., 2014). CD14+ monocytes specialise in phagocytosis, innate sensing 
and migration, CD14+CD16+ monocytes excel at antigen presentation, cytokine 
secretion, apoptosis regulation, and differentiation, while CD14dimCD16+ monocytes 
are involved in phagocytosis and adhesion (reviewed by Kapellos et al., 2019).  
 
1.4 SLAN DC 
The CD16+ monocyte subset, marked by the expression of 6-sulfo LacNAc (SLAN), 
has been the subject of debate, as it was also classified by some authors as a type of 
dendritic cell (Hofer et al., 2019; reviewed by Collin and Bigley et al., 2018). 
However, transcriptional profiling of monocytes and myeloid DCs from human 
peripheral blood proposed their role in inflammatory processes and confirmed the 
relationship of SLAN+ cells with the monocytic compartment rather than with DCs 
(van Leeuwen-Kerkhoff et al., 2017). Furthermore, recent studies used a human in 
vivo cell tracing experiment to show that the non-classical monocytes originate from 
classical CD14+ monocytes (Patel et al., 2017). Contamination of the HLA-DR+Lin- 
flow cytometry gate with non-classical CD14dim CD16++ monocytes, has also led to 
the discovery of a new subset of dendritic cells named DC4 (Villani et al., 2017). 
Further studies identified that these cells differ from all DC subsets and classical 
monocytes and behave like CD16++ SLAN+ monocytes (Calzetti et al., 2017, Dutertre 
et al 2019).  
 
1.4 In vitro-derived DCs 
The first in vitro-generated DCs were produced from monocytes (Gieseler et al, 
1998). As monocytes are found in great numbers in peripheral blood (100,000 to 




DCs. However, natural DCs are heterogeneous, and comprise multiple subsets with 
different functions, while the exact role of moDCs in vivo is not well understood 
(Collin et al, 2013). The DC generation methods shifted to their manufacture from 
bone marrow progenitors, in the presence of cytokines, such as GM-CSF and FLT3L 
(Naik et al., 2005; Helft et al., 2015). Further studies revealed that co-culture of bone 
marrow progenitors with a feeder layer, such as the MS5 or OP9 stromal cell lines, 
allowed the production of all major DC subsets (Lee et al. 2015; Kirkling and Cylak, 
et al., 2018). Chapter 3 of this thesis elaborates further on the in vitro generation of 
DCs, aiming to determine the transcriptional identity of DCs generated in culture. 
 
1.5 DC therapy 
Currently, the field of immunotherapy is dominated by immune checkpoint inhibitors 
that target molecules with inhibiting functions (such as CTLA-4, PD-L1, and PD-1) in 
order to allow T cells to kill cancer cells (van Willigen et al., 2018). As the most potent 
antigen presenting cells, able to shape adaptive immunity, dendritic cells also offer a 
promising prospect in cancer immunotherapy. Numerous clinical trials for DC 
vaccines have been conducted within the last decades, and the first anticancer 
vaccine (sipuleucel-T, used to treat prostate cancer) was approved by the United 
States Food and Drug Administration in 2010 (Hammerstrom et al., 2011). A 
common approach in most DC vaccine protocols is the harvest of DCs from the 
peripheral blood of a patient. As DCs are extremely rare, blood monocytes are often 
harvested instead, and used to generate DCs in vitro via the addition of GM-CSF and 
IL-4. The bona fide DCs or the monocyte-derived DCs are then matured and loaded 
with tumour antigens or synthetic peptides in the presence of an adjuvant, and 
administered to the patient, in order to induce the tumour-specific effector T cells 
(Sadeghzadeh et al., 2020). A number of advantages of using natural circulating DCs 
have been noted, including the preservation of their function due to shorter culture 
time compared to monocyte-derived DCs (van Willigen et al., 2018) and the ability to 
migrate. However, monocytes are still used in most protocols due to their availability, 
and the use of natural DCs (cDC1, cDC2, and pDC) has been underexplored. 
 
In recent years, the ability of immature DCs to induce tolerance has been 
investigated to treat autoimmune conditions. Phase I trials have been conducted at 
Newcastle University, with the aim to establish the safety and efficiency of 




affecting the knee joint (Bell et al., 2017). This method used monocyte-derived tolDC, 
produced from the peripheral blood of the patients using a novel protocol containing 
immunosuppressive and immunomodulatory drugs, and suggested that injection of 
these DCs into the affected joint offered a safe and promising treatment (Harry et al., 
2010; Bell et al., 2017). 
 
1.6 Murine DCs and monocytes 
Dendritic cells are a vital component of the mammalian immune system. pDCs and 
the two cDC subsets have been identified in numerous species, including humans, 
mice, macaques, and pigs (Guilliams, et al., 2016; Edwards et al., 2017). Efforts have 
been made to unify the classification of DCs across species and identify common 
markers of the DC subsets. The identification of murine homologues of human 
mononuclear phagocytes is of particular importance, as most of the knowledge about 
dendritic cells was gained from studies in mice. 
 
cDC1s, or CD141+ DCs in human and CD8/CD103+ DCs in mouse, are marked by 
the expression of CLEC9A, XCR1, CADM1, TLR3, BAFT3 and IRF8 (Haniffa et al., 
2015; Crozat et al., 2010; reviewed by Edwards et al., 2017). In both species, cDC1s 
are potent cross-presenters (Gutiérrez-Martínez et al., 2015; Embgenbroich and 
Burgdorf, 2018). Similarly, cDC2s are conserved across the two species, and are 
marked by CD1c in human and CD11b in mouse (Haniffa et al., 2015). These cells 
express CD11c, FLT3, CD11b, CX3CR1, and SIRPA/CD172, and present 
exogenous antigens to CD4+ T cells in both species (Vu Manh et al, 2015). In 
humans and mice, pDCs are major interferon producers, and can be distinguished by 
expression of CD4, CD123, and CD45RA (Vu Manh et al, 2015; Haniffa et al., 2015). 
pDC markers in mouse also include Ly-6C, Siglec-H, and BST2 (Haniffa et al., 2015). 
 
Two major monocyte subsets have been described in both species: classical (Ly6Chi 
CD43− monocytes in mice and CD14++ CD16− monocytes in humans) and non-
classical (Ly6Clo CD43+ monocytes in mice and CD14dim CD16++ monocytes in 
humans) (reviewed by Wolf et al., 2019). In addition, the equivalents of moDC, LC, 
and macrophages have also been identified in mouse (Vu Manh et al, 2015; Haniffa 





1.7 DC haematopoiesis  
Haematopoiesis is the process by which haematopoietic stem cells give rise to 
immune cellular components. In the developing human, the primitive wave of 
haematopoiesis begins in the yolk sack, while the first multipotent adult-type 
haematopoietic stem cells (HSCs) emerge in the aorta/gonad/mesonephros region 
inside the embryo (Tavian et al., 2010). The HSCs then migrate to the liver, spleen 
and then into the bone marrow, where they are located in adults (Jagannathan-
Bogdan et al., 2013). All natural DCs originate from bone marrow progenitors, 
independently from monocytes, through progenitors and precursors with restricted 
DC potential (Geissman et al., 2010; Puhr et al., 2015). In the classical 
haematopoietic model, involving sequential bifurcation, DCs have an apparent “dual” 
origin (Figure 1.3 A), arising from both myeloid and lymphoid progenitors (Doulatov et 
al, 2010). Human DCs descending from common myeloid progenitors (CMPs) and 
their counterparts arising from common lymphoid progenitors (CLPs), have been 
observed to be exhibiting the same phenotype, function and gene expression in a 
mouse xenotransplantation model (Ishikawa, 2007). The traditional model is based 
on the analysis of cell populations, also referred to as gates, predefined by flow 
cytometry. The apparent dual origin may therefore be explained by the inclusion of 
DC-primed progenitors in both myeloid-defined and lymphoid-defined analysis gates. 
Presently, the traditional hierarchical model of haematopoiesis has largely been 
replaced by the early lineage priming model for haematopoietic lineages (Notta et al., 
2016; Velten et al., 2017). According to the early lineage priming model, cell fate 
specification occurs in the early progenitors and development progresses in a 
continuous manner along increasingly stable unilineage-restricted trajectories (Figure 
1.3 B). 
 
Recent studies have identified precursors with DC potential in human. Breton et al. 
(2015) discovered a peripheral blood population of cells lacking mature DC markers 
but expressing CD117 (also known as KIT or stem cell growth factor receptor), 
CD116 (CSF2RA) and CD135 (FLT3). Via a single cell transcriptomic study of 
peripheral blood cells, Villani et al. (2017) identified a DC population, expressing AXL 
and SIGLEC6, later reclassified as pre-DCs (See et al., 2017). Villani and colleagues 
also described a small population of CD34+CD100+CD116- negative cells which 
could give rise to cDC1s and cDC2s in culture. It has not been established how these 




Figure 1.3. Classical and revised models of human haematopoiesis (Collin and 
Bigley, 2018).  
 A. In classical models of haematopoiesis, cell potential partitions by successive 
bifurcations descending from the apex where common lymphoid and common 
myeloid progenitors (CLP; CMP) arise from the haematopoietic stem cell (HSC). 
Each progenitor population has homogeneous differentiation potential such that 
every cell has an equal probability of two mutually exclusive fates. Hence, dendritic 
cells (DC) were proposed to arise in the sequence: CMPs, granulocyte–macrophage 
DC progenitor (GMDP), macrophage DC progenitor (MDP), common DC progenitor 
(CDP) with a final pre-DC stage leading to conventional cDC1 and cDC2. Each 
population is given a uniform colour to indicate homogeneous potential.  
B. Recent studies support several adjustments to the classical model. First, lineage is 
primed in early progenitors so that most populations contain only cells with a single 
potential. Second, lymphoid and myeloid potential run together originating as the 
lymphoid primed multi-potent progenitor (LMPP) that separates from megakaryocyte 
and erythroid potential (MkE) at the apex. Hence the gates defined by CD38 (blue 
borders) and CD45RA (red borders) contain phenotypically related cells but with 






1.7.1 Transcription regulation in the context of DC haematopoiesis 
In humans, gene expression programmes that establish specific cell states and 
maintain cellular homeostasis are controlled by transcription factors, cofactors, and 
chromatin regulators (Lee and Young, 2013). RNA polymerase II, which synthesizes 
precursors of mRNAs in eukaryotes, collaborates closely with proteins termed 
transcription factors in order to initiate transcription (Hamspsey, 1998).  
 
Transcription factors can be divided into two categories: (1) basal, or general, 
transcription factors, which are expressed ubiquitously and participate in the 
formation of the transcription preinitiation complex, and (2) gene-specific transcription 
factors (sometimes referred to as simply transcription factors) that activate or repress 
basal transcription (Villard, 2004). All gene-specific transcription factors contain at 
least one DNA-binding domain (DBD), while some of the general TFs do not bind 
DNA directly. DBDs bind specific DNA sequences, also called motifs. Gene-specific 
TFs often have a preference for certain motifs over other sequences, driven by 
features such as high or low guanine-cytosine content and DNA shape (Dror et al., 
2016). Over 1,600 TFs are known in humans, classified into “families” based on their 
DBDs (Lambert et al., 2018). 
 
Gene-specific transcription factors can act as activators or repressors of gene 
expression. Gene transcription starts with the assembly of the transcription 
preinitiation complex near the transcription start site (TSS) (Figure 1.4). Enhancer 
regions recruit gene-specific TFs in order to enhance transcription of a regulated 
gene, which is typically located downstream. Regions of DNA with high levels of 
transcription factor binding, comprised of multiple enhancers, are entitled super-
enhancers. Super-enhancers significantly increase the expression of the genes they 
are regulating; however, these genes are very sensitive to transcription perturbation 
(Villicaña et al., 2014). The TFs bind to the enhancers or super-enhancers and act as 
activators, causing the DNA to bend and come closer to the gene promoter. TFs then 
bind coactivators, which bind to RNA polymerase II, which in turn binds to general 
TFs at the TSS, forming the preinitiation complex (Lee and Young, 2013). 
Conformational changes in the complex lead to the positioning of single-stranded 





The repression of gene expression can be achieved via a variety of mechanisms. 
One example is the physical blocking of the biding sites of the basal TFs or RNA 
polymerase II by the gene-specific TFs (Donev, 2017). Often, a set of activators and 
repressors are involved in the regulation of the same gene, a mechanism termed 
combinatorial regulation (Reece, et al., 2011).  
 
 
Figure 1.4. Formation of the preinitiation complex as part of transcriptional 
regulation (adapted from Lee and Young, 2013). 
Transcription factors bind to specific DNA elements (enhancers) and to coactivators, 
which bind to RNA polymerase II, which in turn binds to general transcription factors 
at the transcription start site (TSS, shown as a bent arrow). The DNA loop formed 
between the enhancer and the start site is stabilised by cofactors, such as the 
Mediator complex and cohesin. 
 
As described in section 1.7, DCs develop through increasing commitment, where 
lineage determination is mediated by transcription factors (Figure 1.5). The discovery 
of patients with primary immunodeficiency caused by mutations within the genes 
encoding for transcription factors GATA2, IRF8, and IKZF1, offered valuable insights 
into transcription factor requirements for DC development in human (Dickinson et al., 
2014; Hambleton et al., 2011; Cytlak et al., 2018). Transcription factors essential for 
the development of DC subsets include IRF8, BATF3, and ID2 for cDC1s, IRF4 for 
cDC2s, and IRF8, E2-2/TCF4, and IKZF1 for pDCs (reviewed by Colonna et al., 2004 




Figure 1.5. Model of transcription factors regulating DC haematopoiesis. 
Human dendritic cell subsets develop in the bone marrow from HSC (haematopoietic 
stem cells), under the control of a set of transcription factors. Transcription factor 
GATA2 is required for multiple haematopoietic lineages, and mutations in this gene 
are the cause of dendritic cell, monocyte, B, and natural killer lymphoid deficiency 
(Dickinson et al., 2014). IRF8 is required at early stages of DC development, and is 
expressed at later stages in pDCs and cDC1s. Lineage-specific factors include  
E2.2/TCF4 for pDC, BATF3/BATF and ID2 for cDC1s, IRF4 for cDC2s, and KLF4 for 
monocytes (reviewed by Collin and Bigley, 2018 and Haniffa et al, 2015; Feinberg et 
al., 2007). 
 
1.7.2 Transcription factor IRF8 
IRF8 is part of the interferon regulatory factor (IRF) family which consists of nine 
members in mammals (Tamura et al., 2015). The IRF family regulate expression of 
type I Interferons and interferon-stimulated genes (ISGs) by binding to the IFN-
stimulated response element (ISRE). Several members of the IRF family also play 
critical roles in the cellular differentiation of hematopoietic cells and in inducing innate 
pattern recognition receptors and antigen-specific immune responses (Tamura et al., 
2008). Members of the IRF family contain a conserved N-terminal region with a DNA-
binding domain that binds to the core IRF binding motif, GAAA (Figure 1.6; Fujii et 




mediate the protein–protein interaction of a specific IRF with other family members 
and TFs (Yanai et al., 2012). The regulatory C-terminus region is also referred to as 
the IRF association domain (IAD). 
 
Figure 1.6. Schematic of the IRF8 protein and multiple sequence alignment of 
IRF8 orthologues, illustrating conserved coding sequences across multiple 
species (adapted from Bigley et al., 2018). 
IRF8 contains a conserved N-terminal region with a DNA-binding domain (DBD, 
depicted in orange). Core ISRE binding residues are marked. The IRF8 C-terminus 
region (also referred to as the IRF association domain, IAD, shown in blue) is less 
well conserved and is thought to mediate the protein–protein interaction with other 
transcription factors.  
 
Most of the knowledge about IRF8 has been derived from murine studies. The role 
played by this transcription factor in human has only recently been highlighted by the 
discovery of patents with bi-allelic IRF8 mutations, experiencing a loss of all the 
monocyte and DC subsets (Bigley et al., 2018; Hambleton et al., 2011; Salem et al., 
2014), along with reduced numbers of mature NK cells (Mace et al., 2017). A more 
restricted loss of cDC1 and pDC subsets was observed in mono-allelic IRF8 mutation 
(Cylak and Resteu et al., 2020).  Studies in mouse showed that within the progenitor 
compartment, IRF8 inhibits CEBPA to limit granulocyte production in favour of 
monocyte/DC differentiation (Kurotaki, et al, 2014). It is then required to maintain the 
identity of terminally differentiated cDC1s and control lineage survival (Grajales-







that IRF8 is primarily required for pDC function rather than development (Sichien et 
al., 2016).  
 
1.7.3 Notch signaling pathway and dendritic cell development  
The Notch signaling pathway is highly conserved across multicellular organisms, and 
it is involved in both developmental and homeostatic processes. The mammalian 
Notch signaling pathway consists of membrane-bound ligands of the Delta-like (DL) 
and Jagged families and four receptors: NOTCH 1-4. The signaling is initiated via the 
binding of Notch ligands on an adjacent cell (Figure 1.7), leading to the release of 
intracellular segment of Notch, which migrates to the nucleus, where it interacts with 
the transcription factor CSL (also called RBPJ), converting it from a repressor to an 
activator (Kramer, 2015). Coactivators of the Mastermind family are also recruited to 
activate Notch-dependent gene expression programmes (McElhinny et al., 2008). 
 
During haematopoiesis, Notch is one of the main signalling pathways engaged in the 
direct interaction of progenitors and bone marrow stromal cells, and has long been 
established to play a crucial role in the development of T and B lymphocytes 
(reviewed by Cheng et al., 2010). In human, mutations in Notch signaling pathway 
genes have been reported to cause developmental phenotypes affecting an array of 
organs and are linked to conditions such as T cell acute lymphoblastic leukaemia 
(Penton et al., 2012; Elisen at al.,1991). The role of Notch signaling in DC 
development was first highlighted by studies in mice, which identified that Notch2 
controls differentiation of splenic cDC1s and cDC2s (Lewis et al., 2011). Recent in 
vitro experiments performed by the Human Dendritic Cell Lab and overseas 
collaborators, established the role DL1-Notch2 signaling in the generation of 
authentic cDC1s in mouse and revealed that DL1 signaling facilitates the generation 
of human cDC1s (Kirkling and Cytlak et al., 2018). Chapter 3 of this thesis further 
elaborates on a novel culture system, able to generate large number of cDC1s with 





Figure 1.7. Canonical Notch signaling (Koch et al., 2013).  
A Notch ligand expressed on the surface of a signal-sending cell interacts with a 
Notch receptor on the signal-receiving cell, triggering Notch receptor activation (1). 
The E3 ubiquitin ligase mindbomb 1 (Mib1) promotes ligand endocytosis and is 
required for efficient Notch receptor activation (2). The trans-interaction between 
ligand and receptor induces two consecutive proteolytic cleavages of the 
heterodimeric Notch receptor (3). The first cleavage is mediated by the 
metalloprotease ADAM10/17 (S2 cleavage), followed by a second cleavage through 
the γ-secretase complex (S3 cleavage). These cleavages lead to the generation of a 
free intracellular domain (NICD), which translocates to the nucleus of the signal-
receiving cell (4). In the absence of NICD (5), a transcriptional repressor complex 
composed of CSL and additional co-repressors (CoR), such as N-CoR, keeps Notch 
target genes silent. The interaction of NICD with CSL (6) dissociates the repressor 
complex and leads to the recruitment of MAML and additional co-activators (CoA, 
e.g. p300) to the complex. The assembly of this transcriptional activation complex on 





1.7.4 Growth factor requirements for DC development 
External factors driving the development of dendritic cells include a set of lineage-
specific cytokines or growth factors. These small secreted proteins interact with their 
cognate receptors on the cell surface, activating signaling pathways that result in 
alterations in gene expression and a biological response.  
 
1.7.4.1 FLT3L 
Fms-related tyrosine kinase 3 ligand (FLT3L) is a potent dendritic cell stimulator, with 
the ability to expand DC populations in vivo and in vitro (Dong et al., 2002). 
Administration of FLT3L in vivo dramatically increases the number of DCs in both 
mice and humans (Maraskovsky et al., 1996; Maraskovsky et al., 2000), while 
incorporation of FLT3L in in vitro culture of bone marrow progenitors allows for the 
generation of diverse DC subsets (Brasel et al., 2000; Naik et a., 2005). In murine 
cell culture, Flt3L alone is sufficient to generate DCs from BM, while in human, 
additional factors are required. 
 
1.7.4.2 GM-CSF 
Granulocyte-macrophage colony-stimulating factor (GM-CSF or CSF2) is a cytokine 
commonly used to generate DCs in both murine and human cell culture systems. It 
was the first growth factor recognised to promote the in vitro development of DC, 
along with granulocytes and macrophages, in cultures of murine bone marrow 
progenitors (Inaba et al., 1992). The combined GM-CSF and Flt3L requirement for 
DC homeostasis in vitro was later demonstrated by a double-negative murine model, 
where mature DCs and pre-DC populations were reduced more significantly in 




Stem cell factor (SCF) is the ligand of the c-KIT cytokine receptor. SCF is able to 
regulate DC production in bone marrow progenitor-based in vitro systems 
supplemented with other cytokines, via the recruitment of early progenitors of a high 
proliferative potential with the capacity to differentiate into erythroid and myeloid 






Macrophage colony stimulating factor (M-CSF or CSF-1) is a cytokine known to drive 
the development of the monocyte/macrophage lineage. Evidence from murine 
studies suggests that it can also drive the development of cDCs and pDCs, likely 
because the expression of its receptor is retained through the pre-DC stage (Fancke 
et al., 2008; Sichien et al., 2017). 
 
1.8 Technologies employed in DC research 
Technological advances of the last decades in the fields of cytometry, genomics, and 
transcriptomics enabled great progress to be made in dendritic cell research.  
 
1.8.1 Cytometry 
1.8.1.1 Flow cytometry 
Flow cytometry is a single cell technique widely used in immunophenotyping, due to 
its ability to perform accurate enumeration and identification of immune cells. This 
versatile technique has a vast number of applications and is fundamental for dendritic 
cell research, as it offers a time- and cost-effective means to enumerate ex vivo- and 
in vitro-derived DCs and discern between the dendritic cell subsets in these samples. 
This technique is indispensable for the interrogation of the output of in vitro culture 
systems, and for phenotyping and identifying missing immune cell populations in 
human DC immunodeficiency. Furthermore, fluorescence activated cell sorting 
(FACS) enables the sorting of desired cells populations or individual cells for further 
studies, facilitating the closer inspection of rare populations.  
 
Flow cytometry is a laser-based technique. It operates by passing cells suspended in 
a liquid stream in front of a laser in order to measure the physical and chemical 
characteristics of each individual analysed cell. Several detectors, placed around the 
stream, measure a combination of scattered and fluorescent light, and 
simultaneously produce readings for up to 20 parameters, also known as channels. 
Generally, the forward scatter (FSC) channel values reflect the cell size, while the 
side scatter (SSC) readings provide information on its inner complexity, such as 
granularity. In addition, fluorescence detectors sense fluorescently labelled 
molecules present on the cell surface or within the cells. Fluorescently-conjugated 
antibodies and fluorescence dyes are commonly used to aid the detection of the 




antibody “cocktail”. The signals produced by the detectors are converted to channel 
values and analysed with specialised software. The cell populations are identified 
with the help of markers, many of which are named according to the CD 
nomenclature. The traditional approach to flow cytometry data analysis involves the 
inspection of series of 2D scatter plots, where cell populations are separated by 
“gates”. Figure 1.8 illustrates an example of a gating strategy employed in the flow 
cytometric identification of peripheral blood human DCs and monocytes. Recently, 
novel computational methods have been developed, aiming to provide more rapid 
and less biased analysis techniques, and improve data visualisation. Examples of 
analysis algorithms widely applied to flow cytometry data include t-distributed 
stochastic neighbour embedding (tSNE) and minimum spanning trees. These 
computational techniques become more important as the number of channels or 
parameters increases with advancing flow cytometer capabilities. 
Figure 1.8. Gating strategy for flow cytometric identification of human DCs and 
monocytes in peripheral blood (Collin and Bigley, 2016).  
Monocytes and DCs are found in the HLA-DR positive, and lineage (CD3, 19, 20, and 
56) negative compartment. CD14 versus CD16 displays monocyte subsets. The 
double-negative population contains the DC subsets. In this example, CD123 and 
CD11c are used to define pDCs and myeloid/classical DCs. cDCs can be separated 
into cDC1 and cDC2 using CD141 and CD1c, respectively. Lineage – a set of mature 




1.8.1.2 Mass cytometry 
Mass cytometry, also known as cytometry by time of flight (CyTOF) is a recently 
developed next generation flow cytometry platform. Its main advantage is the ability 
to assess the expression of up to 40 antigens, with further potential for multiplexing.  
Metal isotopes, rather than fluorophores, are used for labelling the antibodies, 
allowing to reduce spectral overlaps compared to multi-colour flow cytometry, with 
little “spillover” between channels. Cells are stained with the metal-labelled 
antibodies, then loaded into a CyTOF mass cytometer, where they are nebulised, 
and the readout is produced by time of flight mass spectrometry. The analysis of the 
mass cytometry data involves a similar approach to that of flow cytometry, and is 
often performed via the gating of cell populations, or more recently, using 
computational approaches.  
 
Drawbacks of this method include the inability to retrieve the analysed cells for 
further analysis, as the cells are nebulised within the instrument in order to be 
analysed by mass spectrometry. In addition, the throughput of this technique (~ 
1,000 cells/s) is typically lower than that of flow cytometry, which is able to analyse 
tens of thousands of cells per second (Li et al., 2018). 
 
1.8.2 Transcriptomics 
1.8.2.1 NanoString gene expression assay 
The nCounter Analysis System performs a highly multiplexed direct digital counting 
of transcripts with no requirement for amplification and is ideal for low amounts of 
input material, such as RNA derived from DCs, present in blood in low numbers. The 
accurate detection of transcripts is achieved by the usage of a pair of short probes for 
the identification of each gene of interest. The reporter probes are approximately 50 
base pairs long RNA sequences complementary to target genes of interest. Each 
reported probe is labelled with a fluorescent barcode, unique for every target. The 
expression of up to 800 individual genes can be measured in one reaction. The 
capture probes have a structure similar to the reporter probes, the fluorescent 
barcode being replaced with a biotin molecule. As a result of a hybridisation step, the 
capture and reporter probes, along with the input RNA from the sample form a probe-
target complex (Figure 1.9). The samples are transferred in the nCounter Prep 




to the imaging surface of a NanoString cartridge via the capture probe’s biotin 
molecule. The probes are then aligned on the cartridge, and the fluorescent barcodes 
are scanned, counted, and assigned to their respective genes by the Digital Analyser 
(Figure 1.10), producing a Reporter Code Count (RCC) dataset. A pre-built ‘Human 
Immunology V2’ panel with 594 genes associated with innate and adaptive immune 







Figure 1.9. Schematic of the NanoString gene expression assay hybridisation 
chemistry (adapted from NanoString Technologies). 
As part of the NanoString assay, the capture and reporter probes are added to 














Figure 1.10. The NanoString nCounter FLEX platform. 
The NanoString nCounter FLEX system consists of the prep station (right) and the 
digital analyser (left). The battery pack in the centre ensures the sample processing 
will not be affected by power outages. The hybridised samples are first placed in the 
nCounter Prep Station, and following the removal of excess probes, the probe-target 
complexes bind to the imaging surface of a NanoString cartridge via the capture 
probe’s biotin molecule. The probes are then aligned on the cartridge via an electric 
current. The cartridge is transferred into the Digital Analyser, where the fluorescent 
barcodes are scanned, counted, and assigned to their respective genes. 
 
1.8.2.2 Bulk RNA-Seq  
As the cost of sequencing has been steadily decreasing in the last two decades, the 
field of transcriptomics shifted rapidly from probe-based microarrays to bulk RNA-
Seq. A standard RNA-Seq workflow begins with the purification or enrichment of the 
cells populations of interest, often performed via FACS or via magnetic-activated cell 
sorting. The RNA is then extracted in bulk from each cell type or biological replicate. 
This is often followed by rRNA depletion or Poly A mRNA enrichment, RNA 
fragmentation, cDNA synthesis (also called reverse transcription), and finally 
sequencing library preparation, which involves adapter ligation and polymerase chain 
reaction (PCR). The libraries are then sequenced on a next generation sequencing 
platform, such as Roche 454, Illumina, Helicos, or PacBio (Chu et al., 2012).  
 
RNA-Seq is indispensable for the profiling of the whole transcriptome of bulk 




the expression values represent an average of the thousands of cells present in each 
sample. This renders the method unsuitable for the analysis of DC development, as 
understanding the mechanisms and patterns of cell decision-making and early 
lineage bias at molecular level can only be achieved by analysing individual cells 
(Nimmo et al, 2015).  
 
1.8.2.3 Single cell RNA-Seq 
Single cell RNA sequencing (scRNA-Seq) is a powerful technique developed in the 
last decade, used for characterising genome-wide mRNA expression of individual 
cells. In the context of dendritic cell research, this technique is vital for studying cell 
fate decisions of individual DC progenitors or precursors, as bulk RNA sequencing 
obscures the cellular heterogeneity by averaging the gene expression in the 
samples. The scRNA-Seq technique has proven useful for unravelling heterogeneity 
across multiple tissues (Human Cell Atlas, https://www.humancellatlas.org; Collin et 
al., 2019). Using methods such as pseudotime to determine the position of a given 
cell in a developmental continuum can help explore developmental pathways. In 
addition, the scRNA-Seq method excels at identifying rare cell populations. 
 
Generally, the workflow for the generation of scRNA-Seq data is similar to that of 
bulk RNA-Seq. The main difference is the tissue dissociation and the isolation of 
single cells, rather than of a bulk population, at the start of the scRNA-Seq protocols. 
Multiple approaches have been developed for this purpose. The first multiplexed 
scRNA-Seq protocols, able to analyse the expression of multiple cells in parallel, 
emerged in 2011 and were plate-based (Wu et al., 2018). As part of the plated-based 
approach, the single cells are isolated into 96 well or 384 well plates (Figure 1.11). A 
widely-used plate-based method is the Smart-seq2 protocol, which enables full-
length coverage across transcripts and is therefore sensitive for gene detection 
(Picelli et al., 2014). Moreover, using FACS to isolate the cell into plates offers an 
additional advantage, as the gene expression for each individual cell can be linked 
with its antigen expression determined by flow cytometry. Droplet based scRNA-seq 
systems, which rely on capturing each cell in its own microfluidic droplet, are also 
widely used for the isolation of single cells. Examples include the Drop-seq, inDrop 
and Chromium 10X technologies. These methods often offer a high cell throughput, 
however, are also generally more prone to more noise and gene dropouts than plate-




Drawbacks of scRNA-Seq are the technical challenges, the complex and noisy data 
output due to false-negative errors, and the prohibitive cost of the procedure. The 
technical challenges include the necessity for standardised sample preparation, 
reliable isolation of single cells, the limited efficiency of RNA capture and subsequent 
conversion to cDNA and sequencing (Grun and van Oudenaarden, 2015). In order to 
assess the sample-to-sample variability of scRNA-Seq data, a set of synthetic control 
genes are often added to each cell’s lysate in a theoretically constant and known 
amount (Vallejos et al., 2017). However, the commonly used External RNA Control 
Consortium (ERCC) molecules may have different molecular properties to the 
molecules of interest (Yuan et al., 2017). 
 
Figure 1.11. Schematic of the plate-based approach to single cell RNA 
sequencing. 
Cells are first isolated in to 96 or 384 well plates, often via fluorescence activated cell 
sorting. The cells are then lysed, and the mRNA molecules are selected via the 
capture of the polyadenylated mRNA tails by complementary poly[T] primers. Next, 
depending on the protocol used, the cells are the barcoded and combined into a 
single tube for library preparation, or separate sequencing libraries are prepared for 







Chromatin immunoprecipitation, followed by high-throughput DNA sequencing (ChIP-
Seq) is used to examine protein-DNA interactions at molecular level. Studying the 
DNA binding sites and binding targets of transcription factors is of particular interest 
in the context of DC research, in order to unveil the roles of transcription factors 
critical for DC haematopoiesis. Standard ChIP-Seq protocols require abundant 
starting material, in the region of 1-20 million cells (Gilfillan et al, 2012). However, 
novel ChIP-Seq protocols, designed for a low cell number, have been able to reduce 
the number of input cells to 50,000-100,000 cells per immunoprecipitation reaction. 
As the name suggest, chromatin immunoprecipitation is performed with an antibody 
against the transcription factor or histone of interest. Chapter 5 of this thesis is 
dedicated to the optimisation of the low cell ChIP-Seq protocol for transcription factor 
IRF8 and describes the ChIP-Seq method in great detail. 
 
1.9 Aims and objectives 
This project aimed to investigate multiple aspects of human DCs and their 
development. First, in order to address the rarity of DC in vivo and make them 
accessible for research, an in vitro culture system was developed by members of the 
Human Dendritic Cell lab. While the system generated DCs with a seemingly 
appropriate phenotype, as determined by flow cytometry, this work was aimed at 
confirming the similarities between the culture-derived DCs and their ex vivo 
counterparts at transcriptomic level. An additional focus was the verification of the 
transcriptomic identities of cDC1s (the rarest DC subset), produced in large numbers 
in culture via Notch stimulation, against blood and tissue DCs. 
 
The second main objective was to identify distinct DC lineages and their precursors 
in human bone marrow, and to establish whether there is a developmental basis for 
the recently described heterogeneity in the cDC2 population. Following the 
verification of the culture output as part of the first aim, the novel culture method was 
used to interrogate multiple phenotypic spaces of the bone marrow in order to 
establish increasingly committed progenitor and precursor populations. This project 
then sought to examine the transcriptomes of individual DC progenitors or precursors 




aimed at inferring the developmental trajectories of the single cells and defining the 
distinct pathways of DC development. A further objective was to determine the link 
between the developmental pathways originating in the bone marrow and the mature 
DC subsets found in peripheral blood. 
 
Following the discovery of two DC developmental pathways marked by the 
expression of transcription factor IRF8, as part of the previous objective, the final 
goal of this project was to establish the role of IRF8 in the homeostasis of human 
cDC1 and pDC. These DC subsets develop through the IRF8 high pathway, retain 
the expression of this transcription factor as they mature, and are the most affected 
by the loss of IRF8 in monoallelic IRF8 mutation in human (Cytlak and Resteu et al., 
2020). Of particular interest were the functional modules controlled by IRF8 in cDC1 
and pDC and the presence of IRF8 auto-activation, a phenomenon previously 
described in murine studies (Grajales-Reyes et al., 2015). This objective was set to 
be achieved via ChIP-Seq, a gold-standard technique for interrogating transcription 
factor binding sites. Previously, this study was not possible in human due to the rarity 
of DC in vivo, however this was overcome via the use of a novel culture system, 
designed to produce large numbers of bona fide DC subsets in vitro.   
 
As the ChIP-Seq assay relies heavily on the quality of the used antibody, it was 
imperative to identify and test ChIP-compatible IRF8 antibodies available on the 
market in order to select an antibody with appropriate sensitivity and specificity prior 
to preforming IRF8 ChIP-Seq on rare human cells. Further aspects of this assay that 















Chapter 2. General materials and methods 
2.1 Buffers and reagents 
2.1.1 Lymphoprep Solution 
Lymphoprep (STEMCELL Technologies) is a density gradient solution used for the 
isolation of human peripheral blood, cord blood, and bone marrow mononuclear cells. 
During centrifugation, granulocytes and erythrocytes sediment trough the 
Lymphoprep medium due to their higher density, while the mononuclear cells form a 
layer on top of the solution (Figure 2.1). Lymphoprep contains sodium diatrizoate 
(9.1% w/v) and polysaccharide (5.7% w/v), along with other (unlisted) ingredients, 
and has a density of 1.077 g/mL. 
 
Figure 2.1. Schematic of samples separated using Lymphoprep. 
Lymphoprep employs density gradient to separate granulocytes and erythrocytes, 
which form a pellet at the bottom of the tube, from mononuclear cells, found in a 
distinct layer above the Lymphoprep solution.  
 
2.1.2 Dulbecco’s Phosphate-Buffered Saline  
Dulbecco’s Phosphate-Buffered Saline (DPBS) is a buffered salt solution used for 
washing and dilution of mammalian cells. The pH of the solution is maintained within 
the range of 7.1 - 7.5 by phosphate buffering. DPBS is water-based solution, and 
each litre of it contains 8g sodium chloride, 0.2g potassium phosphate, monobasic, 




formulation, used in this work, does not contain calcium and magnesium ions, which 
can cause cell clumping.  
 
2.1.3 Foetal calf serum  
Foetal calf serum (FCS) is a media supplement, containing essential nutrients and 
growth factors for cell culture. Heat inactivation at 56°C for 30 minutes is a common 
treatment of FCS, performed to disable the complement system and any potential 
inhibitors of cell growth in culture. 
 
2.1.4 Flow and sort buffer 
Flow and sort buffer, used to dilute the cells in flow cytometry assays and FACS, was 
made up of DPBS, 0.1%–2% Heat Inactivated Foetal Calf Serum (HI-FCS, Gibco) 
and 0.4% EDTA (Sigma-Aldrich). The role of the FCS is to reduce the non-specific 
antibody binding, while the EDTA acts as chelating agent to reduce cell clumping. 
 
2.1.5 Culture media  
All culture media were supplemented with HI-FCS and penicillin/streptomycin 
(Sigma). The role of FCS is described above in subsection 2.1.3. Penicillin-
streptomycin is a mix of antibiotics, used to control bacterial contamination in cell 
culture. All media were supplemented with L-glutamine (Sigma). This amino acid 
supports the growth of cells that have high energy demands and serves as an 
alternative energy source for rapidly diving cells. 
 
2.1.6 Minimum Essential Medium α  
Minimum Essential Medium α (MEM α) is used for the suspension and adherent 
culture of mammalian cells. It is a modification of MEM, containing non-essential 
amino acids, sodium pyruvate, lipoic acid, vitamin B12, biotin, and ascorbic acid. In 
addition, the used formulation contained L-glutamine. MEM α was supplemented with 
1% penicillin/streptomycin, 1% L-glutamine, and 10% HI-FCS. 
 
2.1.7 Dulbecco’s Modified Eagle Medium  
Dulbecco’s Modified Eagle Medium (DMEM) is a medium broadly suitable for the 
culture of adherent cells. The Gibco formulation, used for this work, contained high 




factors. For cell culture, the medium was supplemented with 10% HI-FCS 1% 
penicillin-streptomycin, 1% L-glutamine, and 1% Fungizone (Gibco). 
 
2.1.8 RF-10 
RF-10 was prepared from Roswell Park Memorial Institute (RPMI) 1640 medium 
(Sigma), with the addition of 10% FCS, 1% penicillin-streptomycin, and 1% L-
glutamine. RPMI 1640 medium is suitable for a variety of mammalian cells and 
contains biotin, vitamin B12, para-aminobenzoic acid, inositol and choline. 
 
2.1.9 RNA Lysis Buffers 
RNA Lysis Buffers RLT and RLT plus (QIAGEN) are used for cell lysis prior to RNA 
isolation. RLT buffer contains a high concentration of guanidine isothiocycanate, 
which supports the binding of RNA to the silica membrane in the spin columns used 
for RNA extraction. RLT plus has the same composition, supplemented with a 
proprietary blend of detergents. 1% ß-mercaptoethanol (Sigma) was added to both 
buffers before use in order to effectively inactivate RNAses in the cell lysate. 
 
2.1.10 Freezing solution 
Freezing solution was prepared from 90% HI-FCS (Gibco) and 10% dimethyl 
sulfoxide (NBS Biologicals), which acts as a cryoprotectant. 
 
2.1.11 NanoString nCounter reagents 
The NanoString nCounter kits for gene expression assays are composed of 
CodeSets and a master kit. The CodeSets are shipped in two separate vials with 
reporter and capture probes. The nCounter master kits contain a sodium chloride-
based hybridisation buffer, prep plates, cartridges, and all plastics necessary for the 
assay. 
 
2.2 Cell lines 
2.2.1 OP9 and OP9-DL1 cell lines 
OP9 is a cell line derived from Csf1-/- murine bone marrow stromal cells. The cells 
are adherent and have a fibroblastic appearance. Due to their hematopoietic 
supportive capacity, OP9 can be used as a feeder layer to co-culture stem cells and 




unable to produce M-CSF, as they are derived from the Csf1 knockout “osteopetrotic” 
mouse (hence OP). OP9 cell lines transduced with retroviruses encoding green 
fluorescent protein (GFP) or Notch ligand DL1 (referred to as OP9-DL1 cells) were 
obtained from Juan Carlos Zúñiga-Pflücker and the Sunnybrook Research Institute. 
 
2.2.1 HEK 293T cell line 
HEK 239T is a cell line derived from human embryonic kidney cells. The cells are 
adherent and have an epithelial morphology. The cell line is an altered version of the 
HEK 293 cell line, modified to express the SV40 T-antigen, in order to transiently 
maintain a high copy number of transfected plasmids that carry the SV40 origin of 
replication. HEK 239T (and its parent HEK293) are highly transfectable, making them 
suitable for gene expression, protein production, and retroviral production. HEK 239T 
cells were obtained from American Type Culture Collection. 
 
2.3 Sample collection and processing 
This work was performed in accordance with the Declaration of Helsinki. Written 
informed consent was obtained from participants or their parents. The studies 
relevant to this thesis were approved by local review board NRES Committee North 
East-Newcastle and North Tyneside: 08/H0906/72 and REC 14/NE/1136; REC 
14/NE/1212, 17/NE/0361. 
 
2.3.1 Isolation of peripheral blood and bone marrow aspirate mononuclear cells  
Prior to performing flow cytometry and FACS, as well as before cell storage, 
mononuclear cells were isolated using density centrifugation.  Blood samples, 
collected in Vacutainer EDTA tubes (BD), were diluted at a 1:1 ratio with DPBS 
(Sigma-Aldrich). Bone marrow samples were collected from excess donor material 
from clinical bone marrow transplants or excavated from femoral heads removed in 
joint replacement surgery (see next section). Cells from bone marrow donations were 
obtained by flushing the collection bags and tubes with DPBS. 
 
The blood and bone marrow cells were layered on a volume of Lymphoprep 
equivalent to approximately a quarter of that of the diluted sample in 50mL Falcon 
tubes. The tubes were spun down at room temperature for 15 minutes at 800g. The 




a Pasteur pipette and washed twice with cold DPBS for 5 minutes at 800g. An extra 
wash (7 minutes at 200g) was introduced for the blood samples in order to remove 
platelets. Cells were then washed with DPBS (5 minutes at 800g), and pelleted for 5 
minutes at 800g. 
 
2.3.2 Isolation of cells from hip femoral bone marrow 
Femoral heads were obtained from hip replacement surgery donations in sterile 
DMEM or RPMI 1640 medium. Bone marrow was extracted with bone clippers, then 
placed on a 100μm cell strainer (Corning), and washed with DPBS. BMMCs were 
extracted from the DPBS solution containing cells via the Lymphoprep density 
centrifugation. 
 
2.3.3 Cryopreservation of cells 
Cells were frozen in freezing solution, prepared as described in subsection 2.1.10. 
PBMC and BMMC were stored at a concentration of 6.6 million cells/mL in 1.5 mL 
freezing solution.  OP9 and OP9-DL1 were frozen at a concentration of 0.5 million 
cells/mL in 1 mL freezing solution. HEK 239T were frozen at a concentration of 3.3 
million cells/mL in 1.5mL freezing solution. Cells in freezing solution were stored in 
Nunc cryovials (Sigma-Aldrich), placed at -80°C, then transferred to -140°C for long-
term storage. 
 
For defrosting, vials were removed from -140°C and immediately thawed at 37°C in a 
water bath. The liquid containing the cells was then transferred in a dropwise manner 
into a 15mL Falcon tube with pre-warmed medium (RF-10 for PBMC and BMMC, 
MEM α for OP9 and OP9-DL1, and DMEM for HEK 293T). The tube was then spun 
down at room temperature for 5 minutes at 800g. The supernatant was discarded, 
and the cell pellets were resuspended in the appropriate sort/flow buffer or culture 
media. 
 
2.3.4 Cell counting 
A volume of 10μl was pipetted out the cell suspension and mixed with an equivalent 
volume of trypan blue stain for dead cells (Invitrogen). The cells were then counted 





2.3.5 Co-culture of bone marrow progenitors with OP9 and OP9-DL1 cell lines 
The OP9 and OP9-DL1 cell lines were defrosted as described in section 2.3.3 and 
seeded into 24 well plates (Corning) at a density of 25,000 cells/well in 1 mL growth 
medium or in 96 well plates at a density of 5,000/well in 200μl medium. The feeder 
layer OP9 and OP9-DL1 cells were left to settle for 4-24 hours prior to the addition of 
FACS-purified BM CD34+ progenitors at a density of 15,000 cells/ well for the 24 well 
plates and up to 3,000 cells/well for the 96 well plates. The cells were co-cultured in 
MEM α medium supplemented with 10% HI-FCS and 1% penicillin/streptomycin at 
37°C in a humidified atmosphere at 5% CO2. The medium was also supplemented 
with 20 ng/ml granulocyte-macrophage colony-stimulating factor (GM-CSF, R&D 
systems), 20ng/ml (used for pDC generation for ChIP-Seq) or 100 ng/ml (all other 
experiments) FLT3-ligand (Immunotools), and 20 ng/ml stem cell factor (SCF, 
Immunotools). Half of the volume of MEM α with the same cytokine concentration 
was replaced weekly. Microscopy images of the OP9-DL1 culture are shown in 
Appendix A. Cells were harvested on ice at day 14-21 of culture, passed through a 
50μm filter, then washed with DPBS, and stained for flow cytometric analysis or cell 
sorting.  
 
2.3.6 General flow cytometry and cell sorting 
Fresh or thawed PBMCs or BMMCs, separated by Lymphoprep density 
centrifugation, were aliquoted into flow tubes at a density of 1–3 million cells per 50μl 
of DPBS with 0.1%–2% fetal calf serum (FCS, Gibco) and 0.4% EDTA. 3-5μl of anti-
mouse IgG were added to each sample to prevent non-specific antibody binding, and 
incubated for 10 minutes at room temperature. Only fresh cells were used for bulk 
and single-cell RNA-Seq experiments. The samples were then stained with 
fluorescently-conjugated antibodies and incubated for 30 minutes at room 
temperature in the dark. Cells were washed in flow/sort buffer for 5 minutes at 500g 
and resuspended in 300-500μl flow/sort buffer. Dead cells (typically <5%) were 
excluded by staining cells with Zombie (Biolegend) amine dyes prior to staining, or 
4',6-diamidino-2-phenylindole stain (DAPI, Partec), added immediately before the 
samples were analysed.  Flow cytometry was performed with an LSRFortessa X-20 
(BD Biosciences) running BD FACSDIVA™ 8.0.1.  Cell sorting was performed using 
the FACSAria III sorter (BD Biosciences) running BD FACSDIVA™ 8.0 software. 





2.3.7 NanoString Assay 
Ex vivo or culture-generated DCs were FACS purified (> 98% purity) and lysed in 
RLT buffer containing 1% b-mercaptoethanol, at a concentration of 2,000 cells/µl. 
Samples were analysed on the NanoString nCounter FLEX platform according to 
manufacturer’s instructions. Briefly, 5µl of lysate (10,000 cells) were mixed with 
reporter probes, hybridisation buffer, and capture probes and hybridised at 65°C for 
12-30 hours. Samples were then processed on the NanoString Prep station and 
cartridges were read on the NanoString Digital Analyzer to yield a reporter code 
count (RCC) dataset. The human Immunology_V2 panel was used, supplemented 
with the following 30 genes: ASIP, DAXX, MERTK, C19orf59, DBN1, Ki67, CCL17, 
F13A1, NDRG2, CD1c, FGD6, PACSIN1, CD207, FLT3, PPM1N, CLEC10A, 
GCSAM, PRAM1, CLEC9A, GGT5, S100A12, CLNK, LPAR2, TMEM14A, COBLL1, 
LYVE1, UPK3A, CXCL5, MAFF, ZBTB46. 
 
2.4 Bioinformatic techniques and analysis pipelines 
2.4.1 Clustering and dimensionality reduction  
The majority of the datasets generated and analysed within this thesis (including flow 
and mass cytometry, NanoString, and bulk and single cell RNA-Seq) contained a 
large number of measured variables, and are considered to be high dimensional 
datasets. The data become increasingly more difficult to analyse with the number of 
dimensions, and dimensionality reduction techniques are often employed to aid the 
visual exploration and interpretation of high dimensional data. These techniques can 
be broadly classified into linear and non-linear methods.  The linear methods rely on 
a linear projection of the data on a subspace. The non-linear methods focus on 
recovering the low-dimensional surface of the underlying manifold (low-dimensional 
data embedded in higher dimensional space) that the data have been sampled from. 
 
2.4.1.1 Principal component analysis  
Principal component analysis (PCA) is linear dimensionality reduction technique. An 
orthogonal transformation of the data is performed in order to convert potentially 
correlated variables into a set of linearly uncorrelated variables called principal 
components. The new variables are ranked in order of the amount of variance 
explained, principal component 1 (PC1) explaining the most variance. The PCA 




techniques. An initial PCA step is often performed prior to running non-linear 
methods, in order to reduce noise and speed up the computation. 
 
2.4.1.2 t-distributed stochastic neighbour embedding  
tSNE is a method for data visualisation and exploration suitable for high-dimensional 
datasets (van der Maaten and Hinton, 2008). It is a non-linear dimensionality 
reduction technique, relying on the attraction/repulsion balance (Barnes-Hut 
approximation). tSNE preserves the local structure of the data, and is able to identify 
patterns and clusters in the data. However, the distances between the clusters and 
their density are not meaningful. 
 
2.4.1.3 Diffusion maps 
Diffusion maps are a non-linear technique, based on a distance metric, known as 
diffusion distance. Diffusion maps are able to preserve the developmental continuum 
and can be used to infer cell trajectories. Formulations adapted especially for single 
cell data analysis have been developed (Haghverdi et al., 2015).  
 
2.4.1.4 Hierarchical clustering 
Clustering represents the task of grouping a set of data into clusters. As a result, data 
objects similar to one another are placed within the same cluster, and dissimilar to 
the objects are placed in other clusters. Hierarchical clustering, also known as 
connectivity clustering, is based on connecting the data objects to form clusters 
based on their distance. Clustering results are often represented as dendrograms. 
Strategies for clustering include the bottom-up and top-down approaches. The 
bottom-up approach, also known as agglomerative, starts with single data objects 
and aggregates them into clusters. The top-down, divisive, approach, starts with the 
complete dataset and divides it into partitions. In addition, the clustering methods 
differ by the way the distance is computed. Examples of distance calculation 
methods include single, complete, average, and Ward linkage.  
 
2.4.2 Analysis of transcriptomic data 
Common steps in all used transcriptomic pipelines include quality control (QC) and 
normalisation. Crucial QC steps are read QC (for sequencing data), as well as 




identify and remove poor quality samples/cells, often behaving as outliers in the 
dataset. Gene QC filters out genes with low expression that do not hold any useful 
information. Normalisation aims to make the levels of gene expression across the 
samples directly comparable. Raw data are adjusted for factors that prevent this, 
such as technical variability, differences in input material, and variations in library 
size (for sequencing data). Depending on the type of data, normalisation is 
performed based on library size, distribution, and/or controls. Control methods 
include housekeeping genes and normalisation with ERCC spike-ins (Evans et al., 
2018).  
 
To discover differences in expression levels between experimental groups, 
differential gene expression testing is often employed to perform statistical analysis 
on normalised gene counts. Statistical testing is used to confirm whether differences 
in the expression of certain genes are significant enough to not be attributed to 
random variation. A variety of methods for differential gene expression testing exist, 
appropriate for certain types of data and experimental design.  
 
Gene Set Enrichment Analysis (GSEA) is an analytical method commonly applied to 
transcriptomic data. It determines whether a selected set of genes shows correlation 
with a biological state, in a pairwise comparison manner (Subramanian et al., 2005). 
Bubble GUM (GSEA Unlimited Map), a computational tool based on GSEA, allows to 
automatically extract gene signatures based on transcriptomic data by performing 
multiple GSEA runs in a row (Spinelli et al, 2015).  
 
2.4.3 Analysis of ChIP-Seq data 
The ChIP-Seq analysis pipelines commonly include read QC and alignment to the 
reference genome, followed by filtering of the alignment file to remove PCR 
duplicates and reads with poor alignment quality. A typical processing step for ChIP-
Seq data is peak calling, executed in order to identify the binding sites of the DNA-
binding protein of interest. This is commonly performed against a similarly processed 
reference sample prepared from appropriate control chromatin or a control 
immunoprecipitation (Landt et al., 2010). Peak calls are then compared between 
biological groups, as well as within groups. Peaks are annotated, and further 
analyses often revolve around the functional enrichment analysis of the genes that 




Chapter 3. Transcriptional identity of DCs generated in culture 
 
Questions answered in Chapter 3: 
1. How can human bona fide DCs be generated in vitro? 
2. Is it possible to produce sufficient cDC1s for research applications and therapeutic 
approaches in culture? 
3. Do the culture-derived cDC1s resemble peripheral blood and/or tissue DCs? 
 
3.1. Introduction 
The ability of DCs to initiate and regulate immune responses has made them prime 
candidates for use in immunotherapy and vaccination. Nevertheless, DCs, and 
cDC1s in particular, remain relatively inaccessible for therapeutic use, as well as 
research, due to their rarity in vivo (5,000 pDCs, 4,000 cDC2s, and 500 cDC1s per 
mL of peripheral blood). Due to the relative abundance of peripheral blood 
monocytes, DC research and therapeutics have largely focused on in vitro monocyte-
derived DCs. However, natural DCs show functional specialisation, while the role of 
the inflammatory, monocyte-derived DCs is not well understood. The ability to 
generate functional human DCs in vitro, in a scalable system, could facilitate 
translational studies to exploit their therapeutic benefit.  
 
Common methods for producing DCs in culture include culture of haematopoietic 
stem cells and progenitors from bone marrow with the addition of GM-CSF, a 
cytokine known to stimulate stem cells to differentiate into granulocytes and 
monocytes. The culture output in these conditions is skewed toward macrophages 
and cDC2-like cells in mouse (Helft et al., 2015). Supplementation of murine BM with 
the ligand for the cytokine receptor Flt3 was shown to yield pDCs and cDC2s in 
culture (Naik et al., 2005). However, the produced cDC1s did not express the 
appropriate phenotypic markers and were likely immature (Kirkling and Cytlak et al., 
2018). 
 
In human, co-culture of HSCs and progenitor cells from cord blood, with a mix of 
cytokines, including FLT3L and SCF, produced DCs with the appropriate expression 
profile and function, after an initial progenitor expansion step (Balan et al., 2014). Lee 
et al. (2015) identified that all three major human DC subtypes can be produced 




the presence of cytokines SCF, FLT3L, and GM-CSF. However, the proportion of 
generated cDC1s under these conditions was low. 
 
Stromal cell lines producing M-CSF have been shown to induce the differentiation of 
embryonic stem cells down the monocyte-macrophage route (Nakano et al., 1994). 
The use of a stromal cell line with no M-CSF expression could have the potential to 
improve the DC culture output. One such cell line is OP9. It was established from 
stromal cells derived from a mouse with an M-CSF mutation (Csf1-/-), resulting in the 
lack of functional M-CSF expression. This enables the OP9 stromal cells to promote 
differentiation of progenitors into haematopoietic lineages other than monocytes and 
macrophages, such as the erythroid, myeloid and lymphoid lineages (reviewed by 
Trakarnsanga et al., 2018). 
 
In mouse, Notch2 deficiency results in reduction of splenic CD8+ cDC1s (Lewis et al., 
2011). It was therefore hypothesized that Notch signaling could improve human 
cDC1 differentiation in vitro. To optimise DC production, the differentiation of DCs 
from human CD34+ progenitor cells was studied in liquid media, on the OP9 stromal 
layer or with OP9 expressing Notch ligand DLL1 (OP9-DL1), supplemented with 
FLT3L, SCF and GM-CSF (FSGM cocktail) (Figure 3.1). The transcriptomic profile 
and the surface markers of the in vitro generated DC subsets and their ex vivo 













Figure 3.1. Schematic of the culture conditions used for experiments in 
Chapter 3. 
A range of culture conditions were interrogated in order to investigate human DC 
development. Bone marrow-derived CD34+ progenitors were placed in culture media 
supplemented with a mix of cytokines (FSGM) and in co-culture with the OP9 or 
OP9-DL1 feeder layers with the addition of the cytokine mix. 
FSGM – growth medium supplemented with FLT3 ligand (100ng/ml), SCF (20ng/ml) 
















3.2. Materials and methods 
3.2.1. Co-culture of bone marrow progenitors with OP9 and OP9-DL1 cells 
The OP9 and OP9-DL1 cell lines were defrosted as described in Chapter 2 
subsection 2.3.3 and cultured in 96 well plates as described in Chapter 2 subsection 
2.3.5 by Dr Urszula Cytlak. 
 
3.2.2. Flow cytometry and cell sorting 
Flow cytometry and fluorescence-activated cell sorting were performed by Dr Urszula 
Cytlak as described in Chapter 2 subsection 2.2.6, using the flow panel outlined in 
Table 3.1. 
 
Table 3.1. Antibodies used for flow cytometry and cell sorting.  
For each antibody, the table lists the target antigen, the conjugated fluorochrome, the 
clone, and the manufacturer.  
 
Antigen Fluorochrome Clone Manufacturer 
CD11c BV421/AF700/BV711 B-ly6 BD 
CD123 PerCP-Cy5.5/BUV395 7G3 BD 
CD14 BV650 M5E2 Biolegend 
CD141 APC/BV510 AD5-14H12/1A4 Miltenyi/BD 
CD16 FITC 3G8 BD/Biolegend 
CD19 FITC 4G7 BD 
CD1c PE-Cy7/PERCPCy5.5 L161 Biolegend 
CD2 PE RPA-2.10 BD 
CD20 FITC L27 BD 
CD3 FITC SK7(Leu4) BD 
CD303 APC/BV605 201A Biolegend 
CD304 APC/BV605 12C2/U21-1283 Biolegend/BD 
CD33 BV711 WM53 Biolegend 
CD34 BV605/APCCy7 581 Biolegend 
CD45 AF700 HI30 Biolegend 
CD5 BUV730 UCHT2 BD 
CD7 FITC M-T701 BD 




3.2.3. NanoString gene expression assay 
The NanoString assay was performed as described in Chapter 2 subsection 2.3.7. 
Counts were normalised within the nSolver 3.0 software (NanoString Technologies). 
Samples marked with a QC flag by the nSolver software were removed from 
analysis.  Data were normalised in nSolver advanced analysis module version 1.1.4. 
The module uses the geNorm algorithm to select the best housekeeping genes, 
which are used for normalisation. The log2 transformed normalised output data were 
analysed using R version 3.6.0 (R Core Team, 2019).  
 
Heatmaps and hierarchical clustering of primary DCs or DCs cultured on OP9 or 
OP9-DL1 were performed based on subset specific surface antigen, TLRs and TFs, 
as well as chemokine receptor gene expression using the “heatmap.2” function from 
the pheatmap R package version 1.0.12. 
 
For further analysis, genes that were not expressed at a detectable level and did not 
reach normalised log2 expression values of at least 4 in at least one third of the 
samples were removed from analysis (235 out total 608 endogenous genes were 
filtered out).  
 
A culture signature was derived by performing pairwise comparisons (two-tailed t-test 
with Benjamini-Hochberg correction of p-values) of all culture versus all ex vivo 
populations. The results of the differential gene expression testing were displayed as 
a volcano plot using the EnhancedVolcano version 1.2.0 package in R (Blighe, 
2019). Genes with adjusted p-values < 0.05 (the “culture signature”) were excluded 
(95 out of the 373 expressed genes were removed) and the remaining 278 genes 
were used to construct the combined ex vivo and culture-derived cell PCA plot 
(Figure 3.5 B). For comparison, PCA plot was also constructed using all 608 assayed 
genes (Figure 3.5 A). Principal component analysis was performed using the 
"prcomp" function within the stats package version 3.6.0 and visualised using the 
ggbiplot package version 0.55. 
 
The culture signature was split into genes with higher expression in blood (32/95 
genes) and in culture-derived populations (63/95 genes), according to the fold 
changes in mean expression between the two conditions. The hypergeometric test 




2.50.0 was employed to evaluate the overrepresentation for Gene Ontology (GO) 
terms in culture signature genes with higher expression in blood and in culture. Prior 
to being used in the hypergeometric test, the gene symbols were converted into 
Entrez Gene IDs with the “translate” function within the AnnotationFuncs package 
version 1.34.0. The hypergeometric overrepresentation test was carried out for the 
GO Biological Processes (BP) category using the two converted gene sets as input. 
The 608 genes assayed by NanoString gene expression panel were specified as the 
gene universe. The adjusted p-value cut-off was set at 0.05. The p-values and the 
OddsRatio statistics for the GO BP terms with more that 5 observed genes counts 
were visualised as a bar chart with the ggplot2 package version 3.2.1 (Wickham, 
2016). 
 
3.2.4. Bulk RNA-Seq 
Ex vivo or culture-generated DCs were FACS purified (> 98% purity) and lysed in 
RLT buffer containing 1% b-mercaptoethanol. RNA was extracted using the QIAGEN 
RNeasy Mini Kit. The RNA was quantified with the Qubit RNA HS Assay Kit and 
diluted to 5ng in 10µl. The SMART-Seq v4 protocol was used for cDNA synthesis. 
Sequencing libraries were prepared with the Nextera XT library prep kit. The Illumina 
NextSeq 500 platform was employed to generate 75bp paired-end reads. Library 
preparation and sequencing were performed by the Genomics Core Facility, 
Newcastle University. 
 
Reads were trimmed based on quality with Trimmomatic v 0.36 (Bolger et al., 2014). 
Bases with quality scores below Q20 (inferred base cell accuracy below 99%) were 
trimmed and reads shorter than 50bp were dropped. The remaining reads were 
aligned with the STAR mapping algorithm v 2.4.0 (Dobin and Gingeras, 2015) to the 
human reference genome version GRCh38.p7 (GENCODE release 25). The files 
were converted from SAM format to the more compressed BAM format with 
SAMtools v 1.3 (Li et al., 2009). The count tables were obtained using HTSEQ v 
0.6.1 (Anders et al., 2015). ENSEMBL IDs were converted to HGNC gene names 
using biomaRt v 2.30.0 (Durinck et al., 2015).  
 
Further analyses of the data were undertaken in R v 3.6.0 and Rstudio v 1.0.143. 
15,081 protein coding genes with over 50 reads in total were retained for the 




normalisation. The top 1,000 genes with highest variance across the samples were 
selected for the PCA, performed using the "prcomp" function within the stats package 
version 3.6.0 and visualised using the ggbiplot package version 0.55. 
 
To cluster the samples by similarly, the regularised-logarithm transformation was 
applied to the data. The Euclidean distances between the samples were then 
calculated, and used as input for the hierarchical clustering with the complete linkage 
method. The results were displayed as a heatmap with the pheatmap R package 
version 1.0.12 (Kolde, 2019).  
 
The blood and tissue cDC1 signatures were computed via the BubbleGUM software. 
The peripheral blood (4,957 genes) and tissue (8,086 genes) signatures were used 
as input for the single sample Gene Set Enrichment Analysis (ssGSEA), along with 
the normalised gene expression values for cDC1s from all 5 sources. The enrichment 
scores were displayed as a dot plot. 
 
The hypergeometric test for association of categories and genes within the Catergory 
R package version 2.50.0 was employed to evaluate the overrepresentation for Gene 
Ontology terms in the blood and tissue cDC1 signatures. Prior to being used in the 
hypergeometric test, the gene symbols were converted into Entrez Gene IDs with the 
“translate” function within the AnnotationFuncs package version 1.34.0. 
 
3.3. Results 
3.3.1. Culture output phenotyping and cell enumeration 
To optimise the DC production in vitro, human CD34+ progenitors were FACS-purified 
and placed in culture under 3 different conditions: (1) liquid culture containing growth 
medium supplemented with the cytokine mix FSGM, consisting of FLT3 ligand 
(100ng/ml), SCF (20ng/ml) and GM-CSF (20ng/ml), (2) co-culture with stromal cell 
line OP9, supplemented with FSGM, and 3) co-culture with OP9-DL1 with the 
addition of FSGM.  
 
The phenotype of the cells produced at 14 days of culture was assessed using flow 
cytometry and compared to that of peripheral blood DCs and CD14+ monocytes 




corresponding to blood DCs and monocytes, and were gated in a similar manner. 
The surface markers were expressed appropriately, classical monocytes showing 
high CD14 and CD11c expression, cDC1s were marked by CD141 and CLEC9A, 
cDC2s – by CD1c and CD11c, and pDCs – by CD123 and CD303/304.  Most of the 
APCs, distinguished by high HLA-DR expression, were represented by classical 
monocytes in blood, as well as in liquid culture. The APC gate contained significantly 
lower proportions of classical monocytes in co-culture with feeder layers OP9 and 
OP9-DL1. 
 
The culture output was normalised per input progenitor placed in culture to directly 
compare the efficiency of generating each of the DC subsets under different 
conditions (Figure 3.3). The culture in the liquid medium with FSGM supported only a 
minor expansion of the DC subsets, creating a small proportion of cDC2-like cells, 
and no pDCs or cDC1s were observed. The addition of the OP9 feeder layer saw an 
increase in DC output, the majority of DCs produced still being cDC2s, with little 
pDCs and cDC1s generated. The incorporation of Notch ligand DLL1 in the co-
culture with the use of OP9 cells resulted in the selective expansion of cDC1, with an 










Figure 3.2. Analysis of primary peripheral blood and in vitro-derived cells via 
flow cytometry (Dr Urszula Cytlak and Dr Venetia Bigley). 
Sorted CD34+ progenitor cells purified from human BM were cultured for 14 days in 
liquid culture in the presence of the cytokine cocktail FSGM and on monolayers of 
OP9 or OP9-DL1 cells supplemented with the same cytokine mix. Single, live, and 
CD45+ cells were gated for the analysis of the culture output. Bivariate flow plots 
show expression of cell markers: HLA-DR for APCs, CD14 and CD11c for classical 
monocytes, CD141 and CLEC9A for cDC1, CD1c and CD11c for cDC2, and CD123 
and CD303/304 for pDC. Lineage markers include B, T and NK cell markers CD3, 

















Figure 3.3. The number of output DCs generated per input progenitor cell in 
culture media supplemented with a mix of cytokines (FSGM) and in co-culture 
with the OP9 or OP9-DL1 feeder layers (Kirkling and Cytlak et al., 2018).  
Data points represent values in 14 days BM cultures from different donors (n=4 for 
FSGM, 8 for OP9, and 7 for OP9-DL1); bars represent mean with SEM. Indicated p-
values were derived by unpaired two-tailed Student’s t-test conducted on cDC1 















3.3.2. Confirmation of cultured cell identities via NanoString analysis 
Having identified a culture system able to enrich the output in cDC1s and generate all 
DCs subsets with a seemingly appropriate phenotype, transcriptomic approaches 
were sought to validate the identities of the produced cells. The NanoString gene 
expression assay was selected for this analysis, as it provides robust measurements 
of gene expression from low input material and requires no amplification steps. 
 
All 3 DC subsets from peripheral blood and OP9, along with cDC1s derived from 
OP9-DL1 were subjected to NanoString analysis using the NanoString pre-built 
human Immunology V2 panel. The panel contains 578 immunology-related genes 
and 15 housekeeping genes, and was supplemented with 30 DC-related genes.  
 
To confirm the transcriptomic identity of the cells generated in culture, the expression 
of DC subset-specific genes and chemokine receptors was compared between the 
ex vivo-derived and cultured cells. All culture-derived cells resembled their ex vivo 
counterparts, and clustered closely with them based on the expression of DC subset-
specific genes (hierarchical clustering displayed as a dendrogram above the 
heatmap in Figure 3.4 A). Crucially, genes encoding subset-specific transcription 
factors, surface markers, and TLRs were expressed faithfully.  The marker genes 
included CLEC9A, XCR1, IRF8, BATF3, and TLR3 in cDC1s, CD1C, CD2, IRF4, 
TLR2, TLR8 in cDC2, and IRF8, IRF4, TLR7, TLR9 in pDCs (Figure 3.4 A). Higher 
CD1C expression was noted on the culture-derived cDC1s. Likewise, the expression 
of chemokine receptors was split by subset (Figure 3.4 B), however a higher 









Figure 3.4. Heatmaps of DC subset-specific genes encoding surface markers, 
transcription factors, and TLRs (A) and chemokine receptors (B), as 
determined by NanoString nCounter analysis. 
The dendrograms above the heatmaps represent hierarchical clustering based on the 
log2 gene expression of the listed genes. 
 
Next, principal component analysis was employed to obtain a summary of the 
dataset. In this analysis, all cultured subsets were shifted in a similar direction and by 
a similar distance both on PC1 and PC2 in relation to their ex vivo counterparts, 
implying that a particular set of genes, conserved between all DC subsets, was 
differentially expressed in all blood versus all cultured samples (Figure 3.5 A). 
Removing this set of differentially expressed genes, also referred to as “culture 
signature”, resulted with the perfect alignment of primary and in vitro-generated 
subsets, PC1 splitting cDCs from pDCs, and PC2 splitting cDC1s and cDC2s, 
irrespective of their source (Figure 3.5 B). Notably, both cDC1s generated on OP9 







Figure 3.5. Principal component analysis of mRNA expression from FACS-
purified primary and in vitro-derived DC subsets using the NanoString Human 
Immunology V2 panel plus 30 custom DC-related genes. 
A. PCA performed based on all 608 genes assayed by the NanoString panel. 
B. Analysis based on the expression of 278 genes, performed after the removal of 
genes with low expression (235/608) and of a “culture signature” (95/608) derived by 
pairwise comparison of all culture-generated versus all primary cells via a two-tailed 










Further investigation of the culture signature revealed that it contained 95 genes, 32 
of which had higher expression in blood DCs, and 63 were expressed higher in 
culture.  
 
Among the culture signature components with higher expression in culture (Figure 
3.6) were genes encoding the complement subunits C1QA and C1QB, costimulatory 
molecules CD80 and CD276, chemokines CXCL12, CCL17, and CCL22, 
transmembrane protein CD1A, highly expressed in tissue DCs, dendritic cell 
lysosomal associated membrane glycoprotein LAMP3, phosphatase DUSP4, 
associated with the negative regulation of the cellular proliferation and differentiation, 
as well as LAG3, a protein involved in the maturation and activation of dendritic cells 
(Andreae et al., 2002).  
 
The top genes with higher expression in blood included PRAM1, expressed during 
normal myelopoiesis (National Centre for Biotechnology Information, 
https://www.ncbi.nlm.nih.gov/) and the receptor for granulocyte colony-stimulating 
factor CSF3R (Figure 3.6). 
 
In order to gain functional insight into the lists of differentially expressed genes, an 
overrepresentation test for Gene Ontology terms from the Biological Processes 
category was performed for both gene sets (Figure 3.7). The set of genes with higher 
expression in culture was enriched in GO terms relating to the regulation of 
apoptosis, response to DNA damage, metabolism, cell cycle, and cell growth. The 
biological processes significantly overrepresented in blood included actin 






Figure 3.6. Differential gene expression analysis between all culture-derived 
versus all blood DC subsets, as determined by NanoString nCounter analysis. 
Genes with higher expression in culture are shown on the right, and genes with 
higher expression in blood are displayed on the left. The volcano plot displays the 
log2 fold change and the log10 adjusted p-values obtained via a paired t-test with 
Benjamini-Hochberg correction. Names are shown for top differently expressed 
genes with adjusted p-values below 0.05 and log2 fold change above 1 and below -1 
(equivalent to linear fold change of 2 and 0.5, respectively). All genes passing the 












Figure 3.7. Bar chart depicting the overrepresentation of Gene Ontology terms 
among the culture signature genes with higher expression in blood and in 
culture, as determined by NanoString nCounter analysis. 
The significantly overrepresented GO Biological Processes (p value< 0.05) are 
displayed on the y axis. The x axis and the length of the bars correspond to the 
OddsRatio, derived from the observed and expected gene counts for each GO term. 
The OddsRatio values increase toward the right for terms overrepresented in culture, 
and toward the left for terms overrepresented in blood. The bars are coloured 
according to the p-values resulting from the hypergeometric test for over or under-





The presence of marker CD1A as a top differentially expressed gene with higher 
expression in culture compared to blood suggested that the transcriptome of cultured 
cells could more closely resemble tissue than blood DCs. Typically, CD1A is 
abundantly expressed by LCs (reviewed by Brigl and Brenner, 2004), as well as by 
dermal and other tissue DCs (Haniffa et al., 2012).  
 
3.3.3. Transcriptome analysis of cDC1s from blood, tissue, and culture 
To analyse the relationship between culture-derived cDC1s, grown with OP9 and 
OP9-DL1, and their ex vivo counterparts from human spleen, bone marrow, and 
peripheral blood at the whole transcriptome level, bulk RNA-Seq was undertaken. 
PCA, performed using top 1,000 variable genes showed 3 separate clusters that 
contained; (1) PB cDC1s, (2) spleen and bone marrow cells, and (3) culture-derived 
cells (Figure 3.8). Akin to the NanoString analysis, the cDC1s cultured with OP9 and 
OP9-DL1 clustered very closely.  
 
Next, hierarchical clustering was employed to further assess the overall similarity 
between the cultured and ex vivo-derived cDC1s (Figure 3.9). The initial division of 
the populations in the clustering hierarchy was between all culture derived cells (OP9 
and OP9-DL1) and all ex vivo cells, suggestive of the presence of a set of genes 
specific to cultured cells. Peripheral blood cDC1s were the most dissimilar ex vivo 
compartment to the cultured cells. Interestingly, both the PCA and the clustering 
analyses showed no significant differences between the spleen and BM cDC1s. 










Figure 3.8. Principal component analysis of primary cDC1s from peripheral 
blood (PB), bone marrow (BM), and spleen, and cDC1s co-cultured with OP9 
and OP9-DL1, as determined by bulk RNA-Seq. 

















Figure 3.9. Heatmap and clustering of primary cDC1s from peripheral blood 
(PB), bone marrow (BM), and spleen, and cDC1s co-cultured with OP9 and 
OP9-DL1, as determined by bulk RNA-Seq. 
The colours of the heatmap represent Euclidean distances between the samples, the 
dark blue indicating similarity and lighter blue showing dissimilarity between the 
samples. The mirrored dendrogram depicts the hierarchical clustering using the 
complete linkage method based on the Euclidean distances.  
 
In order to further investigate whether the cultured cells aligned more closely with 
peripheral blood or with spleen and bone marrow cDC1s, the blood and tissue 
signatures from the RNA-Seq dataset were computed via the BubbleGUM software. 
The enrichment scores for the two signatures were theen calculated using the single 
sample Gene Set Enrichment Analysis (ssGSEA) method (Figures 3.10 A and B). As 
expected, the peripheral blood samples had the highest “blood signature” scores, 
while both groups of ex vivo-derived cells had high scores for the “tissue signature”. 
Keeping with their previously observed similarity to tissue cells, culture-derived 
populations were similarly enriched for the “tissue signature” genes. The blood 





Figure 3.10. Enrichment scores of gene signatures across primary cDC1s from 
peripheral blood (PB), bone marrow (BM), and spleen, and cDC1s co-cultured 
with OP9 and OP9-DL1, as determined by bulk RNA-Seq. 
The gene signatures for peripheral blood (A) and tissues (B), derived using the 
BubbleGUM software (Spinelli et al., 2015), were used as input for the ssGSEA 





A Blood signature 




Next, the tissue and blood signatures were explored with an overrepresentation test 
for Gene Ontology terms (Figure 3.11). The tissue signature was enriched in terms 
relating to metabolism, response to DNA damage, cell cycle and division, as well as 
in mitochondrial gene expression. A large proportion of the GO terms overlapped 
with the terms enriched in culture, as determined by the NanoString analysis (Figure 
3.7). The GO terms overrepresented in the peripheral blood cDC1s centred around 
leukocyte activation, immune processes, localisation, transport and exocytosis. A 
fraction of these terms was also observed in the list of terms enriched in blood 









Figure 3.11. Bar chart depicting the overrepresentation of Gene Ontology terms 
among the BubbleGUM signatures for the blood cDC1s and tissue cDC1s, as 
determined by bulk RNA-Seq. 
The top 40 significantly overrepresented GO Biological Process are displayed on the 
y axis. The x axis and the length of the bars correspond to the OddsRatio, derived 
from the observed and expected gene counts for each GO term. The OddsRatio 
values increase toward the right for terms overrepresented in tissue. The OddsRatio 
values increase toward the left for terms overrepresented in blood and are denoted 
with a negative sign. The bars are coloured according to the p-values resulting from 
the hypergeometric test for over or under-representation of each Biological Process 






3.4.1. The production of human DC subsets in vitro 
To address the requirement of large-scale DC production techniques, a method 
enabling the generation of all DC subsets in culture has been developed in the 
Human Dendritic Cell laboratory. The OP9 culture system is able to produce large 
numbers of cDC1s, cDC2s, and pDCs, in proportions of similar to those seen in 
peripheral blood and bone marrow. Together with the cytokines FLT3L, SCF, and 
GM-CSF, the OP9 feeder layer facilitates cell proliferation and differentiation in vitro, 
without the requirement for a progenitor expansion step, used in the past for DC 
production (Naik et al., 2005). Evidence that OP9 support CD34+ cells comes from 
previous experiments which were able to create CD34+ progenitors from human 
embryonic stem cells in co-culture with OP9 (Vodyanik et al., 2005). In these 
experiments, the OP9 cell line proved to be superior at growing progenitors to other 
murine stromal cell lines, such as MS5. This could be attributed to the fact that OP9 
lack M-CSF expression, which inhibits the differentiation of progenitors into 
haematopoietic cells and drives the development of the monocyte/macrophage 
lineage (Nakano et al., 1994).  
 
3.4.2. Confirmation of culture-derived cell identity 
The authenticity of cDC1s, cDC2s, and pDCs produced in co-culture with OP9 and 
OP9-DL1 (for cDC1s) was verified via both proteomic and transcriptomic 
approaches, including gene expression analysis on the NanoString platform and 
surface phenotype analysis using flow cytometry.  
 
The NanoString assay was used to investigate the expression of 578 immunology-
related genes and that of 30 DC-related genes. All DC subsets faithfully expressed 
subset-specific transcription factors, surface markers, and TLRs, previously reported 
as DC markers in literature (Bigley, et al., 2016; Collin and Bigley, 2018; Schlitzer et 
al., 2018). Both peripheral blood and culture-derived cDC1s expressed high levels of 
key markers including CLEC9A, XCR1, IRF8, BATF3, and TLR3. cDC2s were 
marked with CD1C, CD2, IRF4, TLR2, and TLR8, and pDCs exhibited appropriate 
expression of IRF8, IRF4, TLR7, TLR9. The summary of the data based on all genes 




culture. The identification and removal of these genes from the analysis resulted in 
the perfect alignment of the DC subsets with their ex vivo counterparts. 
 
Phenotypic investigation of the OP9 and OP9-DL1-derived cells via flow cytometry 
aligned them closely with their ex vivo counterparts from peripheral blood, showing 
that the cultured and the primary cells occupied the same phenotypic spaces when 
defined by at least two subset-specific surface markers. The gates were determined 
based on the ex vivo populations, with the exception of the APC gate, marked by 
high HLA-DR and low lineage marker expression. The APC gate had to be adjusted 
for the cultured samples, as unlike the peripheral blood, they contained no lineage 
positive cells. This suggests that culture system does not support the growth of cell 
types with lineage markers, such as non-classical monocytes, and B, T, and NK 
cells. Co-expression of two established markers was used to identify each of the DC 
subsets and the classical monocytes. This practice is highly recommended for flow 
cytometry analysis, as using several antibodies coupled with different fluorochromes 
generally improves the reliability of the data.  
 
In addition, the functional integrity of the culture-derived DCs was confirmed via 
assays performed by members of the group showed appropriate cytokine production 
in response to TLR stimulation by culture-derived cDC1s, cDC2s, and pDCs (Kirkling 
and Cytlak et. al, 2018).  
 
3.4.3. The cells produced in culture bear close transcriptional resemblance to 
tissue DCs  
As revealed by the NanoString analysis, the cultured DCs resemble the peripheral 
blood subsets based on markers defined in the literature. However, a set of genes 
was differentially expressed between all cultured versus all peripheral blood DCs (95 
genes out of 608 assayed genes). Disparities in the cell microenvironment in 
peripheral blood and culture are the likely cause of the observed differences in gene 
expression. The factors include cell interactions, soluble factors, haemodynamic 
differences, and epigenetics. 
 
The genes with higher expression in culture were linked to apoptosis, cell growth, 
and cell cycle. Complement component C1Q, upregulated in culture, has previously 




2008), which aligns with the apoptotic signature of the culture. The cultured cells are 
likely more metabolically active, divide more rapidly, and are more prone to 
apoptosis.  
 
Higher CD1C expression was noted on the culture-derived cDC1s. The elevated 
expression of this marker has previously been observed in tissue DCs (Haniffa et al., 
2012). LC marker CD1A also had higher expression in culture than in blood.  
These observations are in agreement with the cDC1 RNA-Seq analysis results, 
which show an enrichment of the “tissue signature” in the OP9 and OP9-DL1-derived 
cDC1s. Together, the NanoString and RNA-Seq analyses reveal an overlap of the 
tissue and culture signatures. This could be due to the similarity of the two 
environments, in particular the contact with stromal cells and lack of consistent shear 
forces in both the culture and the tissue settings.  
 
The peripheral blood DCs had higher expression of genes regulating actin 
cytoskeleton organisation and regulated exocytosis compared to cultured cells. As 
DCs pass through blood vessel endothelium on their journey from bone marrow into 
peripheral blood, they might involve actin rearrangement when moving through tight 
spaces. Peripheral blood, being subject to shear forces, may also require additional 
cytoskeletal activity. Furthermore, blood DCs could be in preparation to migrate 
through endothelium once more in order to enter peripheral or lymphoid tissues.  
 
The upregulation of exocytosis-regulated genes in blood can be attributed to the fact 
that DCs undergo major endocytic processes, such as phagocytosis. Large fractions 
of the plasma membrane are transferred to the cytoplasm, requiring non-secretory 
exocytosis to take place in order to compensate for the internalised volume (Cocucci 
and Meldolesi, 2013). Moreover, the blood DCs appear more activated than their 
tissue and culture counterparts. The analysis of the differentially expressed genes 
between blood and tissue (spleen and bone marrow) cDC1s, showed that the cells in 
blood are marked by the expression of genes related to leukocyte activation and 
immune responses.  
 
3.4.4. Notch signaling facilitates in vitro generation of human cDC1s 
Together, the results of the transcriptomic validation and the surface marker 




numbers of functionally proficient cDC1s with an appropriate gene expression and 
phenotype. Co-culture of human BM CD34+ progenitors with OP9 generated all DC 
subsets in similar proportions to peripheral blood, while addition of Notch Delta like 
Ligand 1 resulted in an eleven-fold increase of CLEC9A+ CD141+ cDC1 output per 
progenitor cell.  
 
The addition of Notch also improved cDC1 functionality and gene expression profile. 
Assays performed by members of the group (Kirkling and Cytlak et. al, 2018) 
demonstrated enhanced CD4 and CD8 T cell activation ability of OP9-DL1 cDC1 
compared to OP9-derived cells and similar to that of ex vivo cDC1s from peripheral 
blood in vitro.  
 
The OP9-DL1 culture system is able to produce large numbers of cDC1 in vitro, 
making them more accessible for therapeutic use and research. A 4mL bone marrow 
aspirate (equivalent to the volume taken in diagnostic procedures) typically yields 
sufficient CD34+ progenitors to generate 1.5-3 million cDC1s on OP9-DL1 in 96 well 
plates. This output is equivalent to the number of cDC1s in 3L whole blood (which 
contains approximately 500 cDC1s per mL), providing sufficient numbers of 
functional cDC1s for further biological study and translational applications. 
Furthermore, the culture is highly scalable, and large numbers of cDC1s have also 
been produced in 24 well plates and successfully used for the ChIP-Seq experiment 
in Chapter 5. The DC output per primary CD34+ stem/progenitor cell may be further 
increased with the addition of a CD34+ cell expansion step prior to DC differentiation. 
The use of moDCs in clinical trials for DC vaccines are often listed as a reason of 
failure. The use of defined, patient-derived DC subsets for next-generation DC 
vaccines could offer better vaccine functionality. cDC1s are particularly important for 
cancer vaccines, as they excel at activating critical effector cell types in antitumor 
immunity, such as cytotoxic T lymphocytes, NK cells, and NKT cells (reviewed by 
Cancel et al., 2019). In addition, cDC1s have superior cross presentation abilities in 
vivo (reviewed by Gutiérrez-Martínez et al., 2015), offering a promising prospect in 
therapy as the most potent anti-cancer DCs. 
 
3.5. Summary and further work 
Experiments undertaken as part of this chapter showed that co-culture of human 




resulting pDCs, cDC1s, and cDC2s aligned closely with their ex vivo counterparts by 
gene expression analysis and exhibited an appropriate phenotype. However, the 
proportion of generated cDC1s was low. Addition of Notch ligand DLL1 resulted in an 
eleven-fold increase of CLEC9A+ CD141+ cDC1 output per progenitor cell. The 
resulting cDC1s showed equivalent T cell stimulatory capacity to ex vivo derived cells 
in further experiments (Kirkling and Cytlak et al., 2018). Interrogation of their 
transcriptome revealed that the cells bear a striking similarity to the tissue cDC1 
compartment. The OP9-DL1 culture system addresses one major hurdle for the utility 
of human cDC1s for vaccination – the rarity of cDC1s in vivo. The system allows the 
production of sufficient numbers of cells for functional study and therapeutic 
applications (Figure 3.12). 
 
 
Figure 3.12: Schematic of OP9-DL1 co-culture process and its cDC1 output. 
Approximately 4mL of bone marrow aspirate are required for culture. Once the 
CD34+ progenitors are FACS-purified, they are co-cultured with the OP9-DL1 stromal 
cell line for 14-21 days in the presence of a cytokine cocktail. The cDC1 output of the 
culture is equivalent to the cDC1 numbers in 3 litres of whole blood. 
 
Future studies, necessary for the use of in vitro-derived DCs in therapy include 
adaptation of culture system to be Good Manufacturing Practice-compliant by 
removing animal-derived products from the culture system. The utilised animal-
derived products include the foetal calf serum, used as a supplement in culture, as 
well as the murine OP9 feeder layer itself. Initial studies will determine whether cell-
cell interactions, soluble factors or both are necessary for DC generation on OP9. For 
Notch stimulation, it is possible that the ligand signal (DLL1) could be provided by 
coating the culture vessel or beads with DLL1. In-depth proteomics of the factors 
produced by OP9 cells could help narrow down the proteins strictly necessary for DC 




contribution of autologous or haematopoietic cell derived factors may also be 
important in the generation of a mixed DC output. Practical factors will also be 
considered, including whether autologous DCs would be necessary or whether “off-



































Chapter 4. The two pathways of DC development defined by IRF8 
expression 
 
Questions to be answered in Chapter 4: 
1. Can distinct DC lineages and their precursors be identified in human bone 
marrow via single cell transcriptomics?  
2. Is there a developmental basis for the recently described heterogeneity in the 
cDC2 population? 
3. Can the developmental pathways originating in the bone marrow be linked to 
peripheral blood DC subsets?  
 
4.1 Introduction 
Human DC subsets develop in the bone marrow under the control of specific 
transcription factors, mutation of which can result in dendritic cell immunodeficiency. 
In humans, important roles are played by transcription factors IRF8 (Hambleton et al., 
2011; Bigley et al., 2018), GATA2 (Dickinson et al., 2014), and IKZF1 (Cytlak et al., 
2018). DCs can be divided into at least 3 subsets, by transcription factor requirement, 
phenotype, and function (Bigley et al., 2016). The subset specialisation in DCs 
results directly from haematopoiesis (Lee et al., 2017; See et al., 2017; Villani et al., 
2017), however, the pathways giving rise to cDC1, cDC2, and pDC in the bone 
marrow are not well mapped. 
 
DCs have an apparent “dual” lympho-myeloid origin and, during their development, 
traverse the phenotypic spaces of hematopoietic stem cells (HSC), multipotent 
progenitors (MPP), common myeloid progenitors (CMP), lymphoid-primed 
multipotent progenitors (LMPP) and granulocyte-macrophage progenitors (GMP) 
(Doulatov et al., 2010; Lee et al., 2015; Lee et al., 2017; Helft et al., 2017). The 
CD123+ region of GMP has been demonstrated to contain potential to generate 
human cDC1s, cDC2s, and pDCs (Lee et al., 2015; Helft et al., 2017). However, the 
phenotypic identities of the unipotent DC progenitors are currently unknown. 
 
Additional complexity is added by the recently described heterogeneity in the cDC2 
compartment. The bulk of cDC2s are comprised of two subpopulations, one closer in 
gene expression and function to cDC1, referred to as DC2, and the other more 




As this is a novel finding, earlier studies investigating DC development did not 
explore the source of cDC2 heterogeneity. It is currently unknown whether both 
subtypes of cDC2 arise from distinct lineage trajectories, regulated by different 
transcription factors, whether some of them are monocyte-derived, or whether they 
represent two transcriptional states of a common lineage originating from the 
CD123high GMP (Figure 4.1). 
 
 
Figure 4.1. Schematic of the development of haematopoietic lineages from 
bone marrow HSCs, illustrating the unknown phenotypic identities of the DC 
progenitors. 
During their development, the DC subsets traverse the phenotypic spaces of 
hematopoietic stem cells (HSC), multipotent progenitors (MPP), common myeloid 
progenitors (CMP), lymphoid-primed multipotent progenitors (LMPP) and 
granulocyte-macrophage progenitors (GMP). Early haematopoietic cells show high 
expression of marker CD34 (depicted in pink). As the cells develop, the CD34 
expression is gradually lost. In this work, the term “progenitor” was used for cells 
expressing marker CD34, and “precursor” - for cells with intermediate or negative 






The apparent dual myeloid and lymphoid origin of DCs may be explained by early 
lineage commitment, not detectable by analysis of a few surface antigens, as used in 
traditional progenitor cell classification by flow cytometry. The work in this chapter 
aimed to employ single cell transcriptomics and mass cytometry, combined with 
phenotyping and in vitro culture, to define distinct pathways of DC development. This 
work was undertaken in close collaboration with other members of the Human DC 
Lab. In particular, Dr Urszula Cytlak performed the in vitro culture and phenotypic 
analysis and Sarah Pagan undertook the CyTOF experiments. The majority of this 
work has been published as a joint first author manuscript in Immunity (Cytlak and 
Resteu et al., 2020). 
 
4.2 Materials and methods 
4.2.1 Contributions 
The following members of the HuDC Lab contributed to the generation and analysis 
of the data presented within this chapter:  
• Urszula Cytlak: Phenotyping analysis, cell purification and in vitro 
differentiation assays (sections 4.2.2 and 4.2.3) 
• Sarah Pagan: Antibody conjugation and cell preparation for CyTOF analysis 
(section 4.2.10) 
• Venetia Bigley: pre-processing of mass cytometry data with the FlowJo 
software (part of section 4.2.11) 
• Anastasia Resteu: visualisation of flow cytometry data to generate a 3D plot of 
antigen expression, generation and analysis of NanoString gene expression 
data, including normalisation, gene filtering, and principal component analysis 
(section 4.2.4), processing and analysis of single cell RNA-Seq data, 
specifically read QC, trimming, and alignment to the reference genome, 
counting of reads, gene and cell QC, filtering, normalisation, hierarchical 
clustering, dimensionality reduction using tSNE, lineage tracing with diffusion 
maps, and pseudotime analysis (sections 4.2.6-4.2.9), computational analysis 
of mass cytometry data, including visualisation of tSNE embeddings, lineage 





4.2.2 Co-culture of bone marrow progenitors with OP9 cells 
The culture was undertaken as described in Chapter 2 subsection 2.3.5. Briefly, 
human bone marrow CD34+ progenitors, progenitor subsets or pre-DC were FACS-
purified and placed into 96 well U-bottomed plates (Corning) with pre-seeded OP9 
stromal cells (5,000/well) in 200μl alpha-MEM (αMEM, Gibco) supplemented with 1% 
penicillin/streptomycin (Sigma), 10% FCS, 20ng/ml granulocyte-macrophage colony-
stimulating factor (GM-CSF, R&D systems), 100ng/ml Flt3-ligand (FLT3, 
Immunotools), 20ng/ml stem cell factor (SCF, Immunotools).  
 
4.2.3 Flow cytometry 
The culture output was assessed via flow cytometry, as described in Chapter 2 
subsection 2.3.6, using fluorescently-conjugated antibodies listed in Appendix B.  
 
4.2.4 Analysis of NanoString gene expression data 
The NanoString assay was performed as described in Chapter 2 subsection 2.3.7. 
Data were normalised in nSolver advanced analysis module version 1.1.4. The log2 
transformed normalised output data were analysed using R version 3.6.0 (R Core 
Team, 2019). For the peripheral blood PCA (Figure 4.3), genes that did not reach 
above–background counts (normalised log2 expression values of at least 4) in at 
least half of the samples were removed (293 out total 608 endogenous genes were 
filtered out). The remaining 315 genes were used to construct the PCA plot. Principal 
component analysis was performed using the "prcomp" function within the stats 
package version 3.6.0 and visualised using the ggbiplot package version 0.55. 
For the combined ex vivo- and culture-derived cell PCA, a culture signature was 
derived by performing pairwise comparisons (two-tailed t-test with Benjamini-
Hochberg correction of p-values) of all culture versus all ex vivo populations. 110 
genes with adjusted p values <0.05 (the ‘culture signature’) were excluded from 
further analysis. The remaining 210 genes were used to construct the PCA plot 
(Figure 4.5).  
 
4.2.5 Generation of single cell RNA-Seq data  
Single human PBMC or BMMC were index-sorted into 96 well round-bottom plates 
containing 2μl cold RNA lysis buffer (RNAse-free water, 2U/μl RNAse inhibitor and 
0.2% Triton X-100, Sigma) (BM progenitor plates) or SMARTer Dilution buffer 




and DC plates). Plates were immediately centrifugated at 500xg for 1 minute, frozen 
on dry ice then stored at -80°C. Each plate included 2 controls; one blank and one 
well containing purified mouse RNA. The reverse transcription was performed using 
an adapted Smart-seq2 protocol (Picelli et al., 2014). Briefly, modifications included 
21 PCR cycles and duplicate Ampure clean-up steps, following cDNA generation. 
The library prep was performed using the Nextera XT DNA Library Prep Kit. The 
Illumina HiSeq 4000 platform was employed to generate paired-end reads (75bp x 2).  
An average of 1.5 million reads were retrieved for each cell from the BM CD34+ 
progenitors and 2.3 million per cell for the BM CD34med precursors and DC. 
 
4.2.6 Processing of single cell RNA-Seq data  
Reads were trimmed based on quality with Trimmomatic v 0.36 (Bolger et al., 2014). 
Bases with quality scores below Q10 (inferred base cell accuracy below 90%) were 
trimmed and reads shorter than 60bp were dropped. The remaining reads were 
aligned with the STAR mapping algorithm v 2.4.0 (Dobin and Gingeras, 2015) to the 
human reference genome version GRCh38.p7 (GENCODE release 25), 
supplemented with External RNA Controls Consortium (ERCC) spike-in controls. The 
files were converted from SAM format to the more compressed BAM format with 
SAMtools v 1.3 (Li et al., 2009). The count tables were obtained using HTSEQ v 
0.6.1 (Anders et al., 2015). ENSEMBL IDs were converted to HGNC gene names 
using biomaRt v 2.30.0 (Durinck et al., 2015). 
 
4.2.7 QC and normalisation of scRNA-Seq data 
Further analysis of the data was undertaken in R v 3.3.3 and Rstudio v 1.0.143. The 
scater R package v 1.2.0 was used to perform cell and gene QC and filtering 
(McCarthy et al., 2017). To remove technical outliers with poor coverage, genes with 
less than 2 counts in at least 2 cells were filtered out. Outlier cells were further 
removed based on number of total features, total counts and percentage of counts 
derived from ERCC spike-ins and mitochondrial genes. The normalisation was 
performed with the RUVg method (Risso et al., 2014) combined with counts per 
million (CPM) adjustment for library size and log transformation [log2(CPM+1)] for all 
downstream analyses. Only the genes annotated as protein coding in the 
“gene_type” column of the GENCODE reference genome GTF file were retained. To 




the genes identified to play a role in cell cycle were downloaded from the 
supplementary materials provided by Macosko et al. (2015) and removed from all our 
analyses.  
 
4.2.8 Clustering of scRNA-Seq data 
Clustering was performed on the remaining genes using the Single-Cell Consensus 
Clustering (SC3) R package v 1.3.18 (Kiselev et al., 2017). The SC3 tool requires the 
k number of number of clusters to be specified by the user. A range of clusters (2 to 
15) were visualised and studied for each of the datasets. The output from the 
“sc3_estimate_k” function guided the minimum number of clusters to be considered 
for each of the datasets.  
  
Heatmaps with marker genes were generated with SC3. The area under the receiver 
operating characteristic curve (AUROC) and p-values assigned by a Wilcoxon signed 
rank test and corrected using the Holm method were used to define the marker 
genes (thresholds for statistics are stated in the figure legends). Clusters were 
annotated based on the top statistically significant marker genes from the SC3 
output, as well as FACS phenotype and culture output.  
 
4.2.9 Dimensionality reduction of scRNA-Seq data 
The tSNE technique for dimensionality reduction was used to visualise the clusters. 
First, SC3 gene filter was applied to further remove genes with low expression, as 
well as ubiquitously expressed genes that do not contribute to clustering. The 
remaining genes were used for tSNE analysis with the Rtsne package v 0.13. An 
initial PCA step was introduced to reduce dimensionality and eliminate noise. Top 
principal components accounting for most variance (25-35%) were retained for the 
tSNE algorithm (the number of PCs is stated in the legend for each plot). Graphics 
were generated with the ggplot2 package v 3.0.0. 
 
Diffusion maps were used to infer a pseudo-temporal ordering and reconstruct 
lineage branching. All protein coding genes that are not known to play a role in cell 
cycle were used in the diffusion map calculation with the destiny tool v 2.14.0 
(Angerer et al., 2016) in R v 3.6.0. An initial PCA step was employed to reduce noise, 




were retained for destiny. PCA was performed using the prcomp and princomp 
functions from the stats R package. Diffusion components 1-3 were used for 
trajectory tracing with slingshot v 1.2.0 (Street et al., 2018) and visualized on 3D 
plots. Graphics were generated with the rgl package v 0.100.19. 
 
4.2.10 Generation of mass cytometry data 
Pre-conjugated antibodies (Fluidigm), purified antibodies conjugated to their 
respective lanthanide metals using the Maxpar antibody labelling kit (as per 
manufacturer’s instructions; DVS Sciences) or fluorophore-conjugated primary with 
anti-fluorophore metal-conjugated secondary antibodies were used for surface or 
intracellular staining (Appendix B).  
 
Healthy control CD45+Lineage- (CD3,19,20,56,161) PBMC (3x106 cells) or BMMC 
(1.5x 106) were FACS purified into 1mL CyTOF staining buffer (PBS plus 2% FCS). 
Cell staining was performed at room temperature in a final staining volume of 100µl.  
Centrifugation was performed at 500xg for 5 minutes. ‘Barcoding’ of PBMC and 
BMMC samples was achieved by staining with 0.5ug anti-CD45-Irr115 or anti-CD45-
89Y, respectively, (30mins) in CyTOF staining buffer before washing twice in PBS. 
Barcoded PBMC and BMMC were combined before addition of 2.5μM cisplatin for 5 
minutes in PBS for live/dead cell discrimination, then washed promptly in CyTOF 
staining buffer. Successive primary and secondary surface staining was performed 
using approximately 0.5µg of each antibody in CyTOF staining buffer (30mins) before 
washing twice with PBS. The cells were fixed in 500ml eBioscience fixation buffer 
(eBioscience FoxP3 fix perm kit) with the addition of 500μl of 3.2% formaldehyde 
(final concentration 1.6%) and incubated for 30 minutes, before washing twice with 
eBioscience perm buffer. Cells were stained successively in perm buffer for 1hr each 
with intracellular primary and secondary antibodies then washed twice with PBS.  
Cells were resuspended in 500μl 250nM Irridium in PBS (final concentration 125nM) 
and 500μl 3.2% formaldehyde (final concentration 1.6%) and incubated for 1hr, 
before centrifugation and resuspension in 500μl CyTOF wash buffer for overnight 
storage at 4°C. Prior to CyTOF acquisition, cells were washed twice in 200μl MilliQ 
water (800xg for 8 minutes), counted, diluted to a maximum final concentration of 




added (10% by volume) and 1.5x106 cells were acquired on the Helios mass 
cytometer running CyTOF software v 6.7.1014. 
 
4.2.11 Mass cytometry data analysis 
Within the CyTOF software, the resultant flow cytometry file (.fcs) was normalised 
against the EQ bead signals and randomised for a uniform negative distribution. 
FlowJo software was used to deconvolute live, lineage(CD3,19,20,56)-HLA-DR+ PB 
or BM cells by manual gating. For diffusion maps and lineage tracing (Figure 4.14), 
cells were down-sampled using random sampling within FlowJo, to select a total of 
14,000 cells consisting of up to 500 or 1,000 cells per progenitor/precursor or mature 
cell population, respectively: CD33+GMP (300), CD33-GMP (200), 
CD123low/medGMP (298), CD123hi303/4low (499), CD2+pDC (490), pDC (490), early 
pre-DC2 (498), pre-DC2 (491), CD5-DC2 (498), CD5+DC2 (800), early pre-DC1 
(500), pre-DC1 (254), cDC1 (800), pre-DC3/mono (500), pre-DC3 (298), CD14-DC3 
(498), CD14+DC3 (1000), pre-mono (500), mono (999). Further analysis was 
undertaken in R version 3.6.0. Diffusion map calculation was performed with the 
destiny tool v 2.14.0 (Angerer et al., 2016) using log2-transformed values for the 
following CD markers: 14, 16, 123, 11b, 116, 303, 304, 2, 38, 10, 33, 11c, 90, 141, 
34, 88, 117, 1c, 5, 15 and CLEC9A, AXL, SIGLEC6, SIRPA, IRF4, IRF8, FCER1A, 
BTLA and FLT3. 3D graphics were produced with the rgl package v 0.100.30. 
 
For combined PB and BM progenitor, pre-DC and DC/monocyte analysis (Figure 
4.15), combined lineage-HLA-DR+ cells were down-sampled to select 75,000 cells 
consisting of 20,000 CD11b+CD14+ monocytes, 4,000 CD11b+CD16+ monocytes and 
50,000 non-monocyte cells. The concatenated .fcs file was subjected to tSNE 
dimensionality reduction with perplexity 30 from 1000 iterations using CD markers 
14, 16, 123, 11b, 116, 303, 304, 2, 38, 10, 33, 11c, 90, 141, 34, 88, 117, 1c, 5 and 
CLEC9A, AXL, SIGLEC6, SIRPA, IRF4, IRF8, FCER1A, and BTLA. tSNE plots and 
marker expression heat plots were generated in ggplot2 R package using tSNE co-







4.3.1 Evaluation of mature cDC2 heterogeneity in human blood 
cDC2 heterogeneity in human has been recently described in the literature, however, 
specific antigens for the isolation of the blood cDC2 subsets were unknown at the 
start of this project. Flow cytometry experiments undertaken by Dr Urszula Cytlak 
(Human DC Lab) identified markers able to split the cDC2 compartment in blood. The 
bulk of cDC2s were marked by high expression of CD2 and CD1c, distinct from 
CD141high cDC1s, and CD123+ and CD303/304+ pDC. The bulk of cDC2 was split 
into subsets using markers BTLA, CD5, and CD14 (Figure 4.2 A). BTLA divided the 
blood cDC2 population into BTLA+ DC2 and BTLA- DC3. BTLA+ DC2 was further split 
into CD5+ and CD5- populations, while BTLA- DC3 were subdivided into CD14+ and 
CD14- fractions. Expression of CD163 (a marker for the monocyte/macrophage 
lineage), negatively correlated with that of BTLA (Figure 4.2 B). With this is mind, the 
two cDC2 subtypes in peripheral blood were defined as CD163- BTLA+ CD5+/- DC2 
and CD163+ BTLA- CD14+/- DC3 (Figure 4.2 C) with CD5 and CD14 marking the 
poles of the phenotypic continuum. 
 
NanoString gene expression analysis of 10,000 ex vivo, FACS-sorted cDC1s, pDCs, 
cDC2s, and classical monocytes, confirmed the presence of cDC2 heterogeneity. 
Mirroring that seen in phenotypic analysis, a transcriptional continuum was evident 
with CD5+ DC2s, clustering near the cDC1s, and CD14+ DC3s, located closer to the 













Figure 4.2. Phenotyping of DC populations in human peripheral blood (Cytlak 
and Resteu, et al., 2020). 
A. Gating strategy for flow cytometry analysis. HLA-DR positive and lineage 
(CD3,16,19,20,34,7) negative cells were used for analysis. cDC2 were defined by 
CD2 and CD1c expression, distinct from CD141+ cDC1, CD123+CD303/304+ pDC 
and monocytes (mono). BTLA expression categorised DC2 (BTLA+) with (red) or 
without (pink) CD5; and DC3 (BTLA-) with (yellow) or without (orange) CD14. 
Numbers on the plots represent percentage of the parent gate. 
B. 3D plot of the expression of CD14, CD5 and BTLA across the cDC2 (CD1c+DC) 
compartment, as measured by flow cytometry. Cell colours represent CD163 antigen 
expression. 
C. Definition of cDC2 subpopulation phenotypes: CD163-CD5+/-(BTLA+ in blood) DC2 














Figure 4.3. Principal component analysis of mRNA expression from FACS- 
purified cDC1s, cDC2s (DC2 and DC3), pDCs and classical monocytes from 
peripheral blood, as determined by the NanoString assay. 
PCA was performed based on 315 genes with expression levels detectable via the 
NanoString Human Immunology V2 panel plus 30 custom DC-related genes. 
 
4.3.2 Interrogation of DC haematopoiesis in vitro 
Following the successful identification and isolation of cDC1, pDC, DC2, and DC3 in 
human peripheral blood, this project aimed to identify the developmental pathways 
giving rise to the different cDC2 subpopulations. The in vitro culture system 
described in Chapter 3 was used to interrogate the progenitors and precursors for 
their potential to generate DC subsets. Firstly, to identify DC2 and DC3 in culture 
output, the phenotyping of culture-derived DCs was performed via conventional flow 
cytometry, as for the peripheral analysis described above. Due to the lack of BTLA 
protein expression in culture, the gating strategy was adjusted (Figure 4.4). CD2 and 
CD1c defined the bulk of the cDC2s. Within this compartment, CD163 was 
exclusively expressed by CD14+ cells, while the CD5+ DC2 population was contained 
within the CD14- gate. Marker CD14 was therefore used to split cDC2s into (CD14-) 
DC2 and (CD14+) DC3. This gating was reproducible for cultured, blood and bone 
marrow cells (Figure 4.4). Akin to the cultured cells, the lack of BTLA expression was 







Figure 4.4. Gating strategy used to identify in vitro-derived DCs and monocytes 
generated from BM CD34+ progenitors, shown with blood and bone marrow 
(BM) for comparison (Dr Venetia Bigley and Dr Urszula Cytlak).  
A minimum of two antigens were used to define each of the populations: 
CD141+CLEC9A+ cDC1, CD2+CD1c+ cDC2 divided as CD14- DC2 and CD14+ DC3, 
CD123+CD303+CD304+ pDC and CD14+CD11c+CD1c- CD2- monocytes. Numbers on 
the plots represent percentage of the parent gate. 
 
 
NanoString gene expression analysis was used to confirm the identity of the culture-
derived DC2s and DC3s defined by CD14 expression. Figure 4.5 shows the joint 
analysis of the culture-derived and peripheral blood DCs and classical monocytes. All 
cultured subsets clustered close to their ex vivo equivalents. The cultured DC2 and 
DC3 subsets were more polarised towards, but remained distinct from cDC1s or 








Figure 4.5. Principal component analysis of mRNA expression from FACS- 
purified primary cDC1, cDC2 (DC2 and DC3), pDC and classical monocytes 
from human peripheral blood and in vitro culture. 
The blood subsets are displayed in darker colours and the in vitro-generated samples 
are shown in lighter colours marked with a black outline. NanoString Human 
Immunology V2 panel supplemented with 30 custom DC-related genes was 
employed to profile the gene expression. PCA was performed based on all genes 
with detectable expression after removal of a culture signature (210 remaining 
genes).  
 
Next, the culture system, able to produce bona fide cDC2 subsets, was used to 
interrogate DC haematopoiesis in vitro. Cells originating from the phenotypic spaces 
known or hypothesized to contain progenitors were FACS-purified and placed in the 
OP9 culture system. The output was assessed via flow cytometry, following 14 days 
of culture. Figure 4.6 shows a schematic of haematopoiesis, overlaid by the sampled 
phenotypic spaces and their output in culture. In culture, HSCs produced DC2s and 
DC3s at a similar ratio to that observed in blood. The DC2 potential was identifiable 
in the HSC, LMPP, CD123+ GMP, and was highest in the gate identified as pre-DC2. 
DC3 were progressively enriched through the HSC, CD33+ GMP, and the pre-DC3 




and pDCs. Despite the culture conditions being designed to inhibit monocyte 
generation, some monocyte potential was observed. This was seen in the 
populations giving rise to DC3, but most enriched in a phenotypically distinct 
precursor population giving rise primarily to monocytes. Detailed gating strategies 
and culture output results are shown in Appendix C (CD34+ progenitors) and 
Appendix D (CD34med/- precursors and DCs/monocytes). 
 
Figure 4.6. Schematic of the development of haematopoietic lineages from 
bone marrow, showing the DC and monocyte culture output of the phenotypic 
spaces as bar charts. 
The bulk culture output of FACS-purified bone marrow CD34+ progenitors was 
assessed with flow cytometry following 14 days of culture. The proportion of 
generated DC subsets and monocytes is expressed as % of the total cells captured 
by all DC and monocyte gates. n=3-9 healthy donors for each population. Bars 




4.3.3 Single cell transcriptomics of human bone marrow progenitors reveals 
two pathways of DC development distinguished by differential IRF8 expression 
The cells from the examined phenotypic spaces in healthy human BM were 
subjected to scRNA-Seq, in order to examine their transcriptomes at single cell 
resolution. The first scRNA-Seq dataset (also referred to as the “progenitor” dataset) 
contained CD34+ bone marrow progenitors. These cells were index-sorted directly 
into 96 well plates as shown in Appendix C, allowing the concurrent interrogation of 
cell-specific surface phenotype and transcriptomic analysis.  
 
Hierarchical clustering of the single cell transcriptomes alone (without considering 
surface phenotype) from the CD34+ bone marrow compartment revealed the 
presence of distinct clusters, roughly corresponding to the annotation from FACS-
guided index sorting. The clusters were annotated based on marker genes as 
determined by scRNA-Seq and related to the information from index sorting and 
culture output. HSCs and MPP were marked by vasopressin (AVP) expression, and 
were index sorted from the CD34+ CD45RA- fraction of the bone marrow. 
Megakaryocyte/erythroid progenitors (referred to as mega/erythro) were identified as 
the erythroid transcription factor GATA1-expressing cluster and were sorted as 
CD33- CMP. Early myeloid cells formed a cluster of mixed cells from CD123- CD33+ 
GMP and CD33+ CMP sort gates, marked with high MYC expression, a gene known 
to drive cell proliferation. LMPP formed a cluster made up almost exclusively of cells 
from the FACS-purified LMPP gate. The monocyte and neutrophil progenitors 
clustered closely and were both marked by myeloid cell associated genes, such as 
myeloperoxidase (MPO) and CD33 antigen expression. The monocyte progenitors, 
were distinguishable by higher lysozyme (LYZ) gene expression and were mainly 
derived from the CD123- CD33+ GMP gate, while neutrophil progenitors expressed 
neutrophil elastase (ELANE) and belonged to the CD33+ CMP sort gate. The cluster 
enriched for monocyte genes also displayed a low/medium level of IRF8 expression. 
Progenitors with in vitro cDC1, pDC, and DC2 potential, also referred to as DC 
progenitors, formed a cluster adjacent to the LMPPs. This cluster was marked with 
high IRF8 expression and contained cells from the phenotypic spaces of CD123- 
CD33low GMP, CD123low GMP, CD123med GMP.  
 
tSNE, a dimensionality reduction and clustering technique, was used to visualise the 




the FACS gates (Figure 4.8 A), or the 10 clusters produced by hierarchical clustering 
(Figure 4.8 B). Both annotations correlated with the tSNE clusters. Distinct clusters 
were noted for HSC/MPP, Mega/erythro, early myeloid cells, adjacent to the 
monocyte and neutrophil progenitors, and DC progenitors, adjacent to the LMPP 
cluster. The expression of IRF8, a top marker gene for the DC cluster (Figure 4.8 C), 
defined the DC cluster on the tSNE. The monocyte cluster displayed intermediate 
IRF8 expression, lower than that of the DC cluster, and higher than the HSC/MPPs 





















Figure 4.7. Hierarchical clustering of single cell transcriptomes of CD34+ 
progenitors isolated from BM showing marker genes that identify 10 clusters of 
all progenitors. 
The colours of the heatmap indicate normalised log2 marker gene expression, as 
determined by scRNA-Seq (p-value < 0.01, AUROC > 0.6). Antigen expression, as 
determined my FACS is displayed above the cells, along with the phenotype. 






Figure 4.8. Visualisation of single cell transcriptomes of CD34+ progenitors. 
A - C. tSNE of 262 single cell transcriptomes of CD34+ progenitor subsets annotated 
by the gate of origin from index-linked flow cytometry (A) or 10 clusters from 
hierarchical clustering (B), or displaying log2 IRF8 gene expression (C).  
D. Violin plot of differential IRF8 expression in clusters 1 (GMP33+), 5 (HSC/MPP) 
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Next, diffusion maps, together with Slingshot pseudotime were used to infer the 
developmental trajectories of the single cells (Figure 4.9 A). HSCs were located at 
the centre of the diffusion map, as they represented the earliest progenitors, common 
for all examined cell types. The cells belonging to the DC cluster formed a branch of 
the diffusion map, rooting from LMPP. The monocyte and neutrophil precursors 
formed two separate trajectories with early myeloid cells at the base. Mega/erythro 
progenitors produced a fourth developmental branch. 
 
Together, the in vitro culture experiments and the scRNA-Seq data were consistent 
with a model whereby cDC1, pDC, and DC2 develop through an IRF8high pathway, 
traversing the phenotypic spaces of LMPP and the CD123+ fraction of GMP, while 
DC3 potential segregates with monocyte potential through a different, CD33+ part of 






























Figure 4.9. 3D diffusion map and lineage tracing of 262 single cell 
transcriptomes from CD34+ progenitor subsets.  
A. Diffusion map showing clusters obtained via hierarchical clustering of the dataset. 
Top 3 diffusion components, displayed as the x, y and z axes of the 3D plot, were 
used as input for a pseudotime analysis. Developmental trajectories, inferred with the 
Slingshot R package (Street et al., 2018), are depicted in grey.  








4.3.4 IRF8high and IRF8low pathways connect bone marrow progenitors with 
mature DC subsets 
Having identified the two DC developmental pathways within the CD34+ fraction of 
the bone marrow, the analysis was extended to potential DC precursors. To achieve 
this, a second scRNA-Seq experiment was performed on CD34 intermediate or 
negative populations defined in vitro as DC precursors generating the “precursor” 
dataset (the detailed gating strategy and culture output of these populations are 
described in Appendix D). Fully differentiated bone marrow DC subsets and 
monocytes were also included. 
 
Hierarchical clustering of the transcriptomes of cells within the new dataset identified 
the presence of 15 clusters (Figure 4.10). The CD34med and mature DC clusters were 
annotated based on marker genes and related to flow cytometric phenotype and in 
vitro culture potential. The precursors defined in previous experiments clustered 
adjacent to their mature counterparts. This was observed for all lineages, apart from 
cDC1, likely due to the rarity of precursors for this population in vivo.  
 
Five clusters related to pDCs were identified: two mature pDC clusters and three pre-
DC clusters (distinguished by CD34 protein expression). All pDCs clusters displayed 
high IRF8 expression and were marked by GZMB and SERPINF1, identified as pDC 
markers by Villani et al. (2017).  
 
Two clusters, each containing a subdivision of cDC2 were observed. Both expressed 
the cDC2 marker FCER1A, along with class II MHC genes, such as HLA-DQB1 and 
HLA-DQB2. Notably, the DC2 cluster had distinguishably higher CD5 antigen 
expression. A number of early DC2 and early DC3 clusters were observed. One of 
the early pre-DC2 clusters was marked with SIGLEC6 expression, a signature gene 
for the (AXL+) AS DC or pre-DC, described by Villani et al. (2017) and See et al, 
respectively. The early pre-DC3 clusters retained MPO expression, while also 
expressing MHC Class II genes.  
 
Two monocyte-related clusters were found: a mature monocyte cluster with high 
CD14 gene expression, and a pre-mono cluster. The pre-mono cluster retained some 
MPO expression, resembling the monocyte progenitors from the CD34+ dataset 




Figure 4.10. Hierarchical clustering of single cell transcriptomes of CD14+ 
monocytes, DCs and precursors isolated from BM, showing signature genes 
that identify 15 clusters. 
The colours of the heatmap indicate normalised log2 marker gene expression, as 
determined by scRNA-Seq (p-value < 0.01, AUROC > 0.85). Antigen expression, as 





tSNE analysis of the single cell transcriptomes identified four poles, corresponding to 
pDC, cDC1, the two cDC2 subpopulations, and monocytes. This was reflected by 
both the phenotypic annotation (by flow cytometry) and the hierarchical clustering 
(Figures 4.11 A and B, respectively). The poles were linked by progenitor populations 
with preserved CD34 expression (Figure 4.12 A). The two hotspots of CD34 
expression corresponded to the early pre-DC2 and early pre-DC3 cluster populations 
defined by the in vitro experiments, as well as hierarchical clustering of the scRNA-
Seq data. The early pre-DC2s exhibited high IRF8 expression and were located in 
the proximity to the DC populations derived from the IRF8-high pathway, including 
DC2, cDC1, and pDC (Figure 4.12 B). The early pre-DC3 clustered closely to pre-
monocytes and pre-DC3 and displayed medium IRF8 levels (Figure 4.11 C).  
 
Diffusion maps, in combination with pseudotime analysis were used to reconstruct 
the developmental trajectories of the DC populations (Figure 4.13). The resulting 
diffusion map showed 4 trajectories, corresponding to pDC, cDC1, monocytes, and 
cDC2, and resembled the tSNE graph. Consistent with their independent origin, DC2 
and DC3 formed two distinct branches of the cDC2 trajectory. The lineage tracing 
with Slingshot linked early pre-DC2 to the DC2 fraction, and early pre-DC3 to the 

















Figure 4.11. tSNE of 244 single cell transcriptomes sampled from mature DCs 
and classical monocytes and pre-DC populations of human BM. 
A. Single cells annotated by the gate of origin from index-linked flow cytometry. 
B. Cells annotated by 15 clusters generated from hierarchical 
clustering of the transcriptomes. 
C. Violin plot of differential IRF8 expression in clusters 10 (pre-DC3/mono) and 12 
(early pre-DC2), as determined by hierarchical clustering of single cell 
















Figure 4.12. tSNE of 244 single cell transcriptomes sampled from pre-DC 
populations of human BM.  
The heatmap shows CD34 antigen expression, as detected by FACS (A) and log2 














Figure 4.13. 3D diffusion map and lineage tracing of 244 single cell 
transcriptomes pre-DC populations of human BM annotated by 15 clusters 
from hierarchical clustering.   
Diffusion map was performed following a principal component analysis, aimed at 
reducing noise. Top 3 diffusion components, displayed on the plot, were used as 
input for the pseudotime analysis. The inferred trajectories, originating from HSCs, 







4.3.5 Coupling the two pathways in bone marrow and peripheral blood via 
mass cytometry 
Following the detection of the two DC pathways in the CD34high and CD34med 
compartments of the human bone marrow via scRNA-Seq, the next steps were to 
validate the link between these compartments, and couple the two pathways with 
mature cells in peripheral blood. Mass cytometry (CyTOF) was chosen for these 
experiments to allow the simultaneous analysis of blood and bone marrow with 
sufficient parameter capacity to analyse the phenotype of progenitors, precursors 
and mature subsets across the same platform.  
 
To this end, a panel of 33 markers was designed, consisting of mature DC and 
monocyte markers, early DC lineage markers (including AXL, SIGLEC6, CD123, 
CD2, CD33, SIRPA), progenitor markers (including CD34 and CD117) and 
transcription factors IRF4 and IRF8, found intracellularly. PB and BM cells were 
stained with distinct CD45 antibody conjugates so they could be distinguished in 
subsequent analyses. Cells were then combined for subsequent experimental steps. 
Including initially only BM derived cells, diffusion maps, employed to infer pseudo-
temporal ordering of cells and reconstruct lineage branching, showed four branches 
dominated by different cell types: GMP, cDC1, pDC, and monocytes (Figure 4.14 A). 
The cells showed appropriate antigen expression, cDC1 being marked by CLEC9A, 
pDC – by CD123, cDC2 subsets – by FCER1, SIRPA and CD2, with mutually 
exclusive expression of CD14 and CD5 (Figure 4.14 B). The earliest progenitors 
were concentrated within the uppermost points of the diffusion map (marked by 
CD34 expression, Figure 4.14 B) and were linked to the peripheral DC populations 
via arms of precursor cells. The DC3 trajectory ran parallel with and in close 
proximity to the branch dominated by monocytes, originating from CD33+ GMP. 
DC2s were located between the other DC subsets descending from CD123low/med 
IRF8high GMP and the IRF8low DC3/monocytes. However, unlike mature pDCs and 
cDC1s, which retained IRF8 expression, differentiated DC2s downregulated this 



































Figure 4.14. 3D diffusion map generated with mass cytometry data for 14,000 
granulocyte-monocyte progenitors (GMP), precursor and mature DC/monocyte 
cells from human bone marrow.  
A. Diffusion map showing cells color-coded according to the gating strategies 
depicted in Appendix Figures C (progenitors) and D (precursors and DC/mono). Diff 
C, diffusion component. 







Next, to validate the link between the two pathways originating in bone marrow and 
peripheral blood DC/mono populations, BMMC and PBMC compartments were 
analysed together. The tSNE dimensionality reduction technique was employed to 
visualise the dataset. On the resulting tSNE plot, most bone marrow cells occupied a 
central position, while the cells derived from blood were found at the peripheries 
(Figure 4.15 A). A cluster containing predominantly CD34+ progenitors was formed of 
almost exclusively bone marrow cells. In addition to that, the BMMC sample 
contained precursors and most mature populations, with the exception of CD16+ 
monocytes (Figure 4.15 B). In keeping with flow cytometric analysis, the majority of 
the cells in blood were mature DC and monocytes, with the exception of AXL+ cells 
and a few progenitors. The two DC development pathways were apparent on the 
joint BMMC and PBMC tSNE plot, when guided by the IRF8 expression (Figure 4.15 
C). The IRF8high pathway progenitors, such as cells from the LMPP and CD33low and 
CD123med GMP compartments were close to mature pDC, CD5+ DC2, and were 
adjacent to the cDC1 cluster in tSNE space. In contrast, IRF8low progenitors were 














Figure 4.15. tSNE analysis of mass cytometry data for a total of 75,000 
progenitors, precursors and mature DCs and monocytes from human PBMC 
and BMMC.  
A. Plot depicting cells derived from bone marrow (grey) and peripheral blood (red), 
barcoded and combined prior to CyTOF analysis. 
B. Progenitor and precursor cells from the IRF8high and IRF8low pathways, as well as 
mature DCs and monocytes, highlighted on the tSNE plot.  







4.4.1 Transcription factor IRF8 defines two DC developmental pathways in 
human 
Recent literature showed that DCs, originate from bone marrow progenitors and 
precursors with increasingly restricted potential. However, the identity of the pre-DC 
was unknown prior to the start of this project.  The combination of several approaches 
employed in this chapter the mapping of two pathways of DC development. A culture 
system, able to support the growth of DCs and monocytes, was used to single out 
increasingly committed progenitor and precursor populations. Single cell 
transcriptomic analyses enabled the reconstruction of lineage branching within the 
progenitor and precursor populations to infer a pseudotemporal ordering of the cells, 
linking them to mature DC subsets. And finally, computational analyses of mass 
cytometry data connected the bone marrow compartment to peripheral blood. 
 
Together, the work undertaken within this chapter revealed the presence of two distinct 
DC development pathways in human bone marrow, defined by expression levels of 
transcription factor IRF8. High IRF8 expression marked a CD123+ developmental 
pathway that gave rise to pDC, cDC1 and DC2, while the IRF8low pathway produced 
DC3, along with classical monocytes. The discovery of the IRF8high CD123+ pathway is 
in line with previous studies reporting the presence of unipotent progenitors of cDC1, 
cDC2, and pDC within the CD123+ compartment of GMP (Lee et al., 2017). However, 
earlier studies did not account for the presence of cDC2 subtypes, recently described 
in literature, and investigated the bulk CD1c+ cDC2 population.  
 
This chapter shows that the two developmental pathways are the source of the blood 
cDC2s, as the DC2 and DC3 subsets develop via different routes. DC2, the 
subpopulation bearing higher resemblance to cDC1, originates within the IRF8high 
pathway, while monocyte-resembling DC3 develops through the IRF8low pathway. 
Importantly, the data support a model whereby DC3 develop independently from 
monocytes. While the two cell types shared a “pre-mono/DC3” phenotypic gate, 
separate immediate precursors for these lineages were captured within the bone 
marrow compartment, and linked to either mature BM monocytes and DC3 via lineage 
branching reconstruction based on scRNA-Seq. In addition, DC3 cells emerged before 
monocytes in progenitor cell culture experiments (data available within the following 




The different levels of IRF8 requirement exhibited by cells of the IRF8hi and IRF8low 
pathways are congruent with the phenotypes exhibited by patients with primary 
immunodeficiency caused by mutations in IRF8. The bi-allelic loss of IRF8 causes 
absence of all monocytes and DC subsets (Hambleton et al., 2011; Bigley et al., 2018), 
while IRF8 haploinsuffiency primarily affects the cells developing via the IRF8hi 
pathway, which have greater requirements for this transcription factor (Cytlak and 
Resteu et al., 2020). 
 
As DCs are relatively short-lived, small numbers of bone marrow-derived cells 
constantly replenish the DC pool, traveling through blood to peripheral organs (Collin 
and Bigley, 2018). Mass cytometry analyses aligned the two pathways originating in 
bone marrow with bone marrow mature DC subsets, as well as their peripheral blood 
counterparts. The segregation of DC potential at an early stage, noted in this chapter, 
is consistent with the early lineage priming model for haematopoietic lineages in 
human (Notta et al., 2016; Velten et al., 2017).  
 
4.4.2 DC2 and DC3 markers support their functional specialisation 
A crucial part of this project was the identification of markers able to discern between 
the cDC2 subpopulations in vivo and in vitro. This was necessary in order to correctly 
assess the output of the progenitor cultures. The identified markers include lymphoid-
associated antigens CD5 and BTLA for DC2 and monocyte-associated markers CD14 
and CD163 for DC3. B and T lymphocyte attenuator BTLA, was originally identified as 
a DC2 marker in peripheral blood, but its use was hindered by the lack of expression 
in culture. The absence of BTLA expression was also noted on bone marrow DC, in 
agreement with the observation that culture produces tissue-like cells, made in Chapter 
3. The use of a second DC2 marker, CD5, which was ubiquitously expressed in blood, 
bone marrow, and culture, greatly aided the separation of ex vivo-derived cDC2 
subsets. This surface marker suggests that cDC2 subtypes might play different roles 
in immunity, as CD5 expression on DCs has a regulatory effect on their activity to 
stimulate T cells and inhibits the production of pro-inflammatory cytokines (Li et al., 
2019).  
 
Both DC3 markers identified in this project have been previously reported as markers 
of the monocyte-macrophage lineage. Pathogen recognition receptor CD14 is well 




et al. (2017). Villani and colleagues also noted that DC3 showed higher CD14 
expression than DC2. The expression of scavenging receptor and bacterial sensor 
CD163 has been previously reported mainly in human monocytes and macrophages, 
as well as on a fraction of peripheral blood DC, where it is thought to induce an 
immunostimulatory response (Maniecki et al., 2006). Overall, the markers are in 
agreement with previous findings that cDC2 subpopulations exhibit functional 
specialisation into anti-inflammatory DC2 and pro-inflammatory DC3 (Yin el al., 2017; 
Villani et al., 2017; Brown et al., 2019; Dutertre et al., 2019; Bourdely et al., 2020). 
 
4.4.3 Advances in single cell technologies help reveal the fate of DCs in human  
The investigation of DC development in the human was made possible by recent 
technological advances and novel analysis algorithms. In the last decade, the field of 
transcriptomics has moved rapidly from microarrays to bulk RNA-Seq, and more 
recently to single cell RNA-Seq. Employing single cell transcriptomics and phenotyping 
in this work allowed the characterisation of the heterogeneity of bulk progenitor and 
precursor populations at single cell level in the BM CD34+ and CD34med compartments, 
and established differential IRF8 expression as a defining feature of the two pathways 
of DC development. The use of a plate-based index-sorted approach in conjunction 
with the Smart-seq2 protocol (Picelli et al., 2014) enabled the coupling of 
transcriptomics data with cell-specific antigen expression parameters by FACS. The 
main benefit of this approach is the traceability of the flow gates for every analysed 
cell, which can be used to enrich the desired DC of pre-DC populations in the future 
via flow cytometry. In addition, antigen expression data were used in the analysis, 
where gene expression values were missing due to a phenomenon called “dropout”,  
characteristic of scRNA-Seq data. Dropouts occur due to low RNA input of these 
experiments and the failure of mRNAs to be reversed transcribed (Andrews and 
Hemberg, 2019).  
 
The chapter also employed novel tools designed specifically for scRNA-Seq data.   
Clustering is a common approach for the identification of groups of cells or samples. 
However, this can be challenging due to high levels of noise specific to scRNA-Seq, 
combined with the high-dimensionality of the transcriptome. Recent methods, such as 
the Single-Cell Consensus Clustering (Kiselev et al., 2017), have been developed with 
this in mind. SC3 is a method for unsupervised clustering, based on techniques such 




a consensus approach. Oher common computational approaches specific to scRNA-
Seq aim to perform trajectory inference in order to arrange the single cells in an order 
that represents their developmental trajectories. Over 70 tools for pseudotemporal 
ordering have been developed in the last years (Saelens et al., 2019). The choice of 
software for the analysis of DC haematopoiesis was determined by the ability to 
recreate multiple lineage branching events. This was crucial for the very complex 
human bone marrow scRNA-Seq datasets, as they encompassed a multitude of 
closely related lineages, including at least 3 DC subsets. The Slingshot software, 
designed for inferring continuous, branching lineage structures (Street et al., 2018), 
was selected for this analysis. The software is flexible enough to handle arbitrarily 
many branching events and allows for the incorporation of prior knowledge, such as 
clustering information (Human Cell Atlas, https://www.humancellatlas.org). In addition, 
it was highly ranked by a study aiming to benchmark single-cell trajectory inference 
methods based on cellular ordering, topology, scalability and usability (Saelens et al., 
2019).  
 
The experiments in this chapter were also made possible by recent advances in 
cytometry. Florescence flow cytometry is the most commonly used platform for 
identifying human DC, and has been invaluable for analysing surface antigens and 
intracellular molecules in cells derived from human peripheral blood, as well as 
single-cell suspensions of tissues including skin, lung, intestine, liver, and body fluids 
(Collin and Bigley, 2018). However, flow cytometry is currently limited to detecting 
15-18 antigens. This technology uses fluorophores with overlapping emission 
spectra, which must be mathematically compensated, limiting the number of 
parameters that can be assessed simultaneously (Gadalla et al., 2019). Mass 
cytometry, a next generation single-cell proteomic analysis technique, utilises rare 
metal isotopes which have relatively little overlap (<2%), as each atom’s time of flight 
is determined by its mass, in order to overcome the limit of multiplexing capability of 
flow cytometry (Gadalla et al., 2019). CyTOF allows the simultaneously assess the 
expression of up to 40 antigens, facilitating the analysis of complex cell populations.  
 
In this chapter, the mass cytometry technique enabled the use of a panel of 33 
antigens to align the DC developmental pathways in bone marrow and peripheral 
blood. However, the mass cytometry technique has a number of limitations, including 




used as input are nebulised, then analysed by mass spectrometry, and cannot be 
retrieved for further experiments, such as cell culture or sequencing. 
 
As many single cell methods produce high dimensional data, a number of algorithms 
have been developed to reduce dimensionality and produce two- or three-
dimensional visualisations where similar cells are grouped together. t-Distributed 
stochastic neighbour embedding is a non-linear dimensionality reduction technique, 
particularly suitable for the visualisation of large high dimensional datasets (van der 
Maaten, 2008). It was indispensable for the analysis of the scRNA-Seq, in order to 
obtain a visualisation of the dataset and the grouping defined by hierarchical 
clustering within the SC3 software. tSNE was also used for the analysis of the 
CyTOF data, and helped directly compare the groups of cells present in the bone 
marrow and in peripheral blood. A different approach was undertaken to map the 
cellular differentiation in these data, as during development cells follow continuous 
branching lineages, instead of forming distinct clusters. Diffusion maps were the 
technique of choice, as they deal with the problem of defining differentiation 
trajectories, and preserve the global relations between data points, are robust to 
noise, and are insensitive to the sampling density, aiding the detection of rare cell 
populations (Angerer et al., 2015).   
 
4.5 Summary and further work 
The experiments undertaken in this chapter support the existence of two 
developmental pathways giving rise to dendritic cells in human bone marrow (Figure 
4.16). High IRF8 expression defines a CD123+ DC developmental pathway giving 
rise to pDC, cDC1 and DC2. In contrast, DC3 arise through an IRF8low pathway with 






Figure 4.16. Schematic summary of the main findings from Chapter 4. 
Human DCs subsets develop in the bone marrow via two pathways marked by IRF8 
expression. The IRF8high pathway gives rise to pDC, cDC1 and DC2, while the 
IRF8low pathway produces DC3 and classical monocytes. The traditional progenitor 
cell classification by flow cytometry is displayed as black rectangles and includes 
haematopoietic stem cells (HSC), lymphoid-primed multipotent progenitors (LMPP) 
and granulocyte-macrophage progenitors (GMP). 
 
To derive further insights into the role of IRF8 in DC development, future work will 
involve the analysis of a scRNA-Seq dataset comprising of cells derived from the 
bone marrow of patients with IRF8 mutations. This will allow the detailed mapping of 
pathways and cells affected by IRF8 deficiency.  
 
To further investigate the early lineage priming model in human, supported by this 
work, future efforts should focus on back-tracing the developmental pathways in 
primitive populations of the bone marrow. This could be achieved via single cell 
culture of human HSC/MPP.  
 
Finally, the two pathways of DC development and the cells they give rise to must be 





Chapter 5. Optimisation of the low cell ChIP-Seq protocol   
 
Questions answered in this chapter: 
1. Can a ChIP-compatible IRF8 antibody be identified? 
2. What are the optimal sonication conditions for performing low cell IRF8 ChIP-
Seq on culture-derived DCs?  
3. Does cell number impact the quality of the resulting ChIP-Seq libraries? 
 
5.1 Introduction  
Protein–DNA interactions take place when a protein binds a DNA molecule and often 
result in the regulation of the biological function of the DNA. DNA-binding proteins 
include transcription factors, involved in the process of transcribing DNA into RNA, 
and histones, able to control DNA accessibility. Chromatin immunoprecipitation, 
followed by high-throughput sequencing analysis is the gold-standard technique for 
examining the distribution of transcription factors and histone modifications in a 
genome-wide manner (Kidder et al., 2011). The ChIP-Seq method is indispensable 
for studying the multitude of biological processes that depend on protein-DNA 
interactions, including cell differentiation and function, cell cycle progression, DNA 
replication, recombination, repair, gene expression, chromosome stability, and 
epigenetic silencing (Mundade et al., 2014). 
 
IRF8, also known as interferon consensus sequence-binding protein (ICSBP), is an 
important immune transcription factor, playing a critical role in the development and 
homeostasis of DC subsets. Most studies of IRF8 have been performed in mice and 
its role in humans is not well understood. Applying the chromatin immunoprecipitation 
(ChIP) technique to its study could help gain significant insights into human immune 
biology and transcriptional programmes and signaling pathways regulated by IRF8 in 
human. First, this method can be applied to study the role of IRF8 in mature DC, an 
experiment that has not previously been performed in human due to the rarity of DC. 
This issue has been recently addressed via the development of a novel culture 
system, confirmed to produce large numbers of bona fide DC in Chapter 3 of this 
work. Next, the study could be extended to understand the behaviour of IRF8 during 





5.1.1 The ChIP-Seq method 
ChIP-Seq is an established and powerful technique for the analysis of protein-DNA 
interactions. However, to obtain accurate and reproducible results, a number of steps 
in the ChIP-Seq assay require careful optimisation. 
 
At the start of most ChIP-Seq protocols (outlined in Figure 5.1), the proteins are 
crosslinked to the DNA with formaldehyde. Formaldehyde readily permeates cell 
membranes and acts in several steps, which result in the formation of covalent bonds 
between macromolecules. Small proteins, such as Tris or glycine, interact with 
formaldehyde, and are used to quench the crosslinking reaction (Hoffman et al., 
2015). Alternative crosslinking methods have also been described (Zeng et al., 
2006). Chromatin shearing is then performed in order to obtain smaller DNA 
fragments, optimal for immunoprecipitation (IP) and sequencing. DNA shearing is 
often achieved via mechanical methods, such as acoustic sonication, or enzymatic 
digestion. Sonication is the preferred approach, as it produces evenly distributed 
fragments, while the enzymes used for digestion often have a preference for specific 
sites, without regard for the distance between them, and may introduce bias into the 
experiment. Sonication consists of several ON/OFF cycles, aiming to produce 200-
1200bp DNA fragments. Typically, samples are immersed in a cold water bath (4°C) 
during sonication. The shearing is achieved during the ON setting. Throughout the 
OFF setting, the sonication is paused and the samples are cooled down to prevent 
DNA degradation. Next, the DNA-binding protein, attached to its specific DNA 
fragments, is immunoprecipitated using a specific ChIP-grade antibody. The antibody 
is incubated with the lysate, along with agarose or sepharose beads covered in an 
immunoglobulin-binding protein, such as Protein A, G, A/G, or L. The protein-DNA 
complexes are then eluted off the beads and descrosslinked, commonly via a 
digestion at 60-65°C, lasting a few hours to overnight. The protein-free DNA is 
extracted and purified, and sequencing libraries are prepared. The DNA 
concentration and fragment size distribution are assessed, and the libraries are 
sequenced. 
 
The ChIP-Seq assay can be difficult to optimise, as multiple aspects, such as the 
duration of the crosslinking, the optimal number and length of sonication cycles, the 
number of PCR amplification rounds applied during preparation of the sequencing 




ChIP-Seq dataset (Mendoza-Parra and Gronemeyer, 2014). In addition, the following 
steps of the ChIP-Seq experimentation may give rise to artefacts: (1) DNA shearing: 
open chromatin regions are easier to shear than closed chromatin regions and 
produce higher background signals; (2) antibody cross reactivity during IP; (3) base-
composition bias during sequencing (Kidder et al., 2011). Two types of controls are 
commonly used in ChIP-Seq experiments: input chromatin and samples 
immunoprecipitated with nonspecific IgG antibodies. The use of input chromatin is 
generally recommended, as it provides enough DNA for a more complex sequencing 
library and requires less input material (Kidder et al., 2011), which is ideal when 
studying rare cell types, such as DC. However, the controls do not account for the 
antibody cross-reactivity, and antibody validation must be performed through 
independent experiments.  
 
The Low Cell ChIP-Seq protocol (Active Motif, Catalog No. 53084) was selected for 
the ChIP-Seq experiments in this chapter, as it provided reagents for a complete 
ChIP-Seq workflow including chromatin preparation, immunoprecipitation and 
Illumina-compatible next generation sequencing library preparation. In addition, the 
protocol has been designed specifically for the use on limited cell numbers of 50,000 
and above. However, the number and length of the sonication cycles and the IRF8 













Figure 5.1. Schematic of the ChIP-Seq workflow. 
The schematic outlines the common steps in most ChIP-Seq protocols: formaldehyde 
cross-linking, cell lysis, sonication, IP, elution and decrosslinking of protein-DNA 





5.1.2 Guidelines for antibody testing 
The success of the ChIP-Seq assay relies heavily on the quality of the selected 
antibody. To ensure the validity of the results, a ChIP-grade antibody, previously 
validated for this application by the vendor, must be utilised for the ChIP-Seq assay. 
Alternatively, antibody testing for ChIP suitability can be performed by the user.  
 
The Encyclopaedia of DNA Elements Consortium (ENCODE; 
https://www.encodeproject.org) is an ongoing international collaboration of research 
groups set up with the goal to build a comprehensive parts list of functional elements 
in the human genome. ENCODE release curated, uniformly processed and validated 
experiments to the scientific community and provide strict guidelines to ensure high 
quality data standards are met. According to the ENCODE consortium, antibody 
deficiencies are of two types: poor reactivity against the intended target (low 
sensitivity) and cross-reactivity with other DNA-associated proteins (poor specificity) 
(Landt et al., 2012). The ENCODE consortium guidance recommends performing 
both primary and secondary characterisation for antibodies against transcription 
factors to ensure that they are suitable for ChIP-Seq experiments. The suggested 
characterisation workflow is outlined in Figure 5.2. The starting method 
recommended for primary characterisation is western blotting. The ENCODE 
consortium state that in order to pass primary characterisation, the antibody must 
detect more than 50% of bands on a western blot. The size of the detected protein 
must be within 20% of the size predicted from amino acid sequence. If the antibody 
fails the test, in can be rescued by an immunofluorescence assay. Multiple options 
are provided for secondary characterisation, including small interfering RNA 
knockdown, IP/mass spectrometry, IP with epitope-tagged version of target, and 
motif enrichment.  
 
A high quality IRF8 antibody (ICSBP Antibody (C-19): sc-6058, Santa Cruz 
Biotechnology, Inc) has been previously successfully used for ChIP-Seq experiments 
in human (Shin et al, 2011; Mohaghegh et al., 2019). Unfortunately, this antibody has 
been discontinued and was therefore unavailable for this project. In addition, the 
ENCODE database did not contain any validated IRF8 antibodies suitable for this 
work. Consequently, a new ChIP-grade antibody had to be identified prior to 







Figure 5.2. Flowchart of antibody characterisation assays, as outlined by 
ENCODE (adapted from Landt et al., 2012). 
One assay is required for primary characterisation. Immunoprecipitation or western 
blotting are suggested as starting experiments. In case of a fail, the characterisation 
ca be saved via a successful immunofluorescence experiment. Once the primary 
characterisation is completed, the secondary characterisation may be performed via 
one of the following approaches: siRNA knockdown, IP against different region of 
target protein or complex, IP coupled with mass spectrometry, IP with epitope tagged 







5.2 Materials and methods  
5.2.1 Shipment and rehydration of expression vectors 
The vectors pIRES2-EGFP-HA-IRF8 (IRF8 vector) and pIRES2-EGFP (empty vector) 
were kindly provided by Dr Gina Doody from the School of Medicine at the University 
of Leeds. The plasmid DNA was shipped and Whatman paper at room temperature. 
On receipt, the 1-2μg plasmid DNA, were placed in 500μl TB buffer (Invitrogen) for 6 
hours at 4°C. After a brief centrifugation, 5μl of the supernatant (equivalent to 10-
20ng DNA) were used for transformation into competent E. coli cells (Promega).  
 
5.2.2 Preparation of LB medium supplemented with kanamycin 
For the preparation of LB medium for bacterial culture, 20.6g Lennox LB Broth 
(Sigma) were stirred with a magnetic stirrer until suspended in 1L water, then 
autoclaved at 121°C for 15 minutes to sterilise. The solution was allowed to cool 
down before the addition of antibiotic kanamycin (Sigma) to obtain a working 
concentration of 50µg/mL, and stored at 4°C. 
 
5.2.3 Preparation of LB agar plates supplemented with kanamycin 
For the preparation of agar plates for bacterial culture, 30.5g of Luria low salt LB 
Broth with agar (Sigma) were heated while stirring until dissolved in 1L water, then 
autoclaved at 121°C for 15 minutes to sterilise. The solution was allowed to cool 
slightly before the addition of antibiotic kanamycin (Sigma) to obtain a working 
concentration of 50µg/mL, then poured into petri dishes (Sigma) and allowed to 
solidify. The plates were stored upside down at 4°C for up to 2 weeks. 
 
5.2.4 Bacterial culture and transformation 
The Promega “single-use cells” protocol was used for the bacterial transformation. 
Briefly, the competent cells were thawed and mixed with 10-20ng plasmid DNA and 
placed on ice for 30 minutes. Cells were then heat-shocked in a water bath at 42°C 
for 15 seconds, and placed on ice for 2 minutes. 450μl room temperature SOC 
medium (New England Biolabs) were added to the cells, and incubated at 37°C for 1 
hour with shaking. 100μl and 50μl undiluted cells were plated on LB agar plates, 
supplemented with 50mg/ml Kanamycin and grown overnight at 37°C. The next day, 
colonies were picked and grown overnight at 37°C with shaking in LB medium 





5.2.5 Plasmid DNA extraction and quantification 
The plasmid DNA was extracted the next day after transformation, using the QIAprep 
Spin kit (Qiagen), then quantified with a NanoDrop spectrophotometer (Thermo 
Scientific). 
 
5.2.6 Restriction enzyme digestion and gel electrophoresis 
Restriction enzyme digestion was performed using restriction enzymes EcoRI, BglII, 
and BamHI (Promega), following manufacturer’s instructions. Gel electrophoresis 
was performed on a 1% agarose gel with the addition of 0.01% GelRed nucleic acid 
stain (Biotium) at 80V for 60 minutes. 300-1,500ng undigested plasmid DNA were 
loaded as control. The gel was visualised using the Odyssey Imaging System (LI-
COR Biosciences). 
 
5.2.7 Sanger sequencing of vectors 
Vectors were sent to GATC Biotech, Germany for Sanger sequencing. 5μl purified 
plasmid DNA at a concentration of 80-100ng/µl were aliquoted in 1.5ml Eppendorf 
tubes (Sigma) and shipped at room temperature. 
 
5.2.18 Culture and transfection of HEK293T cells 
HEK293T cells were defrosted as described in Chapter 2 section 2.3.3 and placed in 
culture in a T25 flask (Sigma) with 5mL DMEM medium, prepared as described in 
section Chapter 2 section 2.1.7. The cells were passaged twice into T75 flasks 
(Sigma) when they reached 70-80% confluency. The cells were then counted using a 
haemocytometer (Hawksley) and seeded into 6 well plates (Costar) to a density of 
300,000 cells per well in 2ml DMEM culture medium (Gibco). The seeded cells were 
incubated overnight at 37°C in a humidified atmosphere at 5% CO2. 
 
For each of the vectors (pIRES2-EGFP-HA-IRF8 and pIRES2-EGFP), 6μg plasmid 
DNA were added to 610μl unsupplemented DMEM medium, and vortexed at full 
speed for 5 seconds. 30μl of 1% Polyethyleneimine (Sigma-Aldrich) were added to 
the transfection mixes. The mixes were then vortexed at full speed for 10 seconds, 
and incubated for 20 minutes at room temperature.  Following an overnight 




were added to each well of the 6 well plates (Costar) in triplicates for each of the 
vectors.  
 
Fluorescence and light microscopy were performed 23 hours post-transfection using 
EVOS FL Cell Imaging System (Life Technologies). The cells were lysed on ice 27 
hours post-transfection with 200μl RIPA cell lysis buffer (Cell Signaling Technology) 
per well, supplemented with cOmplete EDTA-free Protease Inhibitor Cocktail 
(Roche). The triplicates were combined for each vector, yielding lysates containing 
approximately 1.8 million cells, considering the 24-30 hours doubling time of the 
HEK293T cell line (DSMZ; https://www.dsmz.de). The lysates were spun down at full 
speed (21,000g) for 10 minutes at 4°C.  The pellets were discarded and the clarified 
lysates were retained. 30μl of the each of the lysates were frozen at  
-20°C for western blotting the following day, and the rest of the supernatant was used 
for immunoprecipitation immediately.  
 
5.2.9 Immunoprecipitation 
For each IP reaction, 1μg IRF8 antibody (Santa Cruz (E-9): sc-365042) or 1 μg 
Purified Mouse IgG2b, κ isotype control antibody (Biolegend), were added to 570μl 
lysate, and incubated on a rocker (Bibby Stuart) at 4°C overnight. The following day, 
20μl agarose beads coated with Protein G (Cell Signaling Technology) were added 
to each of the lysate and antibody mixes and incubated on a rocker (Bibby Stuart) at 
4°C for 60 minutes. The lysates were spun down at 500g for 2 minutes, and the 
supernatant was discarded. The pellets were washed 4 times with 0.8ml RIPA cell 
lysis buffer (Cell Signaling Technology). 
 
5.2.10 Western blotting 
A loading mix was prepared by adding 20μl reducing agent 10X NuPAGE Sample 
Reducing Agent (Invitrogen) to 180μl sample loading buffer 4X NuPAGE LDS 
Sample Buffer (Invitrogen). For lysates, 10μl loading mix was added to 30μl lysate. 
Considering the HEK293T doubling time of 24-30 hours, the lysates contained 
approximately 90,000 cells. For IPs, 10μl loading mix and 5μl RIPA cell lysis buffer 
(Cell Signaling Technology) were added to the washed IP beads prepared in the 
immunoprecipitation step. All samples were boiled at 95°C for 5 minutes. The lysates 




IPs were centrifuged at 500g for 2 minutes prior to loading onto the same gel. The 
gel was run in Tris/Glycine/SDS running buffer (BIO-RAD) at 120V for 15 minutes, 
then at 150V for 40 minutes. The transfer was performed in Tris/Glycine Buffer 
transfer buffer (BIO-RAD) at 100V for 90 minutes. The membrane was probed with 
the following primary antibodies: IRF8 antibody (Santa Cruz (E-9): sc-365042, 1:500 
dilution), HA-probe antibody (Santa Cruz (F-7): sc-7392, 1:200 dilution), and Vinculin 
antibody (Abcam ab129002, 1:10,000 dilution). A secondary anti-mouse κ light chain 
antibody (Santa Cruz m-IgGκ BP-HRP: sc-516102) was used in combination with all 
primary Santa Cruz antibodies, which were raised in mice. A secondary anti-rabbit 
light chain antibody (Merck Millipore MAB201P, 1:20,000 dilution) was used with the 
primary Vinculin antibody (Abcam), raised in rabbits. The visualisation was performed 
using the chemiluminescent Pierce ECL Substrate (ThermoFisher) and the Odyssey 
Imaging System (LI-COR Biosciences).  
 
5.2.11 Sorting of bone marrow cells for western blotting and cell culture 
Bone marrow cells from hip replacement procedures or haematopoietic stem cell 
transplantation donors were stored and defrosted as described in Chapter 2 
subsection 2.3.3. The cells were stained and FACS-purified as described in Chapter 
2 subsection 2.3.6 using fluorescently-conjugated antibodies listed in Table 3.1. 
CD34+ Lineage- cells were retained for culture and CD34- Lineage- cells were lysed 
with RIPA cell lysis buffer (Cell Signaling Technology) and used for western blotting, 
as part of the primary characterisation of the Santa Cruz (E-9): sc-365042 antibody, 
performed in the same manner as for the lysates in section 5.2.10. 
 
5.2.12 Co-culture of bone marrow progenitors with OP9-DL1 cells 
CD34+ Lineage- progenitors were co-cultured with OP9-DL1 cells for 14-21 days in 
order to enrich the output in cDC1s, as described in Chapter 2 subsection 2.3.5.   
 
5.2.13 Chromatin immunoprecipitation 
The Low Cell ChIP-Seq kit and Next Gen DNA Library Kit (Active Motif) were used 
for cell fixation, immunoprecipitation, DNA extraction, and sequencing library 
preparation, according to manufacturer’s instructions. The workflow of the protocol is 
outlined in Figure 5.3. An additional cell sorting step was introduced at beginning of 




Cultured cDC1s were FACS-sorted into siliconized tubes (Active Motif) with 300µl 
MEM-a medium (Gibco) and kept on ice. The cells were spun down at RT at 1,300g 
for 5 minutes and resuspended into 50µl PBS (Active Motif). The cells were then 
fixed for 10 minutes at RT with 5µl of Complete Cell Fixation Solution, the 55µl 
fixation reaction containing 1% formaldehyde. The fixation was quenched for 5 
minutes with the Stop Solution (Active Motif) at RT. The lysate was transferred into 
1.5ml Bioruptor Pico microtubes with caps (Diagenode) and sonicated on a rotating 
carousel with 6 slots in the Bioruptor Pico device (Diagenode). 2-3 tubes were 
sonicated at a time, balanced on opposite sides of the carousel. As part of the 
optimisation, two sonication settings were tested: (1) 10 cycles of 30 seconds ON 
and 30 seconds OFF, suggested as a starting setting by the Low ell ChIP-Seq kit, 
and (2) 6 cycles of 30 seconds ON and 90 seconds OFF, suggested by Diagenode 
for our sample volume and target DNA fragment size. Following sonication, lysates 
were stored at -80°C. They were thawed on ice prior the pre-clearing step of the 
protocol. IP was performed with 3µg IRF8 antibody (Santa Cruz (E-9): sc-365042). 
The protein-DNA complexes were then eluted, and decrosslinking was performed 
overnight at 65°C in a thermocycler (Applied Biosystems). DNA was extracted and 
stored at -20°C until it was thawed at room temperature and used for sequencing 
library preparation. A two-sided SPRI clean-up was performed after the PCR to 
ensure an appropriate size distribution of DNA fragments for sequencing. 
 
5.2.14 Quantification of sequencing libraries 
The DNA concentration, molarity, and fragment size distribution of the sequencing 
libraries were assessed with the Agilent Bioanalyzer 2100 using the high sensitivity 






Figure 5.3. Flow chart of the low cell ChIP-Seq process (Active Motif).  
The 5-day protocol includes the start-to-end processing of fresh cultured or primary 




fixed with formaldehyde, and sonicated. On day 2, the agarose beads coated in 
Protein G are prepared for the pre-clearing and IP reactions. The chromatin is then 
thawed and the pre-clearing reaction is performed, followed by an overnight 
immunoprecipitation with the desired antibody. On day 3, agarose beads are added 
to the samples. After 3-4 hours of incubation, and the antibody-bound protein-DNA 
complexed are eluted off the beads. The cross-linking induced by formaldehyde on 
day 1 is reversed overnight. The DNA in extracted on day 4, and used for library 
preparation on day 5. The library construction comprises multiple steps, including two 
repair steps, two ligation steps, and a PCR amplification step. 
 
5.3 Results 
5.3.1 Candidate antibodies for characterisation  
Initially, the IRF8 (D20D8) Rabbit mAb #5628 (Cell signaling) was chosen for testing. 
According to information provided by its manufacturer, this antibody is suitable for the 
following applications: western blotting, immunoprecipitation, ChIP, ChIP-Seq. 
However, the Cell signaling IRF8 antibody failed to detect its target by western 
blotting in the IRF8-expressing lymphoblast-like Raji cell line (Figure 5.4). A band 
was expected in the western blot analysis at 48kDa, which is the atomic mass of the 
most common splice variant of the IRF8 protein (Human Protein Atlas; 
https://www.proteinatlas.org). In addition, this antibody lacked specificity, as it 
detected numerous bands in the HeLa cell line, which does not express IRF8 
(Human Protein Atlas; https://www.proteinatlas.org/). Therefore, the testing of this 






Figure 5.4. Western blot of Raji and HeLa cell lines probed with the primary 
antibody IRF8 (D20D8) Rabbit mAb #5628 (Cell signaling).  
Mouse Anti-Rabbit light chain, HRP conjugate Antibody (Merck Millipore MAB201P) 
directed against the species of the primary antibody, was used as secondary 
antibody. Lysates containing 300,000 IRF8-expressing Raji cells and 300,000 IRF8- 
HeLa cells were used in the analysis. The ladder shows atomic mass of proteins in 
kDa.  
 
Next, the ICSBP Antibody (E-9): sc-365042 (Santa Cruz Biotechnology) was selected 
for validation. Its applications recommended by the supplier include IP, western 
blotting, immunohistochemistry, and immunofluorescence. In addition, the antibody 
has been successfully used for generating publication-quality data (Arifuzzaman, et 
al. 2017, Bouamar, et al. 2013). The antibody is a mouse monoclonal IgG2b (kappa 
light chain), raised against amino acids 357-426 (C-terminus) of the IRF8 protein of 
human origin. Analysis of the 70-amino acid long sequence targeted by the antibody 
with the Protein Basic Local Alignment Search Tool (BLASTP) against the NCBI 
Protein Reference Sequences database, revealed that the sequence shared 100% 
identity with all three IRF8 isoforms present in the database. Up to 31% identity was 
also shared with three isoforms of the NLRX1 protein. This minor resemblance did 
not present a concern for the ChIP-Seq experiment, particularly because the NLRX1 
protein does not bind DNA (Xiao et al., 2012). Critically, BLASTP analysis of amino 




DNA-binding members of the IRF family, in particular to IRF4, which shares strong 
homologies with IRF8 and could therefore contaminate the assay. 
 
5.3.2 Primary characterisation 
Primary characterisation of the ICSBP Antibody (E-9): sc-365042 (Santa Cruz 
Biotechnology) was performed via western blotting of CD34- Lineage- bone marrow 
cells. This population contained the bulk of DCs, including cDC1s, cDC2s, and pDCs, 
as well as a small proportion of other immune cells. The CD34- Lineage- cells were 
expected to express high levels of IRF8, sufficient for detection by western botting. In 
addition, testing the bulk of DCs would identify any cross reactivity of the antibody 
with proteins expressed by any of the DC subsets. Western blotting was performed 
with biological duplicates, derived from two different bone marrow samples. The 
western blot was then probed with the candidate ChIP antibody anti-ICSBP (E-9): sc-
365042 (Santa Cruz Biotechnology). 
 
A single band was detected in both of the processed biological replicates at around 
50kDa (Figure 5.5), corresponding to the atomic mass of the most common splice 
variant of the IRF8 protein. No other bands were detected on the membrane. This 








Figure 5.5. Western blot of primary CD34- Lineage- cells from human bone 
marrow, probed with IRF8 antibody ICSBP (E-9): sc-365042 (Santa Cruz 
Biotechnology).  
The labels above the lanes denote two bone marrow samples derived from different 
donors. 500,000 cells were lysed and loaded in the lane labelled BM1 and 1,000,000 
cells – in BM2. The ladder shows atomic mass of proteins in kDa. 
 
5.3.3 Secondary characterisation  
On the successful completion of the primary characterisation, secondary 
characterisation of the ICSBP Antibody (E-9): sc-365042 (Santa Cruz Biotechnology) 
was performed via IP and probing of the epitope-tagged version of IRF8. The 
HEK293T human epithelial cell line was selected for this experiment. The cell line 
does not express IRF8 (Human Protein Atlas; https://www.proteinatlas.org), and 
would serve as a negative control in IP experiments. HA-tagged IRF8 was intended 
to be introduced into the HEK293T cells via transfection, following the confirmation of 




vector identities. The epitope tagging, which is a procedure whereby a short well-
known amino acid sequence is attached to a protein under study, would allow the 
detection of heterologously expressed IRF8 with an HA antibody, as well as with the 
candidate IRF8 antibody. 
 
5.3.3.1 Confirmation of vector identities  
The vectors used in the transfection experiment were gratefully received from Dr 
Gina Doody (University of Leeds) and propagated in E. Coli. The bacteria that 
incorporated the plasmids were selected using agar plates and medium containing 
kanamycin, as the vectors featured an antibiotic resistance gene. The IRF8-
containing vector (pIRES2-EGFP-HA-IRF8) used for transfection is described in 
Figure 5.6 A. This vector was sequenced to confirm that the insert maintained the 
correct orientation and had an appropriate size (Figure 5.6 B). The “empty” vector 
with no gene insert (pIRES2-EGFP, Clontech), was used to control for factors such 
as transfection-induced apoptosis and is described in Figure 5.7 A. The multiple 
cloning site (MCS) of the “empty” vector, where the IRF8 gene and the HA-tag were 
inserted to create the pIRES2-EGFP-HA-IRF8 vector, is displayed in Figure 5.7 B.  
 
Restriction enzyme digestion, followed by gel electrophoresis were performed in 
triplicates in order to further confirm the identities of the two vectors (Figure 5.8). 
Undigested plasmids were loaded alongside vectors digested using restriction 
enzymes BglII and EcoRI. For the “empty” vector, the digestion was expected to 
produce fragments similar in size to a 5.3kb linearised plasmid, as the two restriction 
recognition sites are located in close proximity to each other (Figure 5.7 B). For the 
IRF8-containing vector, the restriction digestion was expected to excise the DNA 
fragment encoding the HA-tag and the IRF8 gene with the combined length of 
1,335bp and produce a second, 5,288bp-long DNA fragment, containing the rest of 
the plasmid (Figure 5.6 A). As expected, a single DNA fragment was produced as a 
result of the “empty” vector digestion and two fragments were produced when 
digesting the IRF8 vector (wells labelled with “D” in Figure 5.8). The produced 
fragments corresponded to the predicted size for all replicates for both the IRF8-
containing (1.3kb and 5.3kb) and the empty vector (5.3kb). All undigested plasmids 








Figure 5.6. The pIRES2-EGFP-HA-IRF8 expression construct. 
A. pIRES2-EGFP-HA-IRF8 vector map, displaying restriction recognition sites used 
for restriction enzyme digestion in this chapter. Unique cutters are shown in bold. The 
vector contains features similar to those of the pIRES2-EGFP vector (Figure 5.7), 
with the exception of the multiple cloning site. The MCS was exploited for inserting 
the IRF8 gene into the “empty” vector. 
B. Sanger sequencing results for the pIRES2-EGFP-HA-IRF8 vector using the CMV 
promoter forward primer. The 963bp-long read contained the sequence encoding the 












Figure 5.7. The pIRES2-EGFP expression construct. 
A. Vector map of pIRES2-EGFP. The plasmid contains the following features at the 
specified locations: human cytomegalovirus (CMV) immediate early promoter: 1–589, 
multiple cloning site (MCS): 591–665, internal ribosome entry site (IRES) sequence: 
666–1250, enhanced green fluorescent protein (EGFP) gene: 1254–1973, SV40 
early mRNA polyadenylation signal: 2096–2217, f1 single-strand DNA origin: 2224–
2679, bacterial promoter for expression of KanR gene 2706–2810, SV40 origin of 
replication: 3020–3155, SV40 early promoter/enhancer: 2812–3169, 
kanamycin/neomycin resistance gene: 3204–3998, herpes simplex virus (HSV) 
thymidine kinase (TK) polyadenylation signals: 4234–4252, pUC E. coli plasmid 
replication origin: 4583–5226. 
B. Enlarged view of the pIRES2-EGFP multiple cloning site. The 75bp-long MCS 










Figure 5.8. Gel electrophoresis of the IRF8-containing vector pIRES2-EGFP-HA-
IRF8 (top) and the empty vector pIRES2-EGFP (bottom). 
The experiment was performed in triplicates picked from different bacterial colonies. 
The wells labelled with “U” were loaded with undigested vectors. Plasmids digested 
with restriction enzymes BglII and EcoRI were loaded in the wells labelled with “D”. 






5.3.3.2 Immunoprecipitation and western blotting of epitope-tagged IRF8 protein 
Following the confirmation of the vector identities, the plasmids were used for 
transfection into HEK293T cells. The success of the transfection was assessed with 
fluorescence microscopy. This was made possible by the presence of a gene 
encoding the Enhanced Green Fluorescent Protein (EGFP) in both vectors. 






Figure 5.9. Overlay of light and fluorescence microscopy images for HEK293T 
cells transfected with the IRF8-containing vector (left) and the empty vector 
(right).  
Light microscopy and fluorescence microscopy in the GFP channel were performed 
23 hours post-transfection with Polyethylenimine. The same microscopy settings 
were used to produce both images. The size of the bars is 400 microns.  
 
Once the success of the transfection was confirmed via fluorescence microscopy, the 
cells were lysed and subjected to IP followed by western blotting, or to western 
blotting alone (Figure 5.10 A). Lysates were probed with the candidate IRF8 antibody 
from Santa Cruz and with an HA-probe antibody. A single band was detected at 
approximately 50kDa by both antibodies in the IRF8-containg lysates. This 
corresponds to the atomic mass of the most common splice variant of the IRF8 
protein – 48kDa.   
IP was performed with the Santa Cruz IRF8 antibody, as well as with a mouse IgG2b 
(kappa light chain) antibody, of the same isotype (class) as the IRF8 antibody. The 




isotype control was necessary to identify nonspecific bands resulting from subjecting 
proteins to immunoprecipitation. All IPs were probed with the Santa Cruz IRF8 
antibody being tested. The IRF8 protein was detected at 48kDa in the lysate of cells 
transfected with the IRF8 vector but not in the “empty” vector-transfected cell lysate. 
Further bands were observed at low molecular weights in all IP wells. They can be 
attributed to the IgG light chains (25kDa), originating from the antibodies used for 
immunoprecipitation and detected by the secondary antibody. The heavy chains of 
the IP antibodies (50kDa) were not detected by the anti-light chain secondary 
antibody, which was used specifically to avoid obscuring the IRF8 protein at 48kDa. 
 
An additional control was used to ensure similar amounts of protein were loaded in 
all wells (Figure 5.10 B). Vinculin, a 117-kDa ubiquitously expressed cytoskeletal 
protein was selected as “loading” control. The bands in all lysates had a consistent 
size, for both the IRF8-containing and “empty” vector-transfected cells. The Vinculin 
antibody showed no bands in the IP reactions, as the IRF8 and the mouse IgG2b 
antibodies did not immunoprecipitate the Vinculin protein.  
 
The Santa Cruz IRF8 antibody proved to be specific, as it detected only one band 
matching the predicted atomic mass of IRF8. The antibody was also able to 
immunoprecipitate the IRF8 protein, as evident from the larger size of the 48 kDa 






Figure 5.10. Western blot performed on lysates and IP reactions of HEK293T 
cells transfected with the IRF8-containing vector pIRES2-EGFP-HA-IRF8 and 
the empty vector pIRES2-EGFP.  
A. HEK293T lysates probed with an anti-HA antibody and the Santa Cruz IRF8 
antibody ICSBP (E-9): sc-365042. Approximately 90,000 cells were loaded in each 
well labelled as “lysate”. IP reactions were performed on 1.7 million transfected cells, 
using the IRF8 antibody and a mIgG control and were probed with the Santa Cruz 
IRF8 antibody. Labels above lanes denote the vector used for transfection. The 
ladder shows atomic mass of proteins in kDa. 







5.3.4 Optimisation of sonication settings 
As a sensitive and specific IRF8 antibody had been identified, the ChIP experiment 
was able to progress to the next optimisation step – the sonication settings. The 
testing covered two main aspects of the sonication: the number of cycles and the 
length of the OFF setting. Two different sonication settings, derived from different 
sources were used for testing. The protocol for the Active Motif kit, used for the ChIP 
experiment, recommended a starting setting of 10 cycles of 30 second ON and 30 
seconds OFF. The setting suggested by the manufacturer of the Bioruptor Pico 
sonicator (Diagenode) for our sample was 6 cycles of 30 seconds On and 90 
seconds OFF.  This recommendation took into account our sample volume (260-
300µl) and desired fragment length of 400bp (falling within the 200-1200bp range 
suggested by the manufacturer of the ChIP-Seq kit). 
 
Both suggested settings were tested on the same number of FACS-purified culture-
derived cDC1s. The Active Motif Low Cell protocol was used for ChIP and library 
prep, and the concentration and the fragment size distribution of the resulting 
libraries were assessed with Bioanalyser (Figure 5.11). A similar fragment size 
distribution was seen in both settings, most DNA fragments falling between 300 and 
450bp in size. However, the library produced from chromatin subjected to 6 cycles of 
sonication had higher concentration and molarity readings than the library produced 
following 10 sonication cycles. The readings for DNA concentration were 595.20 
pg/µl for the 6 cycles setting and 291.27pg/µl for 10 cycles. The molarity readings 
were 2,528.7 pmol/l and 1,278.7 pmol/l, respectively. The fragment size distribution 
and molarity of libraries from both tested setting were suitable for sequencing. 
However, peaks containing small DNA fragments below 200bp were detected in the 
sample subjected to 10 cycles of sonication, but not in the sample subjected to 6. 
These peaks are undesirable in a sequencing library, as they can undergo 





Figure 5.11. Bioanalyser electropherogram for ChIP libraries prepared from 
100,000 cultured, sorted, and formaldehyde-fixed cDC1s subjected to different 
sonication settings and readings for an empty well and the ladder ran on the 
same Bioanalyser chip.  
100,000 cDC1s were produced from CD34+ progenitors in OP9-DL1 culture to test 
each of the sonication conditions, then FACS-purified on day 19. The cells were fixed 
and subjected to 6 or 10 sonication cycles, then immunoprecipitated with 3µg of IRF8 
antibody (Santa Cruz Biotechnology) as part of the Low Cell ChIP-Seq protocol 
(Active Motif). The ChIP DNA was extracted and used for library preparation, 
quantified with the Bioanalyser high sensitivity DNA kit. The x axis indicates fragment 
size in base pairs, while the y axis shows signal intensity in fluorescence units. Peaks 
at 35bp and 10380bp seen on all plots represent lower and upper markers. 
 
Negative baseline dips were detected in all samples, as well as in the empty well and 
the ladder (Figure 5.11). According to the Agilent 2100 Bioanalyzer System 
Maintenance and Troubleshooting Guide (Agilent Technologies), this feature is 
caused by residual RNaseZap on the Bioanalyser instrument electrodes. However, 
this did not interfere with the interpretation of results, as none of the wells had a QC 
flag, and all ladder markers were detected. Based on the Biolanalyser results, both 6 
and 10 cycles of sonication produced useable libraries from 100,000 cDC1. However, 
the library prepared following 6 sonication cycles had a more appropriate fragment 
6 sonication cycles, 100,000 cells 






size distribution and a significantly higher concentration. The 6-cycle setting was 
therefore selected for further experiments. 
 
Next, the effect of cell number on the quality of the sequencing library was explored 
by undertaking the same experiment with 6 sonication cycles while using 50,000 
cDC1 cells as input. The resulting library displayed a fragment distribution of 300-
450bp and had readings for DNA concentration (829.32 pg/µl) and molarity (3,384 
pmol/l) comparable to the ChIP experiment performed with 100,000 cDC1 and 6 
sonication cycles (Figure 5.12). These results suggested that 50,000 cells, which is 
the minimum recommended by the Low Cell ChIP-Seq protocol (Active Motif), are 
sufficient for producing a sequencing library that does not differ in quality from a ChIP 




Figure 5.12. Bioanalyser electropherogram for a ChIP library prepared from 
50,000 cultured, sorted, and formaldehyde-fixed cDC1s subjected to 6 
sonication cycles.   
50,000 cDC1s were produced from CD34+ progenitors in OP9-DL1 culture, then 
FACS-purified on day 19. The cells were fixed and subjected to 6 sonication cycles, 
then immunoprecipitated with 3µg of the Santa Cruz IRF8 antibody of IRF8 antibody 
(Santa Cruz Biotechnology) as part of the Low Cell ChIP-Seq protocol (Active Motif). 
The ChIP DNA was extracted and used for library preparation, quantified with the 
Bioanalyser high sensitivity DNA kit. The x axis indicates fragment size in base pairs, 
while the y axis shows signal intensity in fluorescence units. Peaks at 35bp and 
10380bp represent lower and upper markers. 




5.4 Discussion  
The aim of this chapter was to optimise the IRF8 ChIP-Seq pipeline to probe the 
transcriptional programs and signaling pathways regulated by IRF8 in human IRF8-
expressing DC subsets. First, the identification of a ChIP-grade antibody was 
necessary, as the IRF8 antibody used in previous IRF8 ChIP studies had been 
discontinued. Sonication settings and effect of cell number were also explored for the 
low cell ChIP-Seq protocol. 
 
Performing antibody validation is critical before undertaking ChIP-Seq experiments, 
to ensure accurate and reproducible data, to maximise the financial efficiency and 
avoid wastage of limited human samples. When published, it also avoids duplication 
of work between labs and helps to ensure data quality, facilitating the collaborative 
use data across the research community. The ENCODE: Encyclopaedia of DNA 
Elements outlines rigorous criteria for testing candidate ChIP antibodies. These 
include primary and secondary characterisation steps. The first antibody selected for 
testing failed to detect IRF8 in an IRF8-expressing cell line and exhibited very low 
specificity, highlighting the need of rigorous testing of antibodies prior to preforming 
the ChIP-Seq assay. The second antibody selected for testing was a mouse 
monoclonal antibody manufactured by Santa Cruz Biotechnology, raised against the 
C-terminus of the human IRF8 protein. This antibody passed its primary 
characterisation testing, as it detected a single band corresponding to the atomic 
mass of IRF8 in 500,000 - 1,000,000 bone marrow CD34- cells. The antibody was 
also able to immunoprecipate the IRF8 protein and showed high specificity in IP 
followed by western blotting.  
 
The factors considered when optimising sonication settings included maximising 
DNA yield and generating appropriate sized DNA fragments. These criteria were best 
fulfilled by subjecting cells to 6 sonication cycles, compared to 10. The effect of cell 
number was also explored, and comparable sequencing libraries were produced 
using 50,000 and 100,000 cells. These data demonstrated the feasibility of 
performing IRF8 ChIP-Seq in low numbers of primary human DCs using the Santa 
Cruz IRF8 antibody and the Active Motif Low Cell ChIP-Seq protocol and optimised 





The use of limited human samples in the production of DCs for the optimisation 
experiment, as well as the high cost and the labour-intensive nature of the work (up 
to 3 weeks of cell culture, followed by cell sorting and a 5-day long ChIP-Seq 
protocol) limited the number of replicates and conditions studied during optimisation, 
representing a weakness of this study. Nevertheless, all tested conditions produced 
high quality libraries, suitable for sequencing on an Illumina instrument, which will 
ultimately be employed for the generation of ChIP-Seq data. 
 
5.5 Summary and further work 
Through the work in this chapter, a specific and sensitive IRF8 antibody was 
identified. The Santa Cruz IRF8 antibody met the criteria outlined by the ENCODE 
consortium and was able to detect IRF8 in human primary CD34- Lineage- bone 
marrow cells, as well as immunoprecipitate the heterologously expressed IRF8 
protein in HEK293T cells. The antibody was successfully used for ChIP experiments 
aimed at the optimisation of sonication settings for chromatin derived from culture-
derived DC.  
 
Future efforts should aim at including the Santa Cruz IRF8 antibody in the ENCODE 
database as a ChIP-validated antibody. Currently (2020), ENCODE lists 5 IRF8 






















Chapter 6. The role of IRF8 in cDC1 and pDC homeostasis 
 
Questions answered in this chapter: 
1. How do the functional modules controlled by IRF8 compare in human cDC1s and 
pDCs? 
2. What motifs are bound by IRF8 in cDC1s and pDCs?  
3. Does the auto-activation of IRF8 occur in mature human DC? 
 
6.1 Introduction 
IRF8 is a transcription factor of the interferon regulatory factor family, expressed by 
hematopoietic lineages, including DC, B cells, monocytes, and NK cells. Akin to 
many other members of the IRF family, IRF8 plays several crucial, yet diverse roles, 
in the lineage determination of immune cells, directing innate immune responses 
(including regulation of type I IFNs and IFN-inducible genes), controlling cell growth 
and survival, as well as in oncogenesis (Tamura et al., 2008).  As a transcription 
factor, IRF8 is able to regulate gene transcription in a positive or negative manner 
(Huang et al., 2007; Nelson et al., 1993). Regulation of the ability of IRF8 to activate 
or repress gene transcription is achieved via the association of IRF8 with different 
biding partners, in order to bind to certain promoter elements (Figure 6.1). IRF8 
associates with other IRFs (such as IRF1 and IRF2) to bind the IFN-stimulated 
response element (ISRE). In this case, IRF8 predominantly represses the 
transcription of type I IFNs and IFN-stimulated genes (Tamura et al, 2015). IRF8 
activates transcription via the association with Ets transcription factors (e.g. 
PU.1/SPI1 or SPIB) to bind the Ets–IRF composite element (EICE) or the IRF–Ets 
composite sequence (IECS). IRF8 also promotes gene activation via the formation of 
the IRF8–BATF3–JUN complex, which binds to activating protein-1 (AP-1)–IRF 





Figure 6.1. Transcriptional regulation by IRF8 and its interacting proteins 
(Tamura et al, 2015). 
Transcription factor IRF8 is able to regulate or repress gene expression by 
associating with different binding partners. Association of IRF8 with Ets family 
transcription factors (e.g. PU.1/SPI1) or transcription factor AP-1 (formed by the 
association of bZIP domain containing proteins BATF or BATF3 and JUN) leads to 
transcription activation. The interaction of IRF8 with other members of the IRF family 
often leads to negative regulation of transcription.  
 
From murine studies, IRF8 is known to be vital for the development of mononuclear 
phagocytes and crucial for driving lineage specification. The Irf8-/- mouse displays 
impaired immunity against viral infections, and has absent cDC1s and monocytes, 
reduced pDCs, expanded granulocyte precursors, and unaffected cDC2s (Turcotte et 
al., 2004; Sichien et al., 2016). cDC1s are the only cells sensitive to IRF8 
haploinsufficiency, as one copy of Irf8 is sufficient to support monocyte and pDC 
development (Sichien et al., 2016). IRF8 is required at several steps of cDC1 
development and is a terminal selector for this DC subset, maintaining end stage 
differentiation through its interaction with BATF3 (Grajales-Reyes et al., 2015). IRF8 
was shown not to be essential for pDC development, however it controls several 
functional modules in differentiated pDCs, such as production of type I IFNs and 
antigen presentation (Sichien et al., 2016). At the progenitor stage, IRF8 cooperates 
with PU.1/SPI1 to induce the expression of monocyte-related genes including the 
critical transcription factor KLF4 (Kurotaki et al, 2013). Crucially, IRF8 inhibits CEBPA 




2014). However, IRF8 is not required to maintain terminally differentiated monocytes 
(Sichien et al., 2016). 
 
The mechanisms of induction of Irf8 expression driving DC lineage specification have 
recently been described in mouse. Two distinct enhancers were identified within the 
Irf8 super-enhancer, located at 32 kb and 41 kb downstream of the Irf8 transcriptional 
start site (TSS) (Grajales-Reyes et al., 2015). The +32-kb enhancer is selectively 
active in mature cDC1s and contains several AICE motifs, bound by Irf8 and Batf3, 
suggesting that this enhancer might support Irf8 expression through auto-activation 
(Durai et al., 2019). The +41-kb Irf8 enhancer is active in differentiated pDCs, and is 
transiently accessible in cDC1 progenitors. Several E-box motifs are found within the 
+41-kb Irf8 enhancer, suggesting that E-proteins (e.g. E2-2/TCF4, a TF essential for 
pDC development, Cisse et al, 2008), could use this enhancer to drive Irf8 
expression in pDCs (Durai et al., 2019). Both enhancers are required at different 
stages of cDC1 development, and the switch between them is crucial for this lineage. 
Bagadia et al. (2019) proposed that this switch is controlled by Zeb2-Id2-Nfil3 
interactions that facilitate the development of cDC1s and maintain Irf8 expression. 
 
The majority of the insights into the role of IRF8 in vivo have been derived from 
murine studies, as genetically modified mouse models are powerful tools for 
exploring DC development and function, while human studies rely primarily on in vitro 
systems. The recent discovery of patients with primary immunodeficiency, caused 
solely by mutations in the IRF8 gene (Hambleton et al., 2011; Bigley et al. 2018; 
Cytlak and Resteu, 2020), shed some light on the role of IRF8 in human and 
revealed a phenotype broadly reminiscent of Irf8 deficient mice. In humans, biallelic 
IRF8 mutations cause complex immunodeficiency with myeloproliferation, absence of 
all monocytes and DCs, B and T cell defects, leading to susceptibility to viral and 
intracellular infections (Hambleton et al., 2011; Bigley et al, 2018). As in murine 
systems, the effects of IRF8 in human are gene dose-dependent, and heterozygous 
IRF8 mutations lead to cDC1 and often pDC deficiency, mild-moderate CD14+ 
monocytosis and NK cell defects, causing potential susceptibility to Epstein Barr 
Virus and intracellular organisms (Bigley and Collin, 2020; Cytlak and Resteu, 2020).  
 
Work by the Human DC Lab has previously described two patients with bi-allelic 




R83C/R291Q mutation) with a complete lack of monocytes and DCs (Hambleton et 
al., 2011; Bigley et al., 2018). K108E mutation results in loss of nuclear localization 
and transcriptional activity, as well as decreased protein stability (Salem et al., 2014). 
The R291Q alteration is orthologous to R294, mutated in the BXH2 mouse, which 
exhibits an immunodeficient phenotype similar to the IRF8 knockout mouse. R83C 
shows reduced nuclear translocation, and neither R291Q nor R83C mutant was able 
to regulate the Ets/IRF composite element or ISRE, while R291Q retained BATF-JUN 
interactions in vitro (Bigley et al., 2018). Together, the heterozygous parents of these 
patients, and a newly described kindred with an autosomal dominant phenotype due 






Figure 6.2. Quantification of blood DC and monocyte populations of subjects 
carrying IRF8 mutations (Cytlak and Resteu et al., 2020). 
Cont n=25, Het n=4 (IRF8R83C, IRF8R291Q and two subjects carrying heterozygous 
IRF8K108E mutations), Dom n=3 (IRF8V426fs), Bi n=2 (IRF8R83C/R291Q and 
IRF8K108E/K108E). Bars show mean+/- standard error of the mean, circles represent 
individual subjects. P values derived from two tailed Mann Whitney U testing 
(*p<0.05, **p<0.01). Cont – healthy controls; Het – patients with heterozygous IRF8 
mutation; Dom – patients with heterozygous dominant IRF8 mutation; Bi – patients 





This chapter aimed to elucidate the role of IRF8 in the homeostasis of human pDCs 
and cDC1s by analysing its DNA binding patterns in mature cells. Limited by 
technical restraints related to cell number, this was made possible by the generation 
of DC from primary stem/progenitor cells in vitro using the OP9/OP9-DL1 systems, 
described in detail in Chapter 3 of this thesis and by Kirkling and Cylak et al. (2018). 
This approach was employed to produce sufficient numbers of bona fide mature 
cDC1s and pDCs in order to perform chromatin immunoprecipitation followed by 
high-throughput DNA sequencing. Identification of IRF8 binding sites, related DNA 
motifs and genes in close proximity drove the exploration of pathways regulated by 
IRF8 and its binding partners in human.  
 
6.2 Materials and methods 
6.2.1 In vitro generation of cDC1s and pDCs from human bone marrow 
progenitors 
Bone marrow cells from hip replacement procedures were collected, stored and 
defrosted as described in Chapter 2 subsections 2.3.2 and 2.3.3. The BMMC were 
stained and FACS-purified as described in Chapter 2 subsections 2.3.6 using 
antibodies listed in Table 3.1. CD34+ Lineage- cells were retained for culture. To 
produce mature cDC1, FACS-purified CD34+ Lineage- progenitors were co-cultured 
with OP9-DL1 cells for 21 days, supplemented with 20 ng/ml granulocyte-
macrophage colony-stimulating factor (GM-CSF, R&D systems), 100 ng/ml FLT3-
ligand (Immunotools), and 20 ng/ml stem cell factor (SCF, Immunotools), as 
described in Chapter 2 subsection 2.3.5. For the production of pDC, FACS-purified 
CD34+ Lineage- progenitors were co-cultured with OP9 for 21 days, supplemented 
with a modified cytokine cocktail, as data from members of the lab (not shown) 
showed that lower FLT-ligand concentrations promoted pDC production. Therefore, 
for the generation of pDC, the following cytokine cocktail was used: 20 ng/ml 
granulocyte-macrophage colony-stimulating factor, 20 ng/ml FLT3-ligand and 20 
ng/ml stem cell factor.  
 
6.2.2 Chromatin immunoprecipitation, DNA extraction, and sequencing library 
preparation 
After 21 days of culture, OP9-DL1-derived cDC1s and OP9-derived pDCs were 




described in the methods for Chapter 5. Sonication of lysates following fixation was 
performed with the Bioruptor Pico (Diagenode) using the 6 cycles of 30 seconds ON 
and 90 seconds OFF setting, established to be best in the optimisation experiments. 
The total volume for each lysate (200µl) contained an average of 93,000 cells per 
replicate. Of this, 190µl were used for immunoprecipitation, and 10µl were used as 
input chromatin control.  
 
The Low Cell ChIP-Seq kit and Next Gen DNA Library Kit (Active motif) were used 
for cell fixation, immunoprecipitation, DNA extraction, and sequencing library 
preparation, according to manufacturer’s instructions and as described in detail in 
Chapter 5. 3µg IRF8 antibody (Santa Cruz (E-9): sc-365042) were used for 
immunoprecipitation. The input chromatin controls for each sample were prepared by 
extracting DNA from 10µl of sonicated lysate, as suggested by Dr Stefan Dillinger 
(Active motif). Lysates were transferred to PCR tubes and mixed with 70µl TE pH 8.0 
(Active motif) and 0.4µl RNase A (Invitrogen) via vortexing. The mix was incubated in 
a thermocycler at 37°C for 30 minutes. 0.8μl Proteinase K (Active motif) were added 
to each tube. Following a vortexing step, the tubes were incubated in a thermocycler 
at 55°C for 30 minutes. The temperature was then increased to 80°C for 2 hours. 
Each chromatin input was transferred into a 1.5ml microcentrifuge tube and mixed 
with 33ul of 5M ammonium acetate (Invitrogen), 0.8µl carrier (Active motif), and 
300µl absolute ethanol via vortexing. Tubes were chilled at -80°C for 30 minutes, 
then spun at 4°C in a microcentrifuge at 21,000xg for 15 minutes. The supernatant 
was carefully removed, and the pellet was washed with 500µl 70% ethanol and spun 
at 4°C in a microcentrifuge at 21,000xg for 5 minutes. The supernatant was removed, 
taking care not to disturb the pellet. Residual ethanol was removed with a P10 
pipette. Tubes were left uncapped and air dried for 15 minutes. When the pellets 
dried, 40µl Low EDTA TE (Active motif) were added to each tube and incubated at 
room temperature for 10 minutes, then vortexed to ensure the pellet was completely 
resuspended. The solution, containing the input chromatin, was used for library 
preparation with the Next Gen DNA Library Kit (Active motif). Following library 
preparation for the immunoprecipitation reactions and the controls, the DNA 
concentration, molarity, and fragment size distribution of the sequencing libraries was 





6.2.3 Generation and processing of ChIP-Seq data 
The Illumina NextSeq 500 platform at the Genomics Core Facility, Newcastle 
University, was employed to generate 150bp paired-end reads, averaging 27.7 
million per sample. The reads were demultiplexed with bcl2fastq version 2.19.0.316 
(Illumina). Adapter trimming, removal of low quality bases, and exclusion of short 
reads (below 70bp) were performed with Cutadapt version 1.9.1 (Martin, 2011) and 
FastQC version 0.11.2 (Simon Andrews, Babraham Institute) via the Trim Galore 
wrapper version 0.4.3 (Felix Krueger, Babraham Institute). Reads were aligned to the 
human reference genome GRCh38p12 (release29) with the BWA-MEM algorithm as 
part of the BWA software version 0.7.15 (Li, 2013). The SAM to BAM conversion was 
achieved with samtools version 1.3 (Li et al., 2009). PCR duplicates were removed 
using a Perl script provided by Active Motif, as part of the Low ChIP-Seq protocol. 
Peak calling was performed with MACS version 2.1.0.20150731 (Zhang et al., 2008) 
against input chromatin controls, and employed a q-val cut-off of 0.05. Additionally, 
all peaks identified on the mitochondrial chromosome were filtered out, as the IRF8 
protein is localised exclusively in the nucleoplasm (The Human Protein Atlas, 
https://www.proteinatlas.org), and therefore is not expected to directly regulate 
mitochondrial gene expression. Peaks mapped to chromosome Y were also removed 
from analysis, as all bone marrow donors used in this experiment were female. 
Further analysis was undertaken in R version 3.6 (R Core Team, 2019).  
 
6.2.4 Differential binding analysis  
The DiffBind R package version 2.12.0 (Ross-Innes et al., 2012) was used for 
counting reads within each peak (peak width was set to 500bp) and determining the 
consensus peaks present in at least two biological replicates of cDC1s and pDCs, as 
well as for differential ChIP-Seq analysis, including PCA and hierarchical clustering  
using the complete linkage method based on the Pearson’s distances. The Venn 
diagram displaying the overlap between cDC1s and pDCs consensus peaks was 
produced with the VennDiagram package version 1.6.20 (Chen, 2018).  
 
6.2.5 Peak annotation and pathway enrichment analysis 
The consensus peaks were annotated with the ChiPseeker package version 1.20.0 
(Yu et al., 2015). Gene symbols were converted into Entrez Gene IDs with the 




enrichment analysis for genes regulated by IRF8 in cDC1s and pDCs (with IRF8 
peaks located within the promoter region, +/-3kb from TSS), was performed with 
ClusterProfiler version 3.12.0 (Yu et al., 2012) against the Reactome biological 
pathways (Jassal et al., 2020). 
 
6.2.6 Motif analysis 
The GimmeMotif software (Bruse and van Heeringen, 2018) was used for motif 
enrichment analysis and for known motif scanning. The motif enrichment analysis in 
cDC1s and pDCs was undertaken with the “gimme motifs” command, using 500bp-
wide consensus peaks located within the promoter region of genes. The enrichment 
was performed against the GimmeMotifs database of known vertebrate motifs and 
transcription factors. The p-values for each motif were determined with the 
hypergeometric/Fisher’s exact test. The motif scan for the consensus peaks identified 
in cDC1s within +/-100kb of the IRF8 TSS was performed via the “gimme scan” 
command. The search was performed against the GimmeMotifs database and 
displays known bZIP, Ets, and IRF motifs identified within the 500bp-wide peaks. 
 
6.3 Results 
6.3.1 Overview of the IRF8 ChIP-Seq dataset 
To interrogate the IRF8 binding sites in human, an IRF8 ChIP-Seq experiment 
(optimised in Chapter 5) was performed using in vitro-derived cDC1s and pDCs as 
described in Chapter 3. Based on all IRF8 binding sites detected via ChIP-Seq, the 
two cell types showed a clear separation. This was confirmed both by hierarchical 
clustering and PCA (Figures 6.3 A and 6.3 B, respectively). These analyses also 
suggested that the cDC1 biological replicates bear more similarity to each other than 
the pDC, as they have higher positive correlation between the samples, and cluster 
more tightly together on the PCA plot. 
 
In order to further explore the differences, the number of peaks shared by the 
biological replicated of the two cells types were interrogated (Figure 6.4). Overall, a 
much higher number of peaks was noted in cDC1, with over 11,000 peaks present in 
all cDC1 replicates, in contrast to only 212 peaks shared by all pDC. In addition, a 
higher degree of overlap was evident in cDC1, which shared the majority of their 





Figure 6.3. Overview of the generated IRF8 ChIP-Seq dataset comprised of 
culture-derived cDC1s and pDCs with 3 biological replicates per cell type. 
A. Heatmap and clustering of the ChIP-Seq samples based on the read counts at all 
sites. The dendrogram positions together the samples with similar counts at binding 
sites. The colours of the heatmap represent the correlation between the samples, 
dark blue indicating high positive correlation, and light blue to white - low correlation.  
B. Principal component analysis based on the counts at all binding sites. The percent 









Figure 6.4. Venn diagrams showing IRF8 binding site overlaps in biological 
replicates of cDC1 (left) and pDC (right). 
The peaks were called with MACS2 (Zhang et al., 2008) against input chromatin 
controls corresponding to each sample. Peaks with q-values below 0.01 were 
processed, counted, and visualised within the DiffBind package in R (Ross-Innes et 
al., 2012). 
 
To focus on the high confidence data, peaks called with MACS2 (qval < 0.05) and 
present in at least two out of the three biological replicates, also known as consensus 
peaks, were used for further analysis. Over 20,000 peaks were identified in at least 
two of the cDC1 samples, 1,027 of which were shared with pDC. The number of 
pDC-specific peaks was lower, as only 389 peaks were identified in at least two of 
the pDC replicates (Figure 6.5). 
 
The consensus peaks identified in the IRF8 ChIP-Seq dataset were annotated with 
the ChiPseeker R package (Yu et al., 2015). Peak annotation bar charts (Figure 6.6) 
were used to explore the distribution of peaks. In both cDC1s and pDCs, more than 
half of the peaks were located in enhancer regions (distal intergenic and intronic 
regions), and around 20% of the peaks were found in promoter regions, a profile 





Figure 6.5. Venn diagram displaying the overlap between consensus peak 
regions in cDC1s and pDCs. 
The diagram was constructed using peaks called with MACS2 (qval < 0.05) in at 
least 2 of the 3 biological replicates for each of the cell types. 73% of pDC peaks 






Figure 6.6. Visualisation of the genomic annotation for the IRF8 binding peaks 
in cDC1s and pDCs.  
Annotation was performed with the ChiPseeker R package (Yu et al., 2015) for peaks 





6.3.2 IRF8 differentially regulates immune pathways in mature cDC1s and pDCs  
To determine the pathways regulated by IRF8 and mature cDC1s and pDCs, the 
genes with IRF8 peaks in the promoter region (+/-3kb from TSS) were selected for 
pathway enrichment analysis. The analysis revealed an array of functional modules 
regulated by IRF8 in cDC1s and pDCs (Figure 6.7 and Table 6.1). The vast majority 
of the pathways were linked to the function of the immune system. Neutrophil 
degranulation was the most significant among the commonly regulated pathways, 
both cell types containing a large number of genes from this pathway with IRF8 
peaks in the promoter region. Interferon signaling was also shared by both cell types, 
and interferon gamma signaling in particular was present in both cell types. Interferon 
alpha/beta signaling, however, emerged to be the only pDC-specific pathway 
regulated by IRF8. cDC1-specific pathways included numerous adaptive immune 
system features, such as MHC II antigen presentation, costimulation by the CD28 
family, and immunoregulatory interactions between a lymphoid and non-lymphoid 
cell, as well as innate immune functions, such as pattern recognition thorough NLRs, 
CLRs, and TLRs (within the MyD88 deficiency pathway). Remarkably, IRF8 itself was 
contained within the genes it regulates in cDC1s (Table 6.1), suggesting potential for 























Figure 6.7. Pathway enrichment analysis for genes regulated by IRF8 in cDC1s 
and pDCs. 
The dot plot displays the Reactome biological pathways enriched in one or both cell 
types (adjusted p-value < 0.05). The pathway enrichment analysis was performed 
using genes that have at least one peak identified in the promoter region (+/- 3kb 
from the TSS). The number of identified genes in each category is displayed in 
parentheses. The size of the dots represents the GeneRatio (the overlap between 
genes in each list and the genes associated with a Reactome term), and the colour 
represents the adjusted p-values (calculated based on the hypergeometric model 











Table 6.1. Biological pathways enriched in cDC1s and pDCs (adjusted p-
value<0.05). 
The table displays cells type, name of pathway in the Reactome database, as well as 






Next, motif analysis was undertaken to investigate the role of IRF8 co-operating 
factors and binding partners in cDC1 and pDC homeostasis. The majority of the 
sequences bound by IRF8 in both cell types were Ets and IRF motifs (Table 6.2 and 
Table 6.3) and a very similar top motif was shared. This Ets/C2H2 motif, most 
significantly enriched in both cell types, is known to be bound by IRF8 and IRF4 (a 
member of the IRF family), as well as their binding partners from the Ets family: SPI1 
and SPIB. Further motifs bound by IRF8 (motif GM.5.0.IRF.0013), and other 
members of the IRF family (GM.5.0.IRF.0010 and GM.5.0.IRF.0020) were identified 
in both cell types. In addition, multiple Ets motifs, bound by transcription factors 
ETS1, ETS2, ELF1, ELK1, ETV6 and ETV7, were shared. A number of differentially 
bound sequences were identified, including an IRF motif thought to be bound by 
IRF4 (GM.5.0.IRF.0017), strongly enriched in pDCs but not observed in cDC1s, in 
keeping with the known expression of IRF4 in pDCs but its absence in cDC1. bZIP 
motifs, bound by AP-1 forming transcription factors BATF3, BATF and JUN, were 
found exclusively in cDC1. In mice, the cooperation of Batf3 and Jun with IRF8 is 
crucial for maintaining the expression of Irf8 by auto-activation during the 
development of cDC1s (Grajales-Reyes et al., 2015). This prompted further 















Table 6.2. Known motifs enriched (adjusted p-value <0.005) in cDC1s within the 
IRF8 binding peaks. 
Peaks located in promoter regions were used for analysis. The table shows the motif 
name from the GimmeMotifs database of known vertebrate motifs and transcription 
factors known to bind them directly, and indirect or predicted factors. The p-value for 
the motif, determined with the hypergeometric/Fisher’s exact test, and its sequence 





Table 6.3. Known motifs enriched (adjusted p-value <0.005) in pDCs within the 
IRF8 binding peaks. 
Peaks located in promoter regions were used for analysis. The table shows the motif 
name from the GimmeMotifs database of known vertebrate motifs and transcription 
factors known to bind them directly, and indirect or predicted factors. The p-value for 
the motif, determined with the hypergeometric/Fisher’s exact test, and its sequence 
logo are shown. The height of the characters in the logo indicates their conservation. 
 
6.3.3 cDC1s maintain their cell identity through the auto-activation of IRF8 
Having shown the potential of IRF8 in regulating a number of key immune pathways 
in cDC1, the next step of the analysis focused on the induction and maintenance of 
IRF8 expression through self-activation. This phenomenon has been previously 
described in mouse, where enhancer and superhancer regions surrounding the IRF8 
gene contain motifs bound by IRF8 and its binding partners (Durai et al., 2019). 
Since enhancers can be located at great distances upstream or downstream away 
from the transcription start site of the genes they are regulating, all peaks called in 
the +/-100 kb region around the IRF8 TSS were visualised (Figure 6.8). No evidence 
of IRF8 auto-activation was found in mature pDC, as no common peaks were 
identified across the replicates. In contrast, multitude of peaks were present 




were located upstream of the IRF8 TSS at -32kb, -25kb, -16kb, one near the 3rd exon 
at +10kb, and three downstream at +37kb, +59kb, and +68kb.  
 
To further explore auto-activation of IRF8 in cDC1, a motif scan of the consensus 
peaks for known sites bound by IRF8 and its binding partners was undertaken. The 
scan included the transcription-activating bZIP (bound by JUN and BATF, forming 
AP-1) and Ets motifs (bound by ETS family TFs, such as SPI1), as well as IRF motifs 
(repressive if bound by an IRF8-IRF1,2 complex). Table 6.4 highlights the motifs 
identified in each of the peaks, together with the sequence bound, as well as 
transcription factors that that are known or predicted to bind them. The motif scan 
identified multiple sites with potential to act as enhancers, and all seven of the 
consensus peaks contained at least one of the motifs. The transcription-activating 
Ets motifs bound by known IRF8 partner SPI1(PU.1), were enriched in the peak at -
25kb, which contained eight Ets motifs, and present in the peaks at +10kb and 
+37kb, suggesting capacity for IRF8 auto-activation at these sites. Transcription-
activating bZIP motifs known to be bound by IRF8 partners BATF3, BATF and JUN 
were identified in the -16kb and +68kb. Notably, the motifs identified in the latter peak 
were bound by BATF3, a TF which maintains the expression of IRF8 by auto-
activation during development of cDC1s in cooperation with IRF8 and JUN (Grajales-
Reyes et al., 2015). Further motifs identified by the scan include a sequence bound 






Figure 6.8. Overview of peaks called with MACS2 (qval < 0.05) in the region 
between -50kb and +100kb around the IRF8 TSS in individual cDC1 and pDC 
samples.  
Consensus peaks, present within+/-100kb from IRF8 TSS in at least 2 biological 
replicates of cDC1s are marked with and arrow and their distance from IRF8 TSS is 
shown in red. No consensus peaks were observed in cDC1s or pDCs in the region 








Table 6.4. Motif scanning results for the 7 consensus peaks from the cDC1 
triplicates, highlighting the bZIP, Ets, and IRF motifs identified with 
GimmeMotif.  
For each peak, the following information is listed: rounded distance in relation to the 
IRF8 TSS, type of motifs identified by the scan, motif sequence, list of human and 
murine TF known or predicted to bind the motif, and as well as further notes, 
highlighting ETS family transcription factors and TFs known to form the AP-1 





The evidence of IRF8 auto-activation, along with the multitude of key immune 
modules controlled by IRF8 in cDC1, suggested that IRF8 plays a vital role in the 
homeostasis and function of these cells. To further investigate the role of IRF8 in 
controlling the genes that define the cDC1 identity, a published scRNA-Seq dataset 
encompassing mononuclear phagocyte subsets was interrogated. Via single cell 
transcriptomics, Villani et al. (2017) outlined a list of top six genes that mark the 
cDC1 lineage. The IRF8 ChIP-Seq dataset helped identify that out of the six marker 
genes, four genes (including surface markers CLEC9A and XCR1) had IRF8 peaks 
within the promoter region, and one had multiple intronic and distal intergenic peaks 
(Figure 6.9). In addition, the genes from an extended list of markers published by 
Villani et al. (2017) were interrogated in the ChIP-Seq dataset. Out of 112 cDC1 
signature genes, the majority of the gene showed potential IRF8 regulation. 47 genes 
(including multiple HLA class II genes, FLT3, and TLR10) had consensus peaks in 
the promoter region and a further 30 genes (including BTLA) containing peaks in the 
intronic or distal intergenic regions. This effect was not observed in pDC, where none 
of the top markers were controlled by IRF8, and only 15 out of the 390 marker genes 


















Figure 6.9. Heatmap displaying the expression of cDC1 marker genes identified 
by Villani et al., 2017, across peripheral blood DC and monocyte subsets.  
The heatmap was generated via the Single Cell Portal (The Broad Institute of MIT 
and Harvard) and displays the conventional notation for the DC and monocyte 
subsets. For each cDC1 marker gene, information is given on the consensus IRF8 
peak location in the cDC1 ChIP-Seq experiment, 4/6 cDC1 signature genes having at 
least 1 peak in the promoter region, 1/6 having multiple intronic and distal peaks, and 




Transcription factors are able to control cell fate at different phases of the cell 
lifespan via (1) prompting the specification of precursors toward a given lineage (2) 
suppressing alternative lineages to preserve the commitment of these precursors, (3) 
maintaining the cell identity of terminally differentiated cells, or (4) regulating key 
functional modules (Sichien et al., 2016). This chapter aimed to reveal the role of 
IRF8 in mature human pDC and cDC1, the two DC subsets marked by the 
expression of this transcription factor (Collin and Bigley, 2018), allowing indirect 




binding sites occupied by IRF8 in these DC lineages. Previously, this study was not 
possible in human due to the rarity of these cells in vivo and the requirement for 
millions of cells for the chromatin immunoprecipitation technique. The use of a novel 
OP9/OP9-DL1 culture system, designed to produce large numbers of bona fide DC 
subsets from human bone marrow progenitors, along with advances in the chromatin 
precipitation protocols, such as the development of the Low Cell ChIP-Seq method 
(Active Motif), facilitated the success of this experiment. Significant differences 
between the IRF8 binding sites in pDCs and cDC1s were apparent within the 
generated ChIP-Seq dataset.  
 
6.4.1 Role of IRF8 in cDC1s 
In cDC1, IRF8 regulates multiple immune pathways involved in innate and adaptive 
immunity, indispensable for their function as antigen-presenting cells. Crucially, 
among the functional modules controlled by IRF8 is the DC-defining antigen 
presentation via MHC Class II, which is the first step in CD4 T cell activation. IRF8 
also controls the costimulatory signal, mandatory for the activation of T cells. CD80 
and CD86, regulated by IRF8, are considered the most important costimulatory 
molecules, as they serve as very early costimulatory signals and can lead to both the 
inhibition and activation of T cells (Hubo et al., 2013). The CD80 and CD86 
molecules have intermediate expression in immature DCs and are upregulated in 
terminally differentiated DC, possibly due to the activator effect of transcription factor 
IRF8. The third signal required for T cell polarisation has also been found to be 
controlled by IRF8, mainly the production of IL-10, a potent immunomodulatory 
cytokine. Furthermore, IRF8 is likely to play a role in sensing and elimination of 
pathogens by cDC1. The transcription factor controls the signaling of three out of the 
four major pattern recognition receptors families, namely membrane-bound TLRs and 
CLRs, and cytoplasmic NLRs. Receptors TLR1, 4 and 6, regulated by IRF8, are 
specialised in the recognition of bacterial lipids. Additionally, TLR stimulation leads to 
the secretion of pro-inflammatory cytokines such as IL-6, TNF-alpha and IL-12 or 
anti-inflammatory cytokines such as IL-10, which shape the T-cell responses. CLRs 
recognise fungal and bacterial glycans, and are involved in the recognition of 
glycosylated self-antigens, and as adhesion and/or signalling molecules (van Kooyk, 
2008). NOD1, a member of the NLR family regulated by IRF8, senses intracellular 
bacterial peptidoglycan and can trigger signal transduction via NF-κB and MAPK 




presentation, and T cell priming, IRF8 was found to control cDC1 cell identity, as 
peaks were found in the promoter region of the most cDC1-defining marker genes 
and surface antigens, including the established markers XCR1 and CLEC9A. This 
finding is in line with the role of IRF8 in mouse cDC1s, where it acts as the terminal 
selector for this lineage and is therefore required to maintain the identity of terminally 
differentiated cells (Grajales-Reyes et al., 2015).  
 
Mature cDC1s are likely to maintain the expression of IRF8, critical for their function 
and phenotype, through auto-activation. Evidence of IRF8 auto-activation was found 
in the cDC1 ChIP-Seq in the form of peaks surrounding the IRF8 TSS, consistent 
across biological replicates. Two of the peaks identified upstream of IRF8 TSS 
closely resembled the peaks detected in murine cDC1s via IRF8 ChIP-Seq at -25kb 
and -16kb of IRF8 TSS (Grajales-Reyes et al., 2015). The peaks identified 
downstream of IRF8 TSS fell within the superenhancer region reported in murine 
cDC1, but were not an exact match with the peaks reported in murine studies 
(Grajales-Reyes et al., 2015). Notable peaks which contained several motifs bound 
by Ets factor PU.1/SPI1, a known IRF8 binding partner with an activator role, were 
located at -25kb, +10kb and +37kb relative to IRF8 TSS. Motifs bound by a second 
prominent IRF8 partner, BATF3, were found within the peak at +68 kb relative to the 
IRF8 TSS. These sites are strong candidates for IRF8 auto-activation, as both 
PU.1/SPI1 and BATF3 known to support IRF8 auto-activation at different stages of 
cDC1 development in mouse (Grajales-Reyes et al., 2015). In addition to the above-
described activating motifs bound by IRF8 and its partners, the scan revealed an E-
box canonical sequence motif within the +59kb peak. This advocates for the role for 
E-proteins in the induction of IRF8 expression in cDC1s, a concept recently proposed 
in murine studies (Durai et al., 2019). Further insights derived from the analysis 
include the presence of an IRF motif, known to be bound by Irf3, at +37kb from IRF8 
TSS. As cDC1s show IRF3 and IRF8 expression (Single Cell Portal, 
https://singlecell.broadinstitute.org/single_cell), this could be achieved by the direct 
interaction of the two transcription factors, previously demonstrated to play a role in 







6.4.2 Role of IRF8 in pDCs 
The pDC-specific role of IRF8 comprises the control of one of the pDC functional 
modules - the transcriptional regulation of the IFN α/β signaling. This is a significant 
role, as pDCs are the main producers of type I IFNs in response to viral infections 
(Tel et al., 2012). This observation is consistent with mouse models, where IRF8 
positively regulates essential functional modules in differentiated pDCs, such as 
production of type I IFNs, while being dispensable for pDC development (Sichien et 
al., 2016). Remarkably, no evidence of auto-activation was found in mature pDCs, 
suggesting that other mechanisms are employed to maintain IRF8 expression in 
these cells.  
 
pDCs, but not cDC1s, exhibit high expression of a second transcription factor from 
the IRF family – IRF4. Interestingly, a motif bound by IRF4 was strongly enriched in 
pDC. This can be explained by the direct interaction of the two transcription factors 
as cooperative partners (Humblin et al., 2017). Alternatively, the two IRF family 
transcription factors could bind similar motifs, due to their high homology (Antonczyk 
et al., 2019), and therefore functioning redundantly in binding certain motifs.  
 
6.4.3 Pathways likely to be downregulated by IRF8 
In both cDC1s and pDCs, IRF8 controls pathways relating to two biological terms: 
neutrophil degranulation and IFN g signaling, and likely represses the expression of 
the genes associated with these pathways. IRF8 is known to block the neutrophil 
differentiation programme to favour the development of DCs and monocytes 
(Kurotaki et al, 2014), and could act in a similar manner toward other neutrophil-
related genes, repressing their expression in mature cDC1s and pDCs. In the case of 
IFN g signaling, downregulation of the pathway is the also the most probable 
outcome, as IFN	g is primarily secreted by activated T cells and NK cells, and cDCs 
and pDCs show little capacity for its production (Vremec et al., 2007).  
 
6.4.4 IRF8 in immunodeficiency 
The findings of this chapter are congruent with the gene dosage-related phenotypes 
observed in patients with IRF8 deficiency. IRF8 haploinsufficiency manifests as a 
reduction or depletion of all DC subsets developing through the IRF8high pathway: 




the loss of IRF8, their numbers being selectively depleted as a result of the dominant 
negative T80A mutation in IRF8 (Kong et al., 2018). This observation is in line with 
the critical role IRF8 plays in the multiple aspects of cDC1 function and maintaining 
the identity of these cells, as determined by IRF8 ChIP-Seq. In heterozygotes, pDCs 
exhibit an abnormal pDC function due to deficits in IFNa and TNF production (Cytlak 
and Resteu, et al., 2020). Findings of this chapter revealed that the deficits in IFN 
a could be the direct cause of a lower IRF8 dosage in these individuals, as peaks 
corresponding this the transcription factor’s binding site were found in the promoter 
region of type I IFN-related genes, including the Interferon Alpha 16 (IFNA16) gene. 
An even lower IRF8 dosage is found in biallelic IRF8 deficiency, which leads to the 
complete loss of all monocyte and DC subsets, including cells developing through 
both the IRF8hi and IRF8low pathways (Bigley et al., 2018). Therefore, IRF8 plays and 
important, currently unrevealed roles in development of all monocyte and DC 
precursors in human. 
 
6.4.5 Technical caveats of the study 
This study relied heavily on the FACS-purification of pDCs and cDC1s prior to the 
ChIP-Seq assay. pDCs were defined as CD123+CD303/304+ cells, however the 
expression of the established pDC markers CD303/304 is fickle in culture. In 
addition, other cells have been shown to express CD123, including the pre-DC2 in 
Chapter 4 of this thesis. It is therefore likely that the population sorted as pDC is 
more heterogeneous than the cDC1 population, the markers for which (CLEC9A and 
CD141) are very faithful in culture. 
 
Other caveats include the interpretation of ChIP-Seq peaks. This work focused on 
the peaks located in the immediate vicinity of the gene TSS (+/-3kb), as often 
performed in similar studies. However, the location of the promoter of a gene near a 
peak does not absolutely guarantee that it is regulated by IRF8. In addition, distal 
peaks were excluded from analysis, as it was not possible to determine with 
confidence the genes they regulated. Further experimental data is required to explore 





6.5 Summary and further work 
Together, the findings of this chapter expand the knowledge about the role of 
transcription factor IRF8 in human. A unique ChIP-Seq dataset, generated within this 
project, demonstrated that IRF8 controls different functional modules in the IRF8-
expressing human DC subsets. In pDC, IRF8 controls an important functional 
module, type I IFN signaling. The role of IRF8 is different in cDC1, where it maintains 
both the function and surface phenotype of these cells. Strikingly, evidence of IRF8 
auto-activation was found in mature cDC1, but not pDC. 
 
In order to corroborate the role of IRF8 within the reported biological pathways in 
cDC1 and pDC, future efforts should focus on generating and analysing an RNA-Seq 
dataset that complements the ChIP-Seq samples. This will allow to assess the effect 
of IRF8 on the expression of genes within the pathways deemed significant by the 
ChIP-Seq analysis. The cells for this analysis have been produced in culture and 
subjected to FACS purification by the candidate and members of the Human DC Lab. 
However, the project was paused at the library preparation stage due to the impact of 
COVID19. 
 
To confirm the location of active transcription sites and define the enhancer and 
super-enhancer regions controlling the expression of IRF8 in human, further 
experiments should focus on histone ChIP-Seq in order to identify active promoters 
via H3K4me3 enrichment, inactive promoters via H3K27me3 enrichment, enhancers 
via enrichment of H3K4me1 and H3K27ac in regulatory regions, and active gene 
bodies with H3K36me3 enrichment. In addition, ChIP-Seq of IRF8 binding partners 
could reveal the interactions that are most crucial in maintaining IRF8 expression 
through auto-activation. Furthermore, genome-wide chromatin accessibility could be 
assessed with ATAC-Seq, which can be performed at single cell level, facilitating the 
use of small numbers of rare cells, such as DC and their precursors and progenitors. 
 
IRF8 is required at multiple stages of cDC1 development in mice, however this 
requirement has not yet been explained in human DC precursors. To reveal how 
IRF8 prompts the specification of precursors toward a given lineage, efforts should 
be made to perform IRF8 ChIP-Seq using recently defined pre-DC populations 




these cells in vivo and the difficulty of producing sufficient numbers of precursors in 
vitro under the current culture conditions of the OP9/OP9-DL1 systems. 
 
Finally, the role of IRF8 in the control of type I IFN signaling in pDC, will be explored 
further in the future. Since the produced ChIP-Seq experiment used unstimulated 
cells, the use of DCs stimulated with TLR ligands to actively produce interferons 
































Chapter 7. Overview, discussion, and further work 
7.1 Summary of novel findings 
This work explored multiple aspects of human dendritic cell development. A 
combination of approaches, including cytometry, transcriptomics and genomics, 
enabled the following novel observations to be made: 
 
1. Co-culture of human bone marrow CD34+ progenitors with feeder layer OP9 
in the presence of a cytokine cocktail generates all DC subsets in proportions 
similar to peripheral blood. The resulting pDCs, cDC1s, and cDC2s exhibit an 
appropriate phenotype and align closely with their ex vivo counterparts by gene 
expression analysis. 
 
2.  Addition of Notch ligand DL1 to the OP9 culture system results in an eleven-
fold increase of cDC1 output per progenitor cell (Kirkling and Cytlak et al., 
2018). The OP9-DL1 system, able to produce large numbers of bona fide cDC1s in 
vitro makes these cells more accessible for therapeutic use and research. 
 
3. cDC1s produced in culture closely resemble their ex vivo-derived tissue 
counterparts. Comparative transcriptomics revealed that OP9 and OP9-DL1 derived 
cDC1s bear higher resemblance to spleen and bone marrow cells than to cDC1s 
from peripheral blood. 
 
4. Human DC subsets develop in the bone marrow via two pathways, marked 
by differential expression of transcription factor IRF8 (Cytlak and Resteu et al., 
2020). A combination of cell culture and cutting-edge single cell analysis techniques 
facilitated the discovery that high IRF8 expression defines a developmental pathway 
giving rise to pDC, cDC1 and DC2. In contrast, the DC3 population arises through an 
IRF8low pathway with precursors independent from monocytes.  
 
5. A specific and sensitive IRF8 antibody was validated for ChIP-Seq. The Santa 
Cruz (E-9): sc-365042 IRF8 antibody met the characterisation criteria outlined by the 
ENCODE consortium (Landt et al., 2012). As part of the validation, this antibody was 
able to detect IRF8 in human ex vivo-derived bone marrow cells via western blotting 




HEK293T cell line. Following characterisation, the Santa Cruz antibody was 
successfully used to produce a low cell ChIP-Seq dataset.  
 
6. IRF8 controls different functional modules in the homeostasis of the IRF8-
expressing human DC subsets. Analysis of IRF8 ChIP-Seq data showed that this 
transcription factor is crucial for cDC1, where it maintains both the function and 
surface phenotype. In pDC, IRF8 controls an important functional module, IFN α/β 
signaling. 
 
7. Mature cDC1, but not pDC, show evidence of IRF8 auto-activation in human. 
Visualisation of the ChIP-Seq data revealed the presence of several peaks 
surrounding the IRF8 transcription start site in cDC1. Motif analysis showed that the 
majority of these peaks contained motifs bound by IRF8 and its binding partners with 
an activator role. This was not observed in mature pDC, suggesting that IRF8 
expression in these cells is maintained via different mechanisms. 
 
7.2 Overview of the techniques used 
The above-listed findings were made possible by employing a combination of novel 
and established methods and analysis pipelines. Initial work was performed using the 
NanoString gene expression assay, in order to validate the DC output of a novel in 
vitro culture system against ex vivo-derived DCs from peripheral blood. The 
NanoString system was selected, as it offered a material- and cost-effective method 
of assaying the expression of hundreds of Immunology-related genes via the use of 
the pre-built Immunology panel. The use of fluorescence activated sorting allowed for 
the purification and sorting of the DC subsets into lysis buffer, and due to the 
specialised chemistry of the NanoString assay, the lysates could be used directly for 
hybridisation, omitting the RNA isolation step, and therefore minimising the loss of 
material and cutting down on the cost and time needed for RNA extraction. In 
addition, the system was available in-house, and the samples were processed on the 
NanoString system shortly after cell sorting. This allowed to reduce the number of 
freeze-thaw cycles that cause degradation of RNA during sample shipping. 
Furthermore, the amount of time from cell sorting to obtaining the data on the 
NanoString system from as short as 48 hours. The data produced by the NanoString 
assay is in form of counts, each count being equivalent to one mRNA molecule, 




approaches. In this work, data normalisation was performed with the advanced 
analysis module of the nSolver software (NanoString Technologies), which selects 
the housekeeping genes with the most consistent expression across the samples 
and uses them as reference. Normalisation of NanoString data is a critical step, as 
the gene counts in each sample are affected by the concentration and quality of input 
RNA and by chaotropic agents and other contaminants originating from RNA 
extraction reagents or cell lysis buffers. As the nSolver software is not fully 
customisable, further data analysis was undertaken in the R environment, where it 
was possible to perform additional filtering of genes with background-level 
expression, as well as use a t-test to identify list of differentially expressed genes 
between all culture versus all ex vivo-derived populations, also referred to as “culture 
signature” (Figure 7.1). 
 
 
Figure 7.1. Analysis pipeline for NanoString data. 
The analysis steps are listed in blue boxes and the tools used at each stage are 
shown in grey. Data QC and normalisation steps were undertaken within the nSolver 
software (NanoString Technologies). Further analysis was performed within the R 






The second transcriptomic approach employed in this work was “low input” bulk 
RNA-Seq. A modified single cell protocol was used for this work, rather than standard 
RNA-Seq requiring tens of thousands of cells. This whole transcriptome analysis 
method was used to gain a better understanding of the identity of cDC1s produced in 
OP9 and OP9-DL1 culture, by comparing the transcriptomes of the in vitro-derived 
population to those of their counterparts from peripheral blood, bone marrow, and 
spleen. Generally, the production of RNA-Seq data entails a labour-intensive 
protocol, which involves the isolation or enrichment of cells of interest, RNA 
extraction, library preparation, then sequencing. In addition, the analysis of RNA-Seq 
data is more complex and labour-intensive than that of NanoString system output, 
and requires additional processing steps, often preformed using command line tools. 
In this work, the processing steps were performed on a computer cluster, due to their 
memory-intensive nature. An adaptation of analysis scripts provided by the 
Bioinformatics Support Unit at Newcastle University was used to trim and filter 
sequencing reads based on quality with Trimmomatic (Bolger et al., 2014), align 
them with the STAR mapping algorithm (Dobin and Gingeras, 2015), convert the 
alignment files from SAM format to the more compressed BAM format with SAMtools 
(Li et al., 2009), and count reads with HTSEQ (Anders et al., 2015) in order to 
generate the count table, which reports the number of reads assigned to each gene 
for each sequenced sample. As bulk RNA-Seq is an established technique, a 
multitude of analysis pipelines designed for performing comparative transcriptomics 
using count matrices have been made available, primarily in the R software 
environment. The data analysis in this thesis employed a widely-used pipeline for 
normalisation and differential expression – the DESeq2 R package (Love et al., 
2014). The goal of the RNA-Seq data normalisation is to control for sources of 
variation, such as differences in the sequencing depth of the samples. The DESeq2 
tool also performs the estimation of dispersion values for each gene, followed by the 
fitting of a generalised linear model to minimise sampling noise. Further “custom” 
methods that suited the analysis needs the most include the BubbleGUM software 
(Spinelli et al., 2015), employed to determine the blood and tissue signatures, and 
the single sample GSEA from the GSVA R package (Barbie et al., 2009; 
Hänzelmann, et al, 2013), applied to determine the enrichment of these signatures 






Figure 7.2. Analysis pipeline for bulk RNA-Seq data. 
The analysis steps are listed in blue boxes and the software programmes used for 
each step are shown in grey. The data processing was performed on a computer 
cluster, using command line tools. Further analysis was undertaken in the R 
environment by employing the DESeq2 pipeline, especially designed for RNA-Seq 
experiments. Other R packages, as well as the BubbleGUM software, were 
incorporated in the analysis pipeline in order to analyse the molecular signatures of 
tissue and blood DCs. 
 
Recent advances in sequencing lead to an increase in availability and decrease in 
cost of single cell RNA-Seq, enabling the use of this technology to dissect DC 
haematopoiesis in Chapter 4 of this thesis. The single cell plate-based approach was 
adopted, as it allows the index sorting of each cell and is able to generate better 
quality data and compared to droplet methods, such as 10X. However, this method is 
more expensive and labour intensive. The workflow for the generation of the scRNA-




FACS was employed to isolate single cells, rather than bulk cell populations. Pre-
processing steps of plate-based scRNA-Seq data often mimic those used for bulk 
transcriptome analysis, and in this work an almost identical pipeline was employed. 
However, the two approaches diverge once the count tables are obtained (Figure 
7.3). From this point, single cell specific tools are essential for analysis, primarily due 
to differences in the quality of the data, scRNA-Seq data containing many dropouts 
and having sparser gene counts. Tools specialised to handle single-cell gene 
expression data applied in this work include the scater R package (McCarthy et al., 
2017), employed to perform cell and gene QC and filtering and the SC3 R package 
(Kiselev et al., 2017), used to cluster the cells by gene expression and determine the 
markers defining each cluster of similar cells, and the Slingshot method for inferring 
cell lineages and pseudotimes (Street et al., 2018). As the scRNA-Seq datasets are 
often highly multidimensional, containing hundreds of cells and thousands of genes, 
their visualisation and interpretation can be challenging. Dimensionality reduction 
techniques, such as tSNE and diffusion maps, allow for low-dimensional 
representation of the expression data and are therefore indispensable for the single 
cell transcriptomic analysis (van der Maaten, 2008; Angerer et al., 2016). 
Transformation of data from a high-dimensional space into a low-dimensional space 
is also critical for computational analysis and visualising of flow and mass cytometry 
datasets. In this thesis, dimensionality reduction allowed the representation of all 
parameters constituting the cytometry datasets as 2D or 3D figures, in contrast to the 






Figure 7.3. Analysis pipeline for scRNA-Seq data. 
The analysis steps are listed in blue boxes and the tools used at each stage are 
shown in grey. The data processing was performed on a computer cluster, using 
command line tools. The data analysis was undertaken in the R environment and 
employed packages developed or adapted for scRNA-Seq data. 
 
The final two results chapters of this thesis revolved around the optimisation and 
analysis of low cell IRF8 ChIP-Seq for the cDC1 and pDC subsets. These 
experiments were made possible by recent advances in ChIP protocols, which 
allowed the use of under 100,000 cells for each ChIP reaction, in contrast to over a 
million cells, previously used in ChIP-Seq experiments. In addition, the rarity of cDC1 
in vivo, was addressed via a novel culture system, the output of which was verified by 
two transcriptomic approaches in addition to surface phenotype and functional 
assays (Kirkling and Cytlak et al., 2018). A hurdle encountered in these experiments 
was the commercial discontinuation of high-quality ChIP-grade IRF8 antibodies, 
previously used for most related studies (Langlais et al. 2016, Shin et al, 2011). This 
was overcome by the validation of a different antibody, following the characterisation 




techniques, such as western blotting, bacterial transformation and transfection of 
mammalian cell lines, as well as immunoprecipitation, were combined to ensure the 
specificity and sensitivity of the antibody. The generation of sequencing data was 
guided by the standards outlined by the ENCODE consortium 
(https://www.encodeproject.org) for Transcription Factor ChIP-seq. In accordance to 
the ENCODE experimental guidelines, each experiment had 3 biological replicates 
and employed an appropriately characterised antibody, each ChIP-Seq experiment 
had a corresponding input control experiment with matching run type, read length, 
and replicate structure, and most replicates contained over 20 million reads. In 
addition, ENCODE Uniform Processing Pipeline Restrictions were followed to 
generate 150bp paired-end reads (longer read lengths than 50 base pairs being 
encouraged). Upon production of the datasets, custom data processing and analysis 
pipelines were assembled by the candidate to suit the analysis needs (Figure 7.4). 
For the most  part, the data processing pipeline consisted of a set of established 
genomic tools, such as bcl2fastq (Illumina), used to assign reads to samples 
following multiplexed sequencing based on the indexes incorporated during library 
construction, Cutadapt (Martin, 2011) and FastQC (Simon Andrews, Babraham 
Institute), used for trimming of adapters and low quality bases, BWA-MEM (Li, 2013), 
a fast and accurate algorithm for mapping of DNA sequences against a large 
reference genome, and samtools (Li et al., 2009), a tool used for converting SAM 
files to the more compressed BAM format. To mitigate the effects of PCR 
amplification bias introduced during library preparation, which can interfere with 
downstream peak calling, a custom tool developed by Active Motif, Inc was applied to 
the BAM alignment files. First, a molecular identifier in the form of a 9 base N random 
sequence was incorporated into each DNA fragment prior to library construction. The 
custom tool recognised reads with identical molecular identifies as true PCR 
duplicates, leading to their removal.  Peak calling was undertaken with an improved 
version of a commonly used tool for identifying transcription factor binding sites, 
named Model-based Analysis of ChIP-Seq version 2 (MACS2, Zhang et al., 2008). 
Following the processing steps, performed on a computer cluster due to their 
prohibitive memory requirements, analysis of called peaks was migrated to the R 
environment, which contains a multitude of ChIP-Seq-specific packages and analysis 
pipelines. A blend of R packages was used to create an analysis pipeline that 
computes differentially bound sites from multiple ChIP-Seq experiments using affinity 




most replicates with ChIPseeker (Yu et al., 2015), and performs pathways analysis 
with ClusterProfiler (Yu et al., 2012). Motif analysis was migrated back to the 
command line environed, where a larger number of specialised tools, such as 
GimmeMotif (Bruse and van Heeringen, 2018) are available. Finally, the 
incorporation of the external single cell transcriptomic dataset published by Villani 
and colleagues (2017), was essential to verify and visualise the cDC1 marker genes 




Figure 7.4. Analysis pipeline for ChIP-Seq data. 
The analysis steps are listed in blue boxes and the tools used at each stage are 
shown in grey. Initial data processing and analysis, including peak calling, were 
performed on a computer cluster using command line tools. Further analysis tools 
include R packages, as well as the IGV software, used to visualise the genomic 






7.3 Research impact 
As described in the previous sub-chapter, multiple unique datasets have been 
generated and analysed throughout this project. The biological findings, as well as 
the data and the analysis pipelines represent valuable contributions to immunology. 
They pave the way to tackle future research including the leads and further questions 
raised through the work in this project. 
 
First, this project verified the identity of DCs produced in culture and established the 
critical role of Notch signaling for human cDC1 differentiation. These results were 
published (co-author) in collaboration with a research group that determined the 
crucial role of Notch signaling in the functional maturation of murine cDC1s (Kirkling 
and Cytlak et al., 2018). The OP9-DL1 culture system, able to produce large 
numbers of cDC1s in vitro via Notch stimulation, renders cDC1, the rarest DC subset 
in vivo, more accessible for therapeutic use and research. A research application has 
already been found for this culture method in Chapters 5 and 6 of this work, where it 
was applied to produce sufficient cells for the study of the role of transcription factor 
IRF8 in the homeostasis of cDC1s. The OP9 system, able to generate DC subsets in 
proportions similar to peripheral blood, was applied to produce pDCs for the IRF8 
ChIP-Seq experiment in Chapter 6 and aided the dissection of DC haematopoiesis in 
Chapter 4. The R code created for the analysis of NanoString gene expression data 
from ex vivo and culture-derived DCs and monocytes has been used as learning 
material by BSc and MSc students in the HuDC group. The RNA-Seq data 
processing and analysis pipelines for cDC1s from blood, tissue, and culture has been 
adapted for the exploration of other datasets generated within the HuDC Lab, such 
as the RNA-Seq data created to verify the identity of monocyte-derived Langerhans 
cells produced in culture via Notch stimulation through DLL4. The findings of 
transcriptomic analysis of the moLC have recently been published as part of a 
publication titled “Notch-mediated generation of monocyte-derived Langerhans cells: 
Phenotype and function” (Bellmann et al., 2020). 
 
Using the OP9 in vitro differentiation assay in combination with single cell methods, 
the research undertaken as part of Chapter 4 of this thesis revealed that two 
pathways of DC development are present in human bone marrow. Differential 
expression levels of transcription factor IRF8 marks for the two pathways, high IRF8 




producing DC3 and classical monocytes. This has not been previously reported in 
literature, as most studies of DC haematopoiesis did not account for the cDC2 
heterogeneity, which was first described in detail in 2017 by Villani and colleagues.  
Chapter 4 identifies the two distinct developmental pathways as the source of the 
cDC2 heterogeneity, as the DC2 and DC3 subsets develop via different routes. 
Furthermore, work undertaken this chapter revealed the previously unknown 
phenotypical identities of the progenitor populations with increasingly committed DC 
potential and determined that DC2s develop through subsets of LMPP and CD123-
/lowCD33- GMP, while DC3 follow a trajectory passing through the CD123-/lowCD33+ 
GMP phenotypic space, explaining the apparent dual lympho-myeloid origin of 
dendritic cells. An important observation made in this thesis was that DC3 are not 
monocyte-derived, despite of their inflammatory-like expression profile. Instead, the 
resemblance of DC3 and monocytes can be explained by the similar developmental 
routes followed by these cell types. The single cell transcriptomics data for primary 
human bone marrow progenitors and mature DCs and monocytes generated during 
this project have been deposited within the Gene Expression Omnibus data 
repository (accession numbers GSE142999 and GSE143002) and are available for 
use by other researchers. 
 
As part of Chapter 6 of this work, an IRF8 ChIP-Seq dataset for human cDC1s and 
pDCs has been generated and will be made available to other researchers upon 
publication of the related manuscript. This importance of this dataset lies in its 
uniqueness, as only a small number of ChIP-Seq datasets for transcription factor 
IRF8 in human are currently publicly available and none have been performed using 
human dendritic cells. Due to the lack of ChIP-validated IRF8 antibodies, extensive 
laboratory testing was undertaken as part of this project in order to identify a high-
quality ChIP-grade antibody. Efforts will be made to include the antibody used in this 
experiment in the ENCODE database. Collaborators of the HuDC Lab on the IRF8 
ChIP-Seq project have been informed about the potential of the newly characterised 
antibody and are planning to perform further independent validation and use it for 
ChIP-Seq experiments. Additionally, the analysis of the newly generated ChIP-Seq 
data expanded the knowledge about transcription factor IRF8 and uncovered its 
diverse role in the homeostasis of human DC subsets. A pipeline for the analysis of 




be applied to any ChIP-Seq datasets that will be generated within the HuDC group in 
the future. 
 
7.4 Limitations of the project 
Together, this work greatly expands the knowledge about the development of human 
dendritic cells. However, conducting research on this cell type in human is restricted 
by certain limitations. Dendritic cells are extremely rare in vivo, and are difficult to 
obtain in sufficient numbers for research studies. cDC1 cells are particularly rare, 
found in very low numbers in peripheral blood (an average of 500 cells per mL of 
blood, or 0.1% of PBMC; Collin et al 2013). Although they may be more abundant in 
tissues, for example splenic or lymphoid tissue, this material is less accessible for 
human research. Typically, the volume of blood drawn from healthy volunteers does 
not exceed 180mL, giving a total of 90,000 cDC1s in most samples cells. The loss of 
30-40% of cells during FACS and subsequent steps further reduces the quantity of 
available material (Sutermaster et al., 2019), restricting the genomic and 
transcriptomic methods that can be used to study these cells to low input 
technologies. The most common methods for cell isolation and purification are FACS 
and magnetic-activated cell sorting. While magnetic-activated cell sorting is a faster 
method, the low purity resulting from this protocol renders it suboptimal for DC 
research. The rarity of dendritic cells was overcome by the use of the scalable OP9 
and OP9-DL1 culture systems, able to generate sizable numbers of DC from human 
bone marrow progenitors. Nevertheless, the scarcity of the samples remains an 
issue, and in particular the limited availability of healthy donor bone marrow. In this 
project, bone marrow obtained from hip replacement surgery was used to meet the 
high demand for CD34+ progenitors for cell culture. However, the majority of patients 
undergoing this type of surgery are of an advanced age, limiting the samples further, 
if all age groups are to be represented. As the immune system and the process of 
haematopoiesis undergo changes with aging (Gubbels Bupp et al., 2018), it was 
imperative to not focus on a certain age group in this project. Therefore, the bone 
marrow samples used for culture were carefully selected to include range of age 
groups, and for ChIP-Seq donors were aged between 28 and 50. In addition, only 
samples derived from female donors were used in this analysis, as differences 
between male and female immune systems have recently come to light (Moulton, 





In addition, each of the multitude of techniques employed in this project has its 
advantages and limitations. As mentioned above, the purification of cell populations 
for downstream genomic and transcriptomic applications relied heavily on FACS. 
Drawbacks of this technology include the relatively low number of antigens (up to 18) 
than can be evaluated in each assay. In addition, FACS can only examine the 
expression of surface markers and cannot determine the expression of intercellular 
proteins (including transcription factors) on live cells, as intercellular staining 
commonly requires a permeabilisation step which causes cell damage and death. 
Furthermore, cell sorters commonly employ a gating strategy consisting of a 
sequence of 2D scatter plots. The software used for cell sorting in this project, 
allowed up to 8 scatter plots, leading to the adoption of alternative gating strategies 
for the sorting of large numbers of complex populations in order to accommodate this 
limit. 
 
Further technical limitations stem from the genomic and transcriptomic approaches 
adopted in this work. While the NanoString assay is a robust alternative for a low 
input gene expression assay, its multiplexing capability is limited to 800 genes. The 
pre-built NanoString Immunology panel was the most economical to use for DC 
research. Nevertheless, many genes present in this panel covered other aspects of 
the immune system and were not expressed by DCs. This was in part overcome by 
the addition of 30 custom DC-related genes. However, approximately one third of the 
608 total assayed genes displayed background-level counts. The detection of all 
known DC subsets was still possible based on the expressed genes.  
 
The scRNA-Seq method, while being invaluable for dissecting haematopoiesis in 
Chapter 4, has a number of limitations. The first challenge of this method is the 
isolation of single cells, which often leads to cell loss, and depending on the 
technology used, may cause a high proportion of doublet cells to be sequenced. In 
addition, a variable proportion of low quality data is generated due to sequencing of 
broken or dead cells. QC of single cell data is therefore crucial in order to remove 
poor quality cells. Outlier cells are commonly removed based on the total number of 
detected features, total gene counts and percentage of counts derived from ERCC 
spike-ins and mitochondrial genes. These steps were used in this project to filter out 
doublets with abnormally high numbers of detected features, and remove damaged 




reads derived from spike-ins, rather than endogenous genes, and significant 
mitochondrial contamination. This QC step relies on the proportion of mitochondrial 
genes, increased as the cell dies, but doesn’t take into account of any lineage 
differences in expression of mitochondrial genes. Due to low amounts of starting 
material, the scRNA-Seq data is also prone to dropout events, occurring when 
specific transcripts cannot be detected and adding substantial challenges for the 
computational analysis of this data. As the scRNA-Seq datasets are noisier than bulk 
RNA-Seq, specialised tools must be used for the analysis. The scRNA-Seq methods 
are continuously evolving, which brings benefits such as decrease in cost and 
improvement of data quality. However, this constituted a hindrance in this project, 
due to alterations over the years in the protocol for the generation of the scRNA-Seq 
data at the Wellcome Centre for Human Genetics, where sequencing was performed. 
This led to the inability to efficiently remove batch effects in order to combine the 
datasets containing BM CD34+ progenitors and BM CD34med precursors and mature 
DCs, generated at different points in time. These scRNA-Seq datasets were 
therefore analysed separately, and mass cytometry data were generated to explore 
the BM CD34high and CD34med fractions, along with mature cells as a single dataset.   
 
The transcription factor ChIP-Seq method was used study the role of TF IRF8 in the 
homeostasis of IRF8-expressing DC subsets in human. However, despite being a 
long-established technique, this assay required extensive optimisation, to which 
Chapter 5 was dedicated. The quality of the ChIP-Seq data relies heavily on the 
antibody used for immunoprecipitation, and multiple molecular biology techniques 
had to be used to ensure the adequate specificity of the employed IRF8 antibody. 
The number and duration of sonication cycles was one of the aspects that required 
optimisation. This was a time-consuming experiment, as DCs were first produced in 
14-21 days of culture, then fixed and sonicated, and the full 5-day ChIP-Seq protocol, 
including the library preparation had to be performed in order to assess the effect of 
different sonication settings. Assessment of fragment size was not possible 
immediately after sonication, due to the use of a low number of cells, and was 
performed after PCR amplification as part of library construction protocol. The 
minimal number of cells required for the low input ChIP-Seq protocol is 50,000 for 
each replicate, which allowed us to use this technique for mature culture-derived DC. 




progenitors, which are extremely rare in vivo and transient in culture, and on ex vivo-
derived mature DCs. 
 
7.5 Future research vision 
Further work will aim to: 
1. Study and optimise the OP9/OP9-DL1 culture system. Further optimisation 
of the culture system will be performed, aiming to enhance it as a research 
tool and to adapt it for use in DC therapy. To increase the yield of DCs both for 
research and therapy, introduction of a CD34+ progenitor expansion step in 
the first days of culture will be attempted. Further aspects to be investigated 
include: 
a. Examining the effect of exogenous factors: the effect of alternative or 
additional growth factors or cytokines on the quantity, phenotype or 
function of the output cells, including factors which activate or tolerise the 
cells. The culture will also be altered with the goal to produce sufficient 
numbers of DC progenitors, which can be used for further studies or tolDC 
therapy. 
b. Determining the OP9 factors are necessary for human DC development, 
including cell-cell contact and secreted factors, allowing the design of a 
mouse-stromal cell free system. This approach is in line with the aim to 
reduce the use of the animal-derived products in the culture system, such 
as the feeder layer and the foetal calf serum, in order to allow the adoption 
of this system for therapeutic use. 
c. Determining the autocrine factors that influence the culture output. As DCs 
develop they may secrete factors which inhibit or support other DCs for 
homeostasis.  
 
2. Explore the developmental pathways disrupted by mutations in IRF8. 
This will be achieved via the generation and analysis of scRNA-Seq datasets 
encompassing cells derived from patients with heterozygous and homozygous 
IRF8 mutations. The single cell transcriptomics data will help uncover the 
dose-dependent effect of IRF8 on the development of individual cells within 





a. CRISPR-Cas9 techniques to introduce known mutations into primary 
CD34+ cells to explore the phenotypes in vitro.  
b. Creation of induced pluripotent stem cells from patient cells for in vitro 
studies. 
c. Co-immunoprecipitation experiments to determine whether mutations 
affect the IRF8 binding partners. 
d. ChIP-Seq of cells carrying IRF8 mutations to establish the effect of 
mutations on IRF8 transcriptional regulation – both for cell development 
and for functional responses, e.g. to IFN stimulation. 
 
3. Validate the IRF8 ChIP-Seq findings. IRF8 can act as an activator or 
repressor of gene expression, and the effect of IRF8 on the biological 
pathways deemed significant by the ChIP-Seq analysis is presently unknown. 
Analysis of pDC and cDC1 RNA-Seq data from a complementary experiment 
will reveal the levels of expression of IRF8-regulated genes and help infer the 
role of this transcription factor in regulating the expression of individual genes 
and biological pathways. The active and inactive promoters will be verified via 
histone ChIP-Seq, and the chromatin accessibility at IRF8 binding sites will be 
explored with single cell ATAC-Seq on the 10X platform. Further ChIP-Seq 
experiments involving IRF8 binding partners with an activator role (such as 
BATF3 and PU.1) will reveal the interactions most crucial for the homeostasis 
of human DC subsets. The validation of IRF8 auto-activation in cDC1s will 
also be performed via CRISPR-Cas9 knock out of IRF8 peaks surrounding the 
IRF8 gene in order to determine the sites necessary for the different elements 
of IRF8 function.  
 
4. Investigate the role of IRF8 in the development of cells emerging from 
the IRF8high pathway. This will be explored via an IRF8 ChIP-Seq experiment 
of increasingly committed progenitor populations, the phenotypic identities of 
which were revealed in Chapter 4 of this work. However, this can only be 
achieved via further optimisation of the culture system in order to produce 
larger number of progenitors. Alternatively, modifications can be applied to the 
ChIP-Seq protocol with the aim to decrease the number of cells required per 
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Appendix A.  Microscopy of cells produced in culture 
 
 
Microscopy of the cells produced within the OP9-DL1 culture system on days 
3, 6, and 19 of culture. 
3,000 bone marrow CD34+ progenitors were co-cultured with 5,000 OP9-DL1 murine 
bone marrow stromal cells in the presence of growth factors SCF, GM-CSF, and 

























Appendix B.  List of antibodies used for flow cytometry, FACS and 
mass cytometry in Chapter 4 
 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Mouse anti-APC 176 Yb, clone APC003 Fluidigm Cat# 3176007B 
Mouse anti-human AXL APC, clone 108724 R&D Systems Cat# FAB154A 
Mouse anti-human AXL purified, clone 108724 R&D Systems Cat# MAB154; 
RRID:AB_2062558 
Mouse anti-human BTLA 163Dy, clone MIH26 Fluidigm Cat# 3163009B 
Mouse anti-human BTLA BV650, clone J168-540 BD Biosciences Cat# 564803; 
RRID:AB_2738962 
Mouse anti-human CD1c APC-Cy7, clone L161 BioLegend Cat# 331520; 
RRID:AB_10644008 
Mouse anti-human CD1c PE-Cy7, clone L161 BioLegend Cat# 331516; 
RRID:AB_2275574 
Mouse anti-human CD1c PerCP-Cy5.5 , clone L161 BioLegend Cat# 331513; 
RRID:AB_1227536 
Mouse anti-human CD1c purified, clone L161 BioLegend Cat# 331502; 
RRID:AB_1088995 
Mouse anti-human CD2 151Eu, clone TS1/8 Fluidigm Cat# 3151003B 
Mouse anti-human CD2 BV421, clone TS1/8 BioLegend Cat# 309217; 
RRID:AB_10915139 
Mouse anti-human CD2 PE-CF594, clone RPA-2.10  BD Biosciences Cat# 562300; 
RRID:AB_11153492 
Mouse anti-human CD3 AF700, clone SK7 (Leu-4) BioLegend Cat# 344822; 
RRID:AB_2563420 
Mouse anti-human CD3 FITC, clone SK7(Leu-4) BD Biosciences Cat# 345763 
Mouse anti-human CD3 PE, clone SK7(Leu9) BD Biosciences Cat# 345765 
Mouse anti-human CD5 BUV737, clone UCHT2 BD Biosciences Cat# 564451; 
RRID:AB_2714177 
Mouse anti-human CD5 purified, clone L17F12 BioLegend Cat# 364002; 
RRID:AB_2564477 
Mouse anti-human CD7 FITC, clone Leu-9 BD Biosciences Cat# 347483; 
RRID:AB_400309 
Mouse anti-human CD7 PE, clone M-T701  BD Biosciences Cat# 332774 
Mouse anti-human CD10 156Gd, clone HI10a Fluidigm Cat# 3156001B 
Mouse anti-human CD10 BV650, clone HI10a BD Biosciences Cat# 563734; 
RRID:AB_2738393 
Mouse anti-human CD11b 144Nd, clone ICRF44 Fluidigm Cat# 3144001B 
Mouse anti-human CD11c 159Tb, clone Bu15 Fluidigm Cat# 3159001B 
Mouse anti-human CD11c AF700, clone B-ly6 BD Biosciences Cat# 561352; 
RRID:AB_10612006 
Mouse anti-human CD11c APC-Cy7, clone Bu15 BioLegend Cat# 337218; 
RRID:AB_10662746 
Mouse anti-human CD11c BV711, clone B-ly6 BioLegend Cat# 301630; 
RRID:AB_2562192 
Mouse anti-human CD14 BV650, clone M5E2 BioLegend Cat# 301835; 
RRID:AB_11204241 
Mouse anti-human CD14 FITC, clone M5E2 BD Biosciences Cat# 555397; 
RRID:AB_395798 
Mouse anti-human CD14 PE, clone M5E2 BD Biosciences Cat# 555398; 
RRID:AB_395799 
Mouse anti-human CD14 PE-Cy7, clone HCD14 BioLegend Cat# 325618; 
RRID:AB_830691 
Mouse anti-human CD14 purified, clone M5E2 BioLegend Cat# 301802; 
RRID:AB_314184 
Mouse anti-human CD15 164Dy, clone W6D3 Fluidigm Cat# 3164001B 





Mouse anti-human CD15 BV605, clone W6D3 BD Biosciences Cat# 562979; 
RRID:AB_2744292 
Mouse anti-human CD16 209Bi, clone 3G8 Fluidigm Cat# 3209002B 
Mouse anti-human CD16 AF700 , clone 3G8 BioLegend Cat# 302026; 
RRID:AB_2278418 
Mouse anti-human CD16 FITC, clone 3G8 BD Biosciences Cat# 335035 
Mouse anti-human CD16 PE, clone 3G8 BD Biosciences Cat# 555407; 
RRID:AB_395807 
Mouse anti-human CD16 PE-Dazzle594, clone 3G8 BioLegend Cat# 302054; 
RRID:AB_2563639 
Mouse anti-human CD19 AF700 , clone 4G7/HIB19 BioLegend Cat# 302226; 
RRID:AB_493751 
Mouse anti-human CD19 FITC, clone 4G7 BD Biosciences Cat# 345776 
Mouse anti-human CD19 PE, clone HIB19 BD Biosciences Cat# 555413; 
RRID:AB_395813 
Mouse anti-human CD20 AF700 , clone L27/2H7 BioLegend Cat# 302322; 
RRID:AB_493753 
Mouse anti-human CD20 FITC, clone L27 BD Biosciences Cat# 345792 
Mouse anti-human CD20 PE, clone L27 BD Biosciences Cat# 345793 
Mouse anti-human CD33 158Gd, clone WM53 Fluidigm Cat# 3158001B 
Mouse anti-human CD33 APC, clone P67.6 BD Biosciences Cat# 345800 
Mouse anti-human CD33 BV711, clone WM53 BD Biosciences Cat# 563171; 
RRID:AB_2738045 
Mouse anti-human CD34 166Er, clone 581 Fluidigm Cat# 3166012B 
Mouse anti-human CD34 APC-Cy7, clone 581 BioLegend Cat# 343514; 
RRID:AB_1877168 
Mouse anti-human CD34 BV605, clone 581 BioLegend Cat# 343529; 
RRID:AB_2562193 
Mouse anti-human CD34 FITC, clone 8G12 BD Biosciences Cat# 345801 
Mouse anti-human CD34 PE-CF594, clone 581 BD Biosciences Cat# 562383; 
RRID:AB_11154586 
Mouse anti-human CD36 155Gd, clone 5-271 Fluidigm Cat# 3155012B 
Mouse anti-human CD38 PE-Cy7, clone HB7 BD Biosciences Cat# 335825 
Mouse anti-human CD38 purified, clone HB-7 BioLegend Cat# 356602; 
RRID:AB_2561794 
Mouse anti-human CD45 89Y, clone HI30 Fluidigm Cat# 3089003B 
Mouse anti-human CD45 APC-Cy7, clone 2D1 BD Biosciences Cat# 557833; 
RRID:AB_396891 
Mouse anti-human CD45 V450, clone 2D1 BD Biosciences Cat# 642275; 
RRID:AB_1645755 
Mouse anti-human CD45RA 153Eu, clone HI100 Fluidigm Cat# 3153001B 
Mouse anti-human CD45RA BV510, clone HI100 BioLegend Cat# 304142; 
RRID:AB_2561947 
Rat anti-human CD52 PE, clone YTH34.5 Bio-Rad Cat# SFL1642PE; 
RRID:AB_324131 
Mouse anti-human CD56 FITC, clone NCAM16.2 BD Biosciences Cat# 345811 
Mouse anti-human CD88 PE, clone S5/1 BioLegend Cat# 344304; 
RRID:AB_2067175 
Mouse anti-human CD88 purified, clone C5AR BioLegend Cat# 344302; 
RRID:AB_2259318 
Mouse anti-human CD90 161Dy, clone 5E10 Fluidigm Cat# 3161009 
Mouse anti-human CD90 AF700, clone 5E10 BioLegend Cat# 328120; 
RRID:AB_2203302 
Mouse anti-human CD90 PerCP-Cy5.5, clone 5E10 BioLegend Cat# 328118; 
RRID:AB_2303335 
Human anti-human CD100 APC-Vio770, clone REA316 Miltenyi Biotec Cat# 130-104-604; 
RRID:AB_2654328 
Mouse anti-human CD100 purified, clone A8 BioLegend Cat# 328401; 
RRID:AB_1236386 





Mouse anti-human CD116 BV421, clone hGMCSFR-M1 BD Biosciences Cat# 564045; 
RRID:AB_2738561 
Mouse anti-human CD116 BV650, clone hGMCSFR-M1 BD Biosciences Cat# 564044; 
RRID:AB_2738560 
Mouse anti-human CD116 purified, clone 4H1 BioLegend Cat# 305902; 
RRID:AB_314568 
Mouse anti-human CD117 BV605, clone 104D2 BD Biosciences Cat# 562687; 
RRID:AB_2737721 
Mouse anti-human CD117 PE, clone 104D2 BD Biosciences Cat# 332785 
Mouse anti-human CD117 purified, clone 104D2 BioLegend Cat# 313201; 
RRID:AB_314980 
Mouse anti-human CD123 143Nd, clone 6H6 Fluidigm Cat# 3143014B 
Mouse anti-human CD123 BUV395, clone 7G3 BD Biosciences Cat# 564195; 
RRID:AB_2714171 
Mouse anti-human CD123 BV421, clone 6H6 BioLegend Cat# 306018; 
RRID:AB_10962571 
Mouse anti-human CD123 PerCP-Cy5.5, clone 7G3 BD Biosciences Cat# 558714; 
RRID:AB_1645547 
Mouse anti-human CD135 BV711, clone 4G8 BD Biosciences Cat# 563908; 
RRID:AB_2738479 
Mouse anti-human CD135 purified, clone BV10A4H2 BioLegend Cat# 313302; 
RRID:AB_314987 
Mouse anti-human CD141 BV510, clone 1A4 BD Biosciences Cat# 563298; 
RRID:AB_2728103 
Mouse anti-human CD141 purified, clone M80 BioLegend Cat# 344102; 
RRID:AB_2201808 
Mouse anti-human CD161 PE-Cy7, clone HP-3G10 Thermo Fisher Scientific Cat# 25-1619-42; 
RRID:AB_10807086 
Mouse anti-human CD303 147Sm, clone 201A Fluidigm Cat# 3147009B 
Mouse anti-human CD303 APC, clone 201A BioLegend Cat# 354206; 
RRID:AB_11150412 
Mouse anti-human CD303 BV605, clone 201A BioLegend Cat# 354224; 
RRID:AB_2572149 
Mouse anti-human CD304 169Tm, clone 12C2 Fluidigm Cat# 3169018B 
Mouse anti-human CD304 APC, clone 12C2 BioLegend Cat# 354506; 
RRID:AB_11219600 
Mouse anti-human CD304 BV605, clone U21-1283 BD Biosciences Cat# 743130; 
RRID:AB_2741297 
Mouse anti-human CLEC9A PE, clone 8F9 BioLegend Cat# 353804; 
RRID:AB_10965546 
Mouse anti-human CLEC9A purified, clone 8F9 BioLegend Cat# 353802; 
RRID:AB_10983070 
Rat anti-human CX3CR1 APC, clone 2A9-1 BioLegend Cat# 341610; 
RRID:AB_2087424 
Mouse anti-human FceRI 150Nd, clone AER-37 (CRA-1) Fluidigm Cat# 3150027B 
Mouse anti-FITC purified, clone FIT-22 BioLegend Cat# 408305; 
RRID:AB_2563769 
Mouse anti-human HLA-DR 173Yb, clone L243 Fluidigm Cat# 3173005B 
Mouse anti-human HLA-DR AF700, clone G46-6 BD Biosciences Cat# 560743; 
RRID:AB_1727526 
Mouse anti-human HLA-DR BV785, clone L243 BioLegend Cat# 307642; 
RRID:AB_2563461 
Mouse anti-human HLA-DR PerCP-Cy5.5, clone L243 BioLegend Cat# 307629; 
RRID:AB_893575 
Mouse anti-human ID2 purified, clone 4E12G5 Thermo Fisher Scientific Cat# MA5-17095; 
RRID:AB_2538566 
Mouse anti-human IFN-a PE , clone LT27:295 Miltenyi Biotec Cat# 130-092-601; 
RRID:AB_871560 
Rat anti-human IL-10 APC, clone JES3-9D7 BioLegend Cat# 501410; 
RRID:AB_315176 
Mouse anti-human IL-12p40/p70 BV421, clone C8.6 BD Biosciences Cat# 565023; 
RRID:AB_2739045 





Mouse anti-human IL-8 PE-Cy7, clone E8N1 BioLegend Cat# 511416; 
RRID:AB_2565291 
Rat anti-human IRF4 PE, clone 3E4 Thermo Fisher Scientific Cat# 12-9858-80; 
RRID:AB_10853179 
Mouse anti-human IRF4 purified, clone IRF4.3E4 BioLegend Cat# 646402; 
RRID:AB_2280462 
Mouse anti-human IRF8 efluor710, clone 3GYWCH Thermo Fisher Scientific Cat# 46-9852-80; 
RRID:AB_2573903 
Mouse anti-human IRF8 purified, clone GW4CML3  Thermo Fisher Scientific Cat# 14-7888-82; 
RRID:AB_2572907 
Goat anti-human KLF4 APC, clone POLY R&D Systems Cat# IC3640A; 
RRID:AB_2044690 
Mouse anti-PE purified, clone PE001 BioLegend Cat# 408105; 
RRID:AB_2563787 
Mouse anti-human SIGLEC-6 purified, clone 767329 R&D Systems Cat# MAB2859  
Mouse anti-human SIRPa purified, clone 15-414 BioLegend Cat# 372102; 
RRID:AB_2629807 
Mouse anti-humanSIRPa/b AF700, clone SE5A5 BioLegend Cat# 323816; 
RRID:AB_2687275 
Mouse anti-human SIRPa/b APC, clone SE5A5 BioLegend Cat# 323809; 
RRID:AB_11219399 
Mouse anti-human SIRPa/b PE, clone SE5A5 BioLegend Cat# 323805; 
RRID:AB_830704 





Appendix C. Detailed gating strategy for the FACS-purification of 
bone marrow progenitors for scRNA-Seq 
 
Identification of the components of the CD34+ lineage(CD3,14,16,19,20,7)- 
progenitor compartment of human BM (Cytlak and Resteu et al., 2020). 
A. Gating strategy used for the index sorting of bone marrow progenitors subjected to 
scRNA-Seq, along with IRF8 expression across the GMP region. 
B. Culture output of FACS-purified bone marrow progenitors, assessed with flow 
cytometry following 14 days of culture. The proportion of generated DC subsets and 
monocytes is expressed as % of the total cells captured by all DC and monocyte 
gates. n=3-9 donors for each population. Bars represent mean+SEM. HSC, 
hematopoietic stem cell; MPP, multipotent progenitor; MEP, megakaryocyte erythroid 
progenitor; MLP, multilymphoid progenitor; LMPP, lymphoid primed multipotent 





Appendix D. Detailed gating strategy for the FACS-purification of 













The identification of bone marrow pre-DC subjected to scRNA-Seq (Cytlak and 
Resteu et al., 2020). 
A. Gating strategy used for the isolation of cells for scRNA-Seq. 
B. Culture output of FACS-purified bone marrow DC precursors, assessed with flow 
cytometry following 14 days of culture. The proportion of generated DC subsets and 
monocytes is expressed as % of the total cells captured by all DC and monocyte 
gates. n=3-4 donors for each population. Bars represent mean+SEM. 
